>MC403400.1 JP 2018154648-A/103: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GTTGCATCC
>MC403388.1 JP 2018154648-A/91: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>MC403376.1 JP 2018154648-A/79: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
TTGGGTTCT
>MC403364.1 JP 2018154648-A/67: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
AGTGCCTCC
>MC403352.1 JP 2018154648-A/55: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>MC403340.1 JP 2018154648-A/43: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
TTGGGTTCT
>MC403328.1 JP 2018154648-A/31: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGTATCC
>MC403316.1 JP 2018154648-A/19: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>MC403304.1 JP 2018154648-A/7: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>MD214767.1 JP 2019033757-A/20002: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>MC403003.1 JP 2018153188-A/118: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>MC402922.1 JP 2018153188-A/37: Bispecific T cell activating antigen binding molecules
TTTGACTAC
>MC430278.1 JP 2018203779-A/30: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGGTGCGTA
>MC430259.1 JP 2018203779-A/11: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGGTGCGAA
>MC402346.1 JP 2019508037-A/155: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
AGAGAAAGA
>MC402344.1 JP 2019508037-A/153: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
AGAAAAAAG
>MC402298.1 JP 2019508037-A/107: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TNTNTTTNT
>MC402293.1 JP 2019508037-A/102: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TCTTTCTCT
>MC402292.1 JP 2019508037-A/101: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TCTCTTTCT
>MC402271.1 JP 2019508037-A/80: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TTNNNTTTN
>MC402268.1 JP 2019508037-A/77: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
CTTTCCCTT
>MC402267.1 JP 2019508037-A/76: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TTCCCTTTC
>MC402259.1 JP 2019508037-A/68: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
AAGGGAAAG
>MC402257.1 JP 2019508037-A/66: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
CTTTCCCTT
>MC426356.1 JP 2018203772-A/367: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>MC426344.1 JP 2018203772-A/355: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>MC426332.1 JP 2018203772-A/343: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>MC426320.1 JP 2018203772-A/331: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>MC426308.1 JP 2018203772-A/319: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>MC426296.1 JP 2018203772-A/307: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>MC426284.1 JP 2018203772-A/295: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GATGCATCC
>MC426272.1 JP 2018203772-A/283: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>MC426260.1 JP 2018203772-A/271: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>MC426248.1 JP 2018203772-A/259: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>MC426236.1 JP 2018203772-A/247: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>MC426224.1 JP 2018203772-A/235: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>MC426212.1 JP 2018203772-A/223: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>MC426200.1 JP 2018203772-A/211: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>MC426188.1 JP 2018203772-A/199: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>MC426176.1 JP 2018203772-A/187: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>MC426164.1 JP 2018203772-A/175: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>MC426152.1 JP 2018203772-A/163: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>MC426140.1 JP 2018203772-A/151: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>MC426128.1 JP 2018203772-A/139: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>MC426116.1 JP 2018203772-A/127: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>MC426104.1 JP 2018203772-A/115: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>MC426092.1 JP 2018203772-A/103: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>MD211065.1 JP 2019033757-A/16300: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>MD229956.1 JP 2020508353-A/17: DOSING SCHEDULE FOR A COMBINATION OF CERITINIB AND AN ANTI-PD-1 ANTIBODY MOLECULE
TGGGCCTCT
>MC426080.1 JP 2018203772-A/91: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>MC426068.1 JP 2018203772-A/79: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>MC426056.1 JP 2018203772-A/67: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>MC426044.1 JP 2018203772-A/55: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>MC426032.1 JP 2018203772-A/43: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCATCT
>MC426020.1 JP 2018203772-A/31: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCCTCT
>MC426008.1 JP 2018203772-A/19: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>MC425996.1 JP 2018203772-A/7: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>MC425513.1 JP 2019004892-A/2: Humanized Antibody Against Amyloid Beta
GGTGACTAC
>MD229893.1 JP 2020509027-A/71: ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
GCTGCATCC
>MC422576.1 JP 2018188475-A/6: METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES
GCTAGCAGA
>MD207363.1 JP 2019033757-A/12598: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>MD203661.1 JP 2019033757-A/8896: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAATAG
>MC414423.1 JP 2018183178-A/77: Antisense Nucleic Acid
TGGAGTTCC
>MC184183.1 JP 2019508405-A/1: COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF
CAGGCTACG
>MC184184.1 JP 2019508405-A/2: COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF
CAGGCTACG
>MC182966.1 JP 2019505209-A/75: GENE MODIFICATION ASSAYS
AGAACCTGG
>MC182866.1 JP 2019503179-A/9: HYBRID PROMOTER AND USES THEREOF
CAGCGTCGG
>MC182956.1 JP 2019505209-A/65: GENE MODIFICATION ASSAYS
AGAACCTGG
>MC182944.1 JP 2019505209-A/53: GENE MODIFICATION ASSAYS
GTTGGAAAG
>MC029253.1 JP 2017529080-A/2: REAGENTS AND METHODS FOR IDENTIFYING, ENRICHING, AND/OR EXPANDING ANTIGEN-SPEICFIC T CELLS
ACGATCCGA
>MC029252.1 JP 2017529080-A/1: REAGENTS AND METHODS FOR IDENTIFYING, ENRICHING, AND/OR EXPANDING ANTIGEN-SPEICFIC T CELLS
ACGATTCGA
>MC412080.1 JP 2018171075-A/6: MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF
GCTAGCAGA
>MC026141.1 JP 2018533557-A/160: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
TGGGCATCT
>MC026132.1 JP 2018533557-A/151: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCA
>MC026124.1 JP 2018533557-A/143: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCTTCC
>MC026116.1 JP 2018533557-A/135: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026108.1 JP 2018533557-A/127: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GTTGCATCC
>MC026100.1 JP 2018533557-A/119: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCGTCC
>MC026092.1 JP 2018533557-A/111: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026084.1 JP 2018533557-A/103: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026076.1 JP 2018533557-A/95: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026068.1 JP 2018533557-A/87: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCGTCC
>MC026060.1 JP 2018533557-A/79: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCAGCC
>MC026052.1 JP 2018533557-A/71: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026044.1 JP 2018533557-A/63: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026036.1 JP 2018533557-A/55: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026028.1 JP 2018533557-A/47: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026020.1 JP 2018533557-A/39: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026012.1 JP 2018533557-A/31: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC026004.1 JP 2018533557-A/23: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GGTGCATCC
>MC025996.1 JP 2018533557-A/15: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC025988.1 JP 2018533557-A/7: Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof
GCTGCATCC
>MC176847.1 JP 2019502695-A/88: COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND USES THEREOF
TGGGCCTCT
>MC176836.1 JP 2019502695-A/77: COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND USES THEREOF
TGGGCCTCC
>MC176822.1 JP 2019502695-A/63: COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND USES THEREOF
TGGGCATCC
>MD199959.1 JP 2019033757-A/5194: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>MC410155.1 JP 2018166516-A/88: Anti-ANGPTL3 Antibodies and Uses Thereof
AAGGCGTCT
>MC410146.1 JP 2018166516-A/79: Anti-ANGPTL3 Antibodies and Uses Thereof
GTTGCAGCC
>MC410138.1 JP 2018166516-A/71: Anti-ANGPTL3 Antibodies and Uses Thereof
AAGGTTTCT
>MC410130.1 JP 2018166516-A/63: Anti-ANGPTL3 Antibodies and Uses Thereof
ACTGCATCC
>MC410122.1 JP 2018166516-A/55: Anti-ANGPTL3 Antibodies and Uses Thereof
CCTGCATCC
>MC410114.1 JP 2018166516-A/47: Anti-ANGPTL3 Antibodies and Uses Thereof
ACTACTTCC
>MC410106.1 JP 2018166516-A/39: Anti-ANGPTL3 Antibodies and Uses Thereof
AAGGCGTCT
>MC410098.1 JP 2018166516-A/31: Anti-ANGPTL3 Antibodies and Uses Thereof
AAGGCGTCT
>MC410090.1 JP 2018166516-A/23: Anti-ANGPTL3 Antibodies and Uses Thereof
GCTGCATCC
>MC410082.1 JP 2018166516-A/15: Anti-ANGPTL3 Antibodies and Uses Thereof
AAGGCGTCT
>MC410074.1 JP 2018166516-A/7: Anti-ANGPTL3 Antibodies and Uses Thereof
GCTGCATCC
>MC438221.1 JP 2019037236-A/43: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CTCACATCC
>MC438220.1 JP 2019037236-A/42: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CGTGCATCC
>MC438219.1 JP 2019037236-A/41: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CGGATGTCC
>MC438154.1 JP 2019037235-A/4: MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION
GCCGCCACC
>MC438153.1 JP 2019037235-A/3: MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION
GCCGCCGCC
>MC438152.1 JP 2019037235-A/2: MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION
GCCACCACC
>MC409991.1 JP 2018168186-A/140: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409971.1 JP 2018168186-A/120: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409961.1 JP 2018168186-A/110: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGCGACATC
>MC409951.1 JP 2018168186-A/100: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409941.1 JP 2018168186-A/90: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409931.1 JP 2018168186-A/80: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409921.1 JP 2018168186-A/70: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409911.1 JP 2018168186-A/60: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409901.1 JP 2018168186-A/50: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409891.1 JP 2018168186-A/40: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409881.1 JP 2018168186-A/30: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409871.1 JP 2018168186-A/20: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC175665.1 JP 2019503349-A/88: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCT
>MC175654.1 JP 2019503349-A/77: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCC
>MC175640.1 JP 2019503349-A/63: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCATCC
>MC409861.1 JP 2018168186-A/10: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>MC409813.1 JP 2018183155-A/34: RETROVIRAL VECTOR WITH MINI-PROMOTER CASSETTE
GGAGTTCCC
>MD217375.1 JP 2020054328-A/13: Immunodeficient mouse
CGCTATGCT
>MD217374.1 JP 2020054328-A/12: Immunodeficient mouse
ACGCTAAGC
>MP567765.1 Sequence 133 from Patent WO2020056155
TAGTAGTAG
>MP567764.1 Sequence 132 from Patent WO2020056155
TAATAATAA
>MP567763.1 Sequence 131 from Patent WO2020056155
TGATGATGA
>MP567762.1 Sequence 130 from Patent WO2020056155
TAATAGTAG
>MP567761.1 Sequence 129 from Patent WO2020056155
TAATGATGA
>MP567760.1 Sequence 128 from Patent WO2020056155
TGATAGTAG
>MP567759.1 Sequence 127 from Patent WO2020056155
TGATAATAA
>MP567758.1 Sequence 126 from Patent WO2020056155
TAATGATAG
>MP567757.1 Sequence 125 from Patent WO2020056155
TGATAGTAA
>MP567756.1 Sequence 124 from Patent WO2020056155
TGATAATAG
>MP567721.1 Sequence 87 from Patent WO2020056155
CCRCCATGG
>MP468237.1 Sequence 101 from Patent WO2020005326
GGTATGAAG
>MP567534.1 Sequence 133 from Patent WO2020056239
TAGTAGTAG
>MP567533.1 Sequence 132 from Patent WO2020056239
TAATAATAA
>MP567532.1 Sequence 131 from Patent WO2020056239
TGATGATGA
>MP567531.1 Sequence 130 from Patent WO2020056239
TAATAGTAG
>MP567530.1 Sequence 129 from Patent WO2020056239
TAATGATGA
>MP567529.1 Sequence 128 from Patent WO2020056239
TGATAGTAG
>MP567528.1 Sequence 127 from Patent WO2020056239
TGATAATAA
>MP567527.1 Sequence 126 from Patent WO2020056239
TAATGATAG
>MP567526.1 Sequence 125 from Patent WO2020056239
TGATAGTAA
>MP567525.1 Sequence 124 from Patent WO2020056239
TGATAATAG
>MP567490.1 Sequence 87 from Patent WO2020056239
CCRCCATGG
>MP463035.1 Sequence 61 from Patent WO2019246176
GGTGCATCC
>MP463019.1 Sequence 45 from Patent WO2019246176
AAGGTTTCT
>MP463003.1 Sequence 29 from Patent WO2019246176
ACTGCATCC
>MP462987.1 Sequence 13 from Patent WO2019246176
GCTGCATCC
>MP560507.1 Sequence 133 from Patent WO2020056147
TAGTAGTAG
>MP560506.1 Sequence 132 from Patent WO2020056147
TAATAATAA
>MP560505.1 Sequence 131 from Patent WO2020056147
TGATGATGA
>MP560504.1 Sequence 130 from Patent WO2020056147
TAATAGTAG
>MP560503.1 Sequence 129 from Patent WO2020056147
TAATGATGA
>MP560502.1 Sequence 128 from Patent WO2020056147
TGATAGTAG
>MP560501.1 Sequence 127 from Patent WO2020056147
TGATAATAA
>MP560500.1 Sequence 126 from Patent WO2020056147
TAATGATAG
>MP560499.1 Sequence 125 from Patent WO2020056147
TGATAGTAA
>MP560498.1 Sequence 124 from Patent WO2020056147
TGATAATAG
>MP560463.1 Sequence 87 from Patent WO2020056147
CCRCCATGG
>MP462794.1 Sequence 69 from Patent WO2019246514
GCTGCATCC
>MP462770.1 Sequence 45 from Patent WO2019246514
GCTGCATCC
>MP368950.1 Sequence 104 from Patent EP3555274
TCAGAAACA
>MP368944.1 Sequence 98 from Patent EP3555274
CGACGAGGC
>MP368940.1 Sequence 94 from Patent EP3555274
TCAGAAACA
>MP457049.1 Sequence 70 from Patent EP3594339
TTTCCAAAG
>MP364140.1 Sequence 39 from Patent EP3556768
CGACGACGA
>MP544472.1 Sequence 13 from Patent WO2020033872
GCTGCATTC
>MP543954.1 Sequence 25 from Patent WO2020033951
TNTTTTNTT
>MP544039.1 Sequence 110 from Patent WO2020033951
TNTTNTTNT
>MP543983.1 Sequence 54 from Patent WO2020033951
TTNNTNTTT
>MP543956.1 Sequence 27 from Patent WO2020033951
TTNTTNTTT
>MP543403.1 Sequence 79 from Patent WO2020044252
TGGGCCTCT
>MP543391.1 Sequence 67 from Patent WO2020044252
TGGGCCTCT
>MP455042.1 Sequence 111 from Patent EP3590539
GCTGCATCC
>MP455014.1 Sequence 83 from Patent EP3590539
GATGCCTCC
>MP454982.1 Sequence 51 from Patent EP3590539
GCTGCATCC
>MP454950.1 Sequence 19 from Patent EP3590539
GCTGCATCC
>MP542399.1 Sequence 222 from Patent WO2020047029
GCTGCATCC
>MP542383.1 Sequence 206 from Patent WO2020047029
GATGCATCC
>MP542367.1 Sequence 190 from Patent WO2020047029
GTTGCATCC
>MP542351.1 Sequence 174 from Patent WO2020047029
GCTGCATCC
>MP542335.1 Sequence 158 from Patent WO2020047029
GCTGCATCC
>MP542319.1 Sequence 142 from Patent WO2020047029
GATGCATCC
>MP542303.1 Sequence 126 from Patent WO2020047029
GTTGCATCC
>MP542287.1 Sequence 110 from Patent WO2020047029
GATGCATCC
>MP542271.1 Sequence 94 from Patent WO2020047029
GATGCATCC
>MP542255.1 Sequence 78 from Patent WO2020047029
GATGCATCC
>MP542239.1 Sequence 62 from Patent WO2020047029
GATGCATCC
>MP542223.1 Sequence 46 from Patent WO2020047029
GATGCATCC
>MP542207.1 Sequence 30 from Patent WO2020047029
GGTGCATCC
>MP542191.1 Sequence 14 from Patent WO2020047029
GGTGCATCC
>MP453619.1 Sequence 3 from Patent EP3590969
TTTGATTAC
>MP358394.1 Sequence 25 from Patent EP3551193
TTATTTAWW
>MP358392.1 Sequence 23 from Patent EP3551193
CCRCCATGG
>MP451219.1 Sequence 145 from Patent WO2019241692
ACAAAAACC
>MP538477.1 Sequence 133 from Patent WO2020047201
TAGTAGTAG
>MP538476.1 Sequence 132 from Patent WO2020047201
TAATAATAA
>MP538475.1 Sequence 131 from Patent WO2020047201
TGATGATGA
>MP450664.1 Sequence 21 from Patent EP3594238
GGTGCATCC
>MP538474.1 Sequence 130 from Patent WO2020047201
TAATAGTAG
>MP538473.1 Sequence 129 from Patent WO2020047201
TAATGATGA
>MP538472.1 Sequence 128 from Patent WO2020047201
TGATAGTAG
>MP538471.1 Sequence 127 from Patent WO2020047201
TGATAATAA
>MP538470.1 Sequence 126 from Patent WO2020047201
TAATGATAG
>MP538469.1 Sequence 125 from Patent WO2020047201
TGATAGTAA
>MP538468.1 Sequence 124 from Patent WO2020047201
TGATAATAG
>MP538433.1 Sequence 87 from Patent WO2020047201
CCRCCATGG
>MP354177.1 Sequence 755 from Patent WO2019200229
TACACCTCC
>MP354176.1 Sequence 754 from Patent WO2019200229
TACACTAGC
>MP354112.1 Sequence 637 from Patent WO2019200229
TGGGCCTCT
>MP354067.1 Sequence 533 from Patent WO2019200229
TGGGCCTCT
>MP443177.1 Sequence 9 from Patent EP3587582
AATTCAGAG
>MP443176.1 Sequence 8 from Patent EP3587582
TCGACTCTG
>MP527510.1 Sequence 28 from Patent EP3601570
TTTGTGTAG
>MP527509.1 Sequence 27 from Patent EP3601570
TTCAAGAGA
>MP441397.1 Sequence 12 from Patent EP3582790
CCNCCATGG
>MP608549.1 Sequence 189 from Patent WO2020086406
GGTGCATCC
>MP608533.1 Sequence 173 from Patent WO2020086406
GCTGCATCC
>MP608517.1 Sequence 157 from Patent WO2020086406
GCTGCATCC
>MP608501.1 Sequence 141 from Patent WO2020086406
AAGGCGTCT
>MP608485.1 Sequence 125 from Patent WO2020086406
CCTGCATCC
>MP608469.1 Sequence 109 from Patent WO2020086406
GCTACATCC
>MP608453.1 Sequence 93 from Patent WO2020086406
GTTGCATCC
>MP608437.1 Sequence 77 from Patent WO2020086406
GGTGCATCC
>MP608421.1 Sequence 61 from Patent WO2020086406
TCTGCATCC
>MP608405.1 Sequence 45 from Patent WO2020086406
GGTGCATAC
>MP608389.1 Sequence 29 from Patent WO2020086406
ACTGCATCC
>MP608373.1 Sequence 13 from Patent WO2020086406
GTTGCATCC
>MP523895.1 Sequence 12 from Patent EP3601557
TTTGTGTAG
>MP523894.1 Sequence 11 from Patent EP3601557
TTCAAGAGA
>MP343492.1 Sequence 93 from Patent WO2019195796
GGTGCATCC
>MP343412.1 Sequence 13 from Patent WO2019195796
GCTGCATCC
>MP342865.1 Sequence 12 from Patent WO2019190590
TTTTTGTTT
>MP520164.1 Sequence 2 from Patent EP3604343
CGTGGTGAC
>MP337698.1 Sequence 309 from Patent WO2019190931
GGTGCATCC
>MP337610.1 Sequence 221 from Patent WO2019190931
GCTGCATCC
>MP337594.1 Sequence 205 from Patent WO2019190931
GCTGCATCC
>MP337578.1 Sequence 189 from Patent WO2019190931
GATGCATCC
>MP337562.1 Sequence 173 from Patent WO2019190931
GATGCATCC
>MP337546.1 Sequence 157 from Patent WO2019190931
GCTGCATCC
>MP337530.1 Sequence 141 from Patent WO2019190931
GGTGCATCC
>MP337514.1 Sequence 125 from Patent WO2019190931
GCTGCATCC
>MP337498.1 Sequence 109 from Patent WO2019190931
GCTGCATCC
>MP337482.1 Sequence 93 from Patent WO2019190931
GCTGCATCC
>MP337466.1 Sequence 77 from Patent WO2019190931
GATGCATCC
>MP337450.1 Sequence 61 from Patent WO2019190931
GCTGCATCC
>MP337434.1 Sequence 45 from Patent WO2019190931
TATGCTTCC
>MP337418.1 Sequence 29 from Patent WO2019190931
GATGCATCC
>MP337402.1 Sequence 13 from Patent WO2019190931
GCTGCATCC
>MP518981.1 Sequence 29 from Patent WO2020041537
GCTGCATCC
>MP517874.1 Sequence 65 from Patent EP3607996
TCTGGATCC
>MP516896.1 Sequence 168 from Patent EP3608338
TGGGCATCT
>MP516849.1 Sequence 121 from Patent EP3608338
GCTGCATCC
>MP516809.1 Sequence 81 from Patent EP3608338
GCTGCATCC
>MP516916.1 Sequence 188 from Patent EP3608338
TTGGGTTCT
>MP516869.1 Sequence 141 from Patent EP3608338
ACTGCATTC
>MP516829.1 Sequence 101 from Patent EP3608338
GCTACATCC
>MP516789.1 Sequence 61 from Patent EP3608338
ACTGCATCC
>MP516773.1 Sequence 45 from Patent EP3608338
TTGGGTTCT
>MP516757.1 Sequence 29 from Patent EP3608338
TTGGGTTCT
>MP516741.1 Sequence 13 from Patent EP3608338
TTGGGTTCT
>MP333258.1 Sequence 154 from Patent EP3539980
TTTGTAGAT
>MP332534.1 Sequence 10 from Patent WO2019180658
GCTGCATCC
>MP425658.1 Sequence 1 from Patent WO2019231743
TATAGGGAT
>MP423824.1 Sequence 755 from Patent WO2019232244
TACACCTCC
>MP423823.1 Sequence 754 from Patent WO2019232244
TACACTAGC
>MP423759.1 Sequence 637 from Patent WO2019232244
TGGGCCTCT
>MP423714.1 Sequence 533 from Patent WO2019232244
TGGGCCTCT
>MP422684.1 Sequence 755 from Patent WO2019229658
TACACCTCC
>MP422683.1 Sequence 754 from Patent WO2019229658
TACACTAGC
>MP422619.1 Sequence 637 from Patent WO2019229658
TGGGCCTCT
>MP422574.1 Sequence 533 from Patent WO2019229658
TGGGCCTCT
>MP418238.1 Sequence 74 from Patent WO2019236673
TGTAGGACT
>MP418237.1 Sequence 73 from Patent WO2019236673
GGTTCTACA
>MP510397.1 Sequence 3 from Patent EP3610003
CTAGGACTG
>MP510069.1 Sequence 5 from Patent EP3610025
CTAGGACTG
>MP415698.1 Sequence 246 from Patent EP3576751
CCRCCATGG
>MP324968.1 Sequence 604 from Patent WO2019169283
GGTGCATCC
>MP414941.1 Sequence 6 from Patent EP3578195
CCCGTGCAT
>MP414940.1 Sequence 5 from Patent EP3578195
ATGCACGGG
>MP324904.1 Sequence 540 from Patent WO2019169283
GGGGCAAGT
>MP324848.1 Sequence 484 from Patent WO2019169283
GCTGCATCC
>MP324832.1 Sequence 468 from Patent WO2019169283
GATGCATCC
>MP324816.1 Sequence 452 from Patent WO2019169283
GATGCTTCC
>MP324800.1 Sequence 436 from Patent WO2019169283
GAGACATCC
>MP324784.1 Sequence 420 from Patent WO2019169283
GCTGCATCC
>MP324768.1 Sequence 404 from Patent WO2019169283
TGGGCATCT
>MP324751.1 Sequence 387 from Patent WO2019169283
GCTGCATCC
>MP324735.1 Sequence 371 from Patent WO2019169283
ACTACATCC
>MP324689.1 Sequence 325 from Patent WO2019169283
AAGATTTCT
>MP324681.1 Sequence 317 from Patent WO2019169283
TTGGGTTCT
>MP324665.1 Sequence 301 from Patent WO2019169283
GCTGCATCC
>MP324649.1 Sequence 285 from Patent WO2019169283
GGTGCATCC
>MP324633.1 Sequence 269 from Patent WO2019169283
TTGGGTTCT
>MP324617.1 Sequence 253 from Patent WO2019169283
GGTGCATCC
>MP324601.1 Sequence 237 from Patent WO2019169283
GGTGCATCC
>MP324585.1 Sequence 221 from Patent WO2019169283
GGTGCATCC
>MP324569.1 Sequence 205 from Patent WO2019169283
GGTGCATCC
>MP324553.1 Sequence 189 from Patent WO2019169283
GCTACATCC
>MP324537.1 Sequence 173 from Patent WO2019169283
GGTGCATCC
>MP324521.1 Sequence 157 from Patent WO2019169283
GCTGCATCC
>MP324505.1 Sequence 141 from Patent WO2019169283
GTTGCATCC
>MP324489.1 Sequence 125 from Patent WO2019169283
CGGATGTCC
>MP324473.1 Sequence 109 from Patent WO2019169283
GCTGCATCC
>MP324457.1 Sequence 93 from Patent WO2019169283
GCTGCATCC
>MP324441.1 Sequence 77 from Patent WO2019169283
GCTGCATCC
>MP324425.1 Sequence 61 from Patent WO2019169283
GCTGCATCC
>MP324409.1 Sequence 45 from Patent WO2019169283
GCTGCATCC
>MP324393.1 Sequence 29 from Patent WO2019169283
GCTGCATCC
>MP324377.1 Sequence 13 from Patent WO2019169283
GGTGTATCC
>MP412020.1 Sequence 285 from Patent WO2019222663
GCTGCATCC
>MP507669.1 Sequence 108 from Patent EP3607057
TTNNNNNAA
>MP412004.1 Sequence 269 from Patent WO2019222663
GCTGCATCC
>MP411988.1 Sequence 253 from Patent WO2019222663
GCTGCATCC
>MP411972.1 Sequence 237 from Patent WO2019222663
GGTGCATCC
>MP411956.1 Sequence 221 from Patent WO2019222663
GGTCCATCC
>MP411940.1 Sequence 205 from Patent WO2019222663
GGTGCATCC
>MP411924.1 Sequence 189 from Patent WO2019222663
GGTGCATCC
>MP411908.1 Sequence 173 from Patent WO2019222663
GGTGCATCC
>MP411892.1 Sequence 157 from Patent WO2019222663
GCTGCATCC
>MP411876.1 Sequence 141 from Patent WO2019222663
GCTGCATCC
>MP411860.1 Sequence 125 from Patent WO2019222663
GGTGCATCC
>MP411844.1 Sequence 109 from Patent WO2019222663
GTAGCATCC
>MP411828.1 Sequence 93 from Patent WO2019222663
GGTGCATCC
>MP411812.1 Sequence 77 from Patent WO2019222663
GCTGCATCC
>MP411796.1 Sequence 61 from Patent WO2019222663
GGTGCATCC
>MP411780.1 Sequence 45 from Patent WO2019222663
GGTGCATCC
>MP411764.1 Sequence 29 from Patent WO2019222663
GGTGGATCC
>MP411748.1 Sequence 13 from Patent WO2019222663
GGTGTATTC
>MP317689.1 Sequence 16 from Patent EP3535404
AGGGCCATA
>MP313694.1 Sequence 61 from Patent EP3409269
GTTGCATCC
>MP313678.1 Sequence 45 from Patent EP3409269
GCTGCATCC
>MP313662.1 Sequence 29 from Patent EP3409269
GGTGCATCC
>MP313646.1 Sequence 13 from Patent EP3409269
GGTGCATCC
>MP589991.1 Sequence 15 from Patent EP3635132
GGAAGCGGA
>MP497370.1 Sequence 10 from Patent WO2020025953
TAACAATTA
>MP497369.1 Sequence 9 from Patent WO2020025953
TAGCAATTA
>MP497368.1 Sequence 8 from Patent WO2020025953
TGACAATTA
>MP497364.1 Sequence 4 from Patent WO2020025953
TTTTTTTAA
>MP497363.1 Sequence 3 from Patent WO2020025953
TTTTTTTAG
>MP497362.1 Sequence 2 from Patent WO2020025953
TTTTTTTGA
>MP399484.1 Sequence 299 from Patent EP3568416
TATGCTTCC
>MP399472.1 Sequence 287 from Patent EP3568416
GCTGCATCC
>MP584877.1 Sequence 502 from Patent WO2020082042
TCGGTCCAG
>MP584876.1 Sequence 501 from Patent WO2020082042
TCGGTCCAG
>MP584875.1 Sequence 500 from Patent WO2020082042
CTGGACCGA
>MP584426.1 Sequence 502 from Patent WO2020082041
TCGGTCCAG
>MP584425.1 Sequence 501 from Patent WO2020082041
TCGGTCCAG
>MP584424.1 Sequence 500 from Patent WO2020082041
CTGGACCGA
>MP584118.1 Sequence 502 from Patent WO2020082046
TCGGTCCAG
>MP584117.1 Sequence 501 from Patent WO2020082046
TCGGTCCAG
>MP584116.1 Sequence 500 from Patent WO2020082046
CTGGACCGA
>MP484893.1 Sequence 133 from Patent WO2020023390
TAGTAGTAG
>MP484892.1 Sequence 132 from Patent WO2020023390
TAATAATAA
>MP484891.1 Sequence 131 from Patent WO2020023390
TGATGATGA
>MP484890.1 Sequence 130 from Patent WO2020023390
TAATAGTAG
>MP484889.1 Sequence 129 from Patent WO2020023390
TAATGATGA
>MP484888.1 Sequence 128 from Patent WO2020023390
TGATAGTAG
>MP484887.1 Sequence 127 from Patent WO2020023390
TGATAATAA
>MP484886.1 Sequence 126 from Patent WO2020023390
TAATGATAG
>MP484885.1 Sequence 125 from Patent WO2020023390
TGATAGTAA
>MP484884.1 Sequence 124 from Patent WO2020023390
TGATAATAG
>MP484849.1 Sequence 87 from Patent WO2020023390
CCRCCATGG
>MP583245.1 Sequence 533 from Patent WO2020079581
TGGGCCTCT
>MP483257.1 Sequence 27 from Patent WO2020023619
GAGGTCAGT
>MP483250.1 Sequence 20 from Patent WO2020023619
GATAACAAC
>MP397204.1 Sequence 35 from Patent EP3572072
GGGTTAGGG
>MP397203.1 Sequence 34 from Patent EP3572072
GAGTATGAG
>MP397196.1 Sequence 27 from Patent EP3572072
TTAGGGTTA
>MP397195.1 Sequence 26 from Patent EP3572072
GTTAGGGTT
>MP396308.1 Sequence 11 from Patent EP3565596
AAAGTTTCC
>MP481702.1 Sequence 755 from Patent WO2020021465
TACACCTCC
>MP481701.1 Sequence 754 from Patent WO2020021465
TACACTAGC
>MP481637.1 Sequence 637 from Patent WO2020021465
TGGGCCTCT
>MP481592.1 Sequence 533 from Patent WO2020021465
TGGGCCTCT
>MP579570.1 Sequence 133 from Patent WO2020069169
TAGTAGTAG
>MP579569.1 Sequence 132 from Patent WO2020069169
TAATAATAA
>MP579568.1 Sequence 131 from Patent WO2020069169
TGATGATGA
>MP579567.1 Sequence 130 from Patent WO2020069169
TAATAGTAG
>MP579566.1 Sequence 129 from Patent WO2020069169
TAATGATGA
>MP579565.1 Sequence 128 from Patent WO2020069169
TGATAGTAG
>MP579564.1 Sequence 127 from Patent WO2020069169
TGATAATAA
>MP579563.1 Sequence 126 from Patent WO2020069169
TAATGATAG
>MP579562.1 Sequence 125 from Patent WO2020069169
TGATAGTAA
>MP579561.1 Sequence 124 from Patent WO2020069169
TGATAATAG
>MP579526.1 Sequence 87 from Patent WO2020069169
CCRCCATGG
>MP393061.1 Sequence 463 from Patent WO2019217591
GCTGCATCC
>MP393045.1 Sequence 447 from Patent WO2019217591
GCTGCATCC
>MP393029.1 Sequence 431 from Patent WO2019217591
GTTGCATCC
>MP392963.1 Sequence 365 from Patent WO2019217591
GGTGCATCC
>MP392915.1 Sequence 317 from Patent WO2019217591
AAGGCGTCT
>MP392899.1 Sequence 301 from Patent WO2019217591
GCTGCATTC
>MP392883.1 Sequence 285 from Patent WO2019217591
AAGATTTCT
>MP392867.1 Sequence 269 from Patent WO2019217591
GGTGCATCC
>MP392851.1 Sequence 253 from Patent WO2019217591
GCTACATCC
>MP392835.1 Sequence 237 from Patent WO2019217591
GGTGCATCC
>MP392819.1 Sequence 221 from Patent WO2019217591
GGTGCATCC
>MP392803.1 Sequence 205 from Patent WO2019217591
AAGGCGTCT
>MP392787.1 Sequence 189 from Patent WO2019217591
GCTGCATCC
>MP392771.1 Sequence 173 from Patent WO2019217591
GCTGCATCC
>MP392755.1 Sequence 157 from Patent WO2019217591
TATACATCC
>MP392739.1 Sequence 141 from Patent WO2019217591
GCTGCATCC
>MP392723.1 Sequence 125 from Patent WO2019217591
GGTGCATCC
>MP392707.1 Sequence 109 from Patent WO2019217591
GCTGCGTCC
>MP392691.1 Sequence 93 from Patent WO2019217591
GCTGCATCC
>MP392675.1 Sequence 77 from Patent WO2019217591
GCTGCATCC
>MP392659.1 Sequence 61 from Patent WO2019217591
GGTGCATCC
>MP392643.1 Sequence 45 from Patent WO2019217591
GCTGCATCC
>MP392627.1 Sequence 29 from Patent WO2019217591
GCTGCATCC
>MP392611.1 Sequence 13 from Patent WO2019217591
ACTGCATCC
>MP477969.1 Sequence 162 from Patent WO2020012337
TACACCTCC
>MP477968.1 Sequence 161 from Patent WO2020012337
TACACTAGC
>MP477905.1 Sequence 98 from Patent WO2020012337
TGGGCCTCT
>MP477861.1 Sequence 54 from Patent WO2020012337
TGGGCCTCT
>MP477257.1 Sequence 162 from Patent WO2020012334
TACACCTCC
>MP477256.1 Sequence 161 from Patent WO2020012334
TACACTAGC
>MP477193.1 Sequence 98 from Patent WO2020012334
TGGGCCTCT
>MP477149.1 Sequence 54 from Patent WO2020012334
TGGGCCTCT
>MP631083.1 Sequence 264 from Patent EP3573448
GTATGATGG
>MP631082.1 Sequence 263 from Patent EP3573448
CTCAAGTGA
>MP631078.1 Sequence 259 from Patent EP3573448
CTCCTAATT
>MP631077.1 Sequence 258 from Patent EP3573448
TGTATATAT
>MP631076.1 Sequence 257 from Patent EP3573448
ATAAAACGT
>MP631064.1 Sequence 245 from Patent EP3573448
AAACCCTAA
>MP631061.1 Sequence 242 from Patent EP3573448
TNCGTACAA
>MP631050.1 Sequence 231 from Patent EP3573448
AGATCGACG
>MP631047.1 Sequence 228 from Patent EP3573448
TAACTNGTT
>MP631029.1 Sequence 210 from Patent EP3573448
AAAATATCT
>MP631022.1 Sequence 203 from Patent EP3573448
TCTCCCGCC
>MP631018.1 Sequence 199 from Patent EP3573448
TACCGACAT
>MP631017.1 Sequence 198 from Patent EP3573448
TACCGACAT
>MP631003.1 Sequence 184 from Patent EP3573448
CAATTATTA
>MP631002.1 Sequence 183 from Patent EP3573448
CAATNATTG
>MP631001.1 Sequence 182 from Patent EP3573448
CAATNATTG
>MP631000.1 Sequence 181 from Patent EP3573448
CAATNATTG
>MP387501.1 Sequence 13 from Patent WO2019212965
GCTGCATCC
>MP385645.1 Sequence 138 from Patent EP3567122
CTCCGACCG
>MP382595.1 Sequence 47 from Patent EP3564671
GATGCATCC
>MP382577.1 Sequence 29 from Patent EP3564671
AAGGCGTCT
>MP382561.1 Sequence 13 from Patent EP3564671
GCTGCATCC
>MP640801.1 Sequence 502 from Patent WO2020082047
TCGGTCCAG
>MP640800.1 Sequence 501 from Patent WO2020082047
TCGGTCCAG
>MP640799.1 Sequence 500 from Patent WO2020082047
CTGGACCGA
>MP469386.1 Sequence 10 from Patent WO2019243391
ACAGGAGCA
>MP469385.1 Sequence 9 from Patent WO2019243391
TGCTCCTGT
>MP389811.1 Sequence 72 from Patent WO2019209859
TAGTTATAG
>MP389802.1 Sequence 63 from Patent WO2019209859
GCCGCCACC
>MC006145.1 JP 2020500162-A/1: METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE
GCCACCATG
>MB494664.1 JP 2020019718-A/21: agent and method for promoting cardiac differentiation
TGAGGGTGA
>MB487885.1 JP 2020002136-A/35: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GGGTTAGGG
>MB487884.1 JP 2020002136-A/34: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GAGTATGAG
>MB487877.1 JP 2020002136-A/27: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
TTAGGGTTA
>MB487876.1 JP 2020002136-A/26: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTT
>MB484025.1 JP 2019205446-A/2: EXPRESSION AND PURIFICATION OF CRM197 AND RELATED PROTEINS
GATATACCA
>MB483366.1 JP 2019528312-A/27: MRNA-MEDIATED IMMUNIZATION METHODS
AACAATGGC
>MB483347.1 JP 2019528312-A/8: MRNA-MEDIATED IMMUNIZATION METHODS
GCCACCATG
>MB483340.1 JP 2019528312-A/1: MRNA-MEDIATED IMMUNIZATION METHODS
GCCACCATG
>MB482004.1 JP 2019528039-A/175: Anti-C5 Antibodies and Uses Thereof
GATGCATCC
>MB481996.1 JP 2019528039-A/167: Anti-C5 Antibodies and Uses Thereof
GGTGCATCC
>MB481988.1 JP 2019528039-A/159: Anti-C5 Antibodies and Uses Thereof
GATGCATCC
>MB481980.1 JP 2019528039-A/151: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481960.1 JP 2019528039-A/131: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481952.1 JP 2019528039-A/123: Anti-C5 Antibodies and Uses Thereof
GATGCATCC
>MB481944.1 JP 2019528039-A/115: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481936.1 JP 2019528039-A/107: Anti-C5 Antibodies and Uses Thereof
AAGGCGTCT
>MB481928.1 JP 2019528039-A/99: Anti-C5 Antibodies and Uses Thereof
GATGCATCC
>MB481920.1 JP 2019528039-A/91: Anti-C5 Antibodies and Uses Thereof
ACTGCATCC
>MB481912.1 JP 2019528039-A/83: Anti-C5 Antibodies and Uses Thereof
ACTGCATCC
>MB481896.1 JP 2019528039-A/67: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481888.1 JP 2019528039-A/59: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481884.1 JP 2019528039-A/55: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481876.1 JP 2019528039-A/47: Anti-C5 Antibodies and Uses Thereof
GATGCATCG
>MB481868.1 JP 2019528039-A/39: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481860.1 JP 2019528039-A/31: Anti-C5 Antibodies and Uses Thereof
GCTGCATCC
>MB481852.1 JP 2019528039-A/23: Anti-C5 Antibodies and Uses Thereof
AAGGCGTCT
>MB481844.1 JP 2019528039-A/15: Anti-C5 Antibodies and Uses Thereof
GATGCATCC
>MB481836.1 JP 2019528039-A/7: Anti-C5 Antibodies and Uses Thereof
AAGGCGTCT
>MB480641.1 JP 2019196377-A/11: ANTIBODY COMPOSITIONS FOR TUMOR TREATMENT
GGTGCATCC
>MB480602.1 JP 2019193662-A/6: COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
ACGGGTAGA
>MB463827.1 JP 2018526007-A/2: RECOMBINANT VECTORS COMPRISING 2A PEPTIDE
GGAAGCGGA
>MB461988.1 JP 2018525383-A/127: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GCTGCATCC
>MB461980.1 JP 2018525383-A/119: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
TTGGGTTCT
>MB461972.1 JP 2018525383-A/111: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GATGCATCC
>MB461964.1 JP 2018525383-A/103: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
TGGGCATCT
>MB461956.1 JP 2018525383-A/95: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GATGCTTCC
>MB461948.1 JP 2018525383-A/87: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GATGCATCC
>MB461940.1 JP 2018525383-A/79: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GCTGCATCC
>MB461932.1 JP 2018525383-A/71: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
TCTGCATCC
>MB461924.1 JP 2018525383-A/63: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
TTGGGTTCT
>MB461916.1 JP 2018525383-A/55: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
AAGATTTCT
>MB461908.1 JP 2018525383-A/47: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GCTGCATCC
>MB461900.1 JP 2018525383-A/39: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
TGGGCATCT
>MB461892.1 JP 2018525383-A/31: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
AAGATTTTT
>MB461884.1 JP 2018525383-A/23: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GCTGCATCC
>MB461876.1 JP 2018525383-A/15: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
AAGGCGTCT
>MB461868.1 JP 2018525383-A/7: ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF
GCTGCATCC
>MB461800.1 JP 2018524396-A/819: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461716.1 JP 2018524396-A/735: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461708.1 JP 2018524396-A/727: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461700.1 JP 2018524396-A/719: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461692.1 JP 2018524396-A/711: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461684.1 JP 2018524396-A/703: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461676.1 JP 2018524396-A/695: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461576.1 JP 2018524396-A/595: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GTTGCATCC
>MB461568.1 JP 2018524396-A/587: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461560.1 JP 2018524396-A/579: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461552.1 JP 2018524396-A/571: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GTTGCATCC
>MB461544.1 JP 2018524396-A/563: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461536.1 JP 2018524396-A/555: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461528.1 JP 2018524396-A/547: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GTTGCATCC
>MB461520.1 JP 2018524396-A/539: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461512.1 JP 2018524396-A/531: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461504.1 JP 2018524396-A/523: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461496.1 JP 2018524396-A/515: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461488.1 JP 2018524396-A/507: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461480.1 JP 2018524396-A/499: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
TGGGCATCT
>MB461472.1 JP 2018524396-A/491: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
AAGGCGTCT
>MB461464.1 JP 2018524396-A/483: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCGTCC
>MB461456.1 JP 2018524396-A/475: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCGTCC
>MB461448.1 JP 2018524396-A/467: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461440.1 JP 2018524396-A/459: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCGTCC
>MB461432.1 JP 2018524396-A/451: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCGTCC
>MB461424.1 JP 2018524396-A/443: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCGTCC
>MB461416.1 JP 2018524396-A/435: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCGTCC
>MB461408.1 JP 2018524396-A/427: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461400.1 JP 2018524396-A/419: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCGTCC
>MB461392.1 JP 2018524396-A/411: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461384.1 JP 2018524396-A/403: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461376.1 JP 2018524396-A/395: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461368.1 JP 2018524396-A/387: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461360.1 JP 2018524396-A/379: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461352.1 JP 2018524396-A/371: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GATGCATCC
>MB461344.1 JP 2018524396-A/363: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGTATCC
>MB461336.1 JP 2018524396-A/355: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GAAGCTTCT
>MB461328.1 JP 2018524396-A/347: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCTTCC
>MB461320.1 JP 2018524396-A/339: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461312.1 JP 2018524396-A/331: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461304.1 JP 2018524396-A/323: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461296.1 JP 2018524396-A/315: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461288.1 JP 2018524396-A/307: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461280.1 JP 2018524396-A/299: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461272.1 JP 2018524396-A/291: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCAACC
>MB461264.1 JP 2018524396-A/283: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCAACC
>MB461256.1 JP 2018524396-A/275: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461248.1 JP 2018524396-A/267: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461240.1 JP 2018524396-A/259: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
TGGGCATCT
>MB461232.1 JP 2018524396-A/251: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461224.1 JP 2018524396-A/243: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461216.1 JP 2018524396-A/235: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCAACC
>MB461208.1 JP 2018524396-A/227: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCAACC
>MB461200.1 JP 2018524396-A/219: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461192.1 JP 2018524396-A/211: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461184.1 JP 2018524396-A/203: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461176.1 JP 2018524396-A/195: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461168.1 JP 2018524396-A/187: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461160.1 JP 2018524396-A/179: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461152.1 JP 2018524396-A/171: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461144.1 JP 2018524396-A/163: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461136.1 JP 2018524396-A/155: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461128.1 JP 2018524396-A/147: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461120.1 JP 2018524396-A/139: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461112.1 JP 2018524396-A/131: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GATGCATCC
>MB461104.1 JP 2018524396-A/123: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461096.1 JP 2018524396-A/115: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461088.1 JP 2018524396-A/107: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461080.1 JP 2018524396-A/99: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GCTGCATCC
>MB461072.1 JP 2018524396-A/91: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461064.1 JP 2018524396-A/83: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB461056.1 JP 2018524396-A/75: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
ACTGCATCC
>MB461048.1 JP 2018524396-A/67: ANTI-PSMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, AND USES THEREOF
GGTGCATCC
>MB460549.1 JP 2018523490-A/5: ANTIBODY FOR DETERMINING SEX OF SPERM, AND USE THEREOF
CTTGTATCC
>MB460547.1 JP 2018523490-A/3: ANTIBODY FOR DETERMINING SEX OF SPERM, AND USE THEREOF
GCAAGACCA
>MB460404.1 JP 2018523480-A/9: CHLOROPLAST TRANSIT PEPTIDES
GCTTCTTCT
>MB459102.1 JP 2018522565-A/358: PROMOTER VARIANTS
TCCGGGGAT
>MB459100.1 JP 2018522565-A/356: PROMOTER VARIANTS
TCCCCGGAA
>MB459095.1 JP 2018522565-A/351: PROMOTER VARIANTS
TACCCCACC
>MB459051.1 JP 2018522565-A/307: PROMOTER VARIANTS
ATTTTGCGC
>MB459044.1 JP 2018522565-A/300: PROMOTER VARIANTS
CATATGCGC
>MB459029.1 JP 2018522565-A/285: PROMOTER VARIANTS
AACCCCACT
>MB459015.1 JP 2018522565-A/271: PROMOTER VARIANTS
TCCCTGGAG
>MB458746.1 JP 2018522565-A/2: PROMOTER VARIANTS
ATAAATGGA
>MB458181.1 JP 2018522027-A/88: COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1
TGGGCCTCT
>MB458170.1 JP 2018522027-A/77: COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1
TGGGCCTCC
>MB458156.1 JP 2018522027-A/63: COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1
TGGGCATCC
>MB456115.1 JP 2018518199-A/39: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GNNGTGGNC
>MB456114.1 JP 2018518199-A/38: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CTNNGCACN
>MB456113.1 JP 2018518199-A/37: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TGNNCNNTT
>MB456112.1 JP 2018518199-A/36: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CNTGNNCGA
>MB456111.1 JP 2018518199-A/35: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTNTATTNT
>MB456110.1 JP 2018518199-A/34: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CCGGNNGNG
>MB456109.1 JP 2018518199-A/33: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GNNCNGATT
>MB456108.1 JP 2018518199-A/32: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CNNACNANC
>MB456107.1 JP 2018518199-A/31: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNGNAANTT
>MB456106.1 JP 2018518199-A/30: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTTNGNNTA
>MB456105.1 JP 2018518199-A/29: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCCNACNNT
>MB456104.1 JP 2018518199-A/28: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TTGCANNNC
>MB456103.1 JP 2018518199-A/27: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GTNCCGCNC
>MB456102.1 JP 2018518199-A/26: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CGANCNACC
>MB456101.1 JP 2018518199-A/25: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CANNANGNT
>MB456100.1 JP 2018518199-A/24: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNCGNATTN
>MB456099.1 JP 2018518199-A/23: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NACACNNAA
>MB456098.1 JP 2018518199-A/22: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GANNCCGGC
>MB456097.1 JP 2018518199-A/21: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNANTNGAC
>MB456096.1 JP 2018518199-A/20: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCGGTTTTN
>MB456095.1 JP 2018518199-A/19: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCAAAAANN
>MB456094.1 JP 2018518199-A/18: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
AGTNCANNG
>MB456093.1 JP 2018518199-A/17: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CACCTNTNC
>MB456092.1 JP 2018518199-A/16: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCCNACNNT
>MB456091.1 JP 2018518199-A/15: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ANNAANGCN
>MB456090.1 JP 2018518199-A/14: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ANATATNNG
>MB456089.1 JP 2018518199-A/13: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTTNCGTNG
>MB456088.1 JP 2018518199-A/12: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ATTNNCNTG
>MB456087.1 JP 2018518199-A/11: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTNNNGAGC
>MB456086.1 JP 2018518199-A/10: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTGCCNGCG
>MB456085.1 JP 2018518199-A/9: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GGGNCGNNG
>MB456084.1 JP 2018518199-A/8: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TGCNAAGNN
>MB456083.1 JP 2018518199-A/7: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ANCAGCATG
>MB456082.1 JP 2018518199-A/6: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CANANATNN
>MB456081.1 JP 2018518199-A/5: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GGGNANNCA
>MB456080.1 JP 2018518199-A/4: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TTGCANATT
>MB456079.1 JP 2018518199-A/3: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GTNNANGAT
>MB456078.1 JP 2018518199-A/2: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNGCANANC
>MB456077.1 JP 2018518199-A/1: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CANANATNN
>MB450113.1 JP 2018143252-A/200: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450105.1 JP 2018143252-A/192: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450096.1 JP 2018143252-A/183: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450088.1 JP 2018143252-A/175: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
ACTACATCC
>MB450080.1 JP 2018143252-A/167: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
AAGGCGTCT
>MB450072.1 JP 2018143252-A/159: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450064.1 JP 2018143252-A/151: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GGTGCATCC
>MB450056.1 JP 2018143252-A/143: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450048.1 JP 2018143252-A/135: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450040.1 JP 2018143252-A/127: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
TCTGCATCC
>MB450032.1 JP 2018143252-A/119: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450024.1 JP 2018143252-A/111: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450016.1 JP 2018143252-A/103: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450008.1 JP 2018143252-A/95: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB450000.1 JP 2018143252-A/87: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
ACTGCATCC
>MB449992.1 JP 2018143252-A/79: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB449984.1 JP 2018143252-A/71: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB449976.1 JP 2018143252-A/63: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB449968.1 JP 2018143252-A/55: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB449960.1 JP 2018143252-A/47: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
TGGGCATCT
>MB449952.1 JP 2018143252-A/39: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
AGTGCATCC
>MB449944.1 JP 2018143252-A/31: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB449936.1 JP 2018143252-A/23: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>MB449928.1 JP 2018143252-A/15: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
TGGGCATCT
>MB449920.1 JP 2018143252-A/7: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
AAGGCGTCT
>MB449576.1 JP 2018135396-A/53: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
CAGGCAGGC
>MB449570.1 JP 2018135396-A/47: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
GCAGCAGCA
>MB449566.1 JP 2018135396-A/43: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
AGCAGCAGC
>MB449562.1 JP 2018135396-A/39: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
CAGCAGCAG
>MB449394.1 JP 2018086010-A/17: Modified Oligonucleotides for Telomerase Inhibition
CAGTTAGGG
>MB449393.1 JP 2018086010-A/16: Modified Oligonucleotides for Telomerase Inhibition
GGGTTAGAC
>MB444531.1 JP 2018126153-A/63: IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
GCCGCCACC
>MB474341.1 JP 2019526285-A/22: Gold Optimized CAR T-cells
CTGCTGCTG
>MB474338.1 JP 2019526285-A/19: Gold Optimized CAR T-cells
TTATTTATT
>MB474333.1 JP 2019526285-A/14: Gold Optimized CAR T-cells
NNTTNNTTT
>MB437504.1 JP 2018086005-A/74: TEM-1 DIAGNOSTIC ANTIBODIES
AATATAAAT
>MB437496.1 JP 2018086005-A/66: TEM-1 DIAGNOSTIC ANTIBODIES
TATGTCTCA
>MB437488.1 JP 2018086005-A/58: TEM-1 DIAGNOSTIC ANTIBODIES
TATGTCTCA
>MB437480.1 JP 2018086005-A/50: TEM-1 DIAGNOSTIC ANTIBODIES
CGGATGTCC
>MB437472.1 JP 2018086005-A/42: TEM-1 DIAGNOSTIC ANTIBODIES
TGGGCATCC
>MB437464.1 JP 2018086005-A/34: TEM-1 DIAGNOSTIC ANTIBODIES
CGGATGTCC
>MB437456.1 JP 2018086005-A/26: TEM-1 DIAGNOSTIC ANTIBODIES
TGGGCATCC
>MB437448.1 JP 2018086005-A/18: TEM-1 DIAGNOSTIC ANTIBODIES
GATGCCTCA
>MB437440.1 JP 2018086005-A/10: TEM-1 DIAGNOSTIC ANTIBODIES
ACGGCATCC
>MB437432.1 JP 2018086005-A/2: TEM-1 DIAGNOSTIC ANTIBODIES
TTGGTATCC
>MB472040.1 WO 2019194236-A/1: METHOD FOR CONTROLING AN AMOUNT OF GENE EXPRESSION
TRACATGMT
>MB472035.1 WO 2019194217-A/15: Anti-IL-18 antibody
CTGGTGTCT
>MB436373.1 JP 2018095647-A/2: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>MB469523.1 JP 2018524373-A/540: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCC
>MB469516.1 JP 2018524373-A/533: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469497.1 JP 2018524373-A/514: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACAAGC
>MB469474.1 JP 2018524373-A/491: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCA
>MB469467.1 JP 2018524373-A/484: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469452.1 JP 2018524373-A/469: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCA
>MB469226.1 JP 2018524373-A/243: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCA
>MB469215.1 JP 2018524373-A/232: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469204.1 JP 2018524373-A/221: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469193.1 JP 2018524373-A/210: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCA
>MB469187.1 JP 2018524373-A/204: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
TATGCTAGC
>MB469176.1 JP 2018524373-A/193: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469169.1 JP 2018524373-A/186: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACCTCC
>MB469154.1 JP 2018524373-A/171: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCA
>MB469148.1 JP 2018524373-A/165: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCC
>MB469137.1 JP 2018524373-A/154: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCAGC
>MB469126.1 JP 2018524373-A/143: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCAGC
>MB469115.1 JP 2018524373-A/132: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACTTCC
>MB469104.1 JP 2018524373-A/121: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACTTCC
>MB469097.1 JP 2018524373-A/114: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GATACCAGC
>MB469079.1 JP 2018524373-A/96: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACCTCT
>MB469044.1 JP 2018524373-A/61: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCTTCA
>MB469429.1 JP 2018524373-A/446: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GGAACAAAG
>MB469414.1 JP 2018524373-A/431: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469403.1 JP 2018524373-A/420: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469397.1 JP 2018524373-A/414: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
TCTGCATCC
>MB469383.1 JP 2018524373-A/400: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
TGGGCTAGT
>MB469372.1 JP 2018524373-A/389: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACTTCC
>MB469365.1 JP 2018524373-A/382: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACCTCC
>MB469354.1 JP 2018524373-A/371: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469345.1 JP 2018524373-A/362: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACCTCC
>MB469333.1 JP 2018524373-A/350: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCA
>MB469327.1 JP 2018524373-A/344: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
CGGACTTCC
>MB469289.1 JP 2018524373-A/306: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCC
>MB469270.1 JP 2018524373-A/287: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCT
>MB469263.1 JP 2018524373-A/280: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GATACCAGC
>MB469252.1 JP 2018524373-A/269: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GATACCAGC
>MB469241.1 JP 2018524373-A/258: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GATACCAGC
>MB431821.1 JP 2018064580-A/43: MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF
CTGGCGAGC
>MB431814.1 JP 2018064580-A/36: MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF
CGTGCATCC
>MB431798.1 JP 2018064580-A/20: MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF
AAAGTTTCC
>MB431745.1 JP 2018050636-A/27: Materials and Methods for Respiratory Disease Control in Canines
GATGTACCC
>MB469037.1 JP 2018524373-A/54: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB469022.1 JP 2018524373-A/39: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCA
>MB469016.1 JP 2018524373-A/33: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACGCCTCT
>MB469010.1 JP 2018524373-A/27: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GATACCTCA
>MB468999.1 JP 2018524373-A/16: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB468988.1 JP 2018524373-A/5: DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
GACACATCC
>MB431743.1 JP 2018050636-A/25: Materials and Methods for Respiratory Disease Control in Canines
ACAATGAGT
>MB431738.1 JP 2018050636-A/20: Materials and Methods for Respiratory Disease Control in Canines
AGAACTGGG
>MB431737.1 JP 2018050636-A/19: Materials and Methods for Respiratory Disease Control in Canines
CAAACCAGA
>MB431736.1 JP 2018050636-A/18: Materials and Methods for Respiratory Disease Control in Canines
CCGTTGGTC
>MB431735.1 JP 2018050636-A/17: Materials and Methods for Respiratory Disease Control in Canines
GAGAGTTGG
>MB466019.1 JP 2018526029-A/118: DETECTING GASTRIC NEOPLASM
CCACGGACG
>MB466018.1 JP 2018526029-A/117: DETECTING GASTRIC NEOPLASM
GACGCGGAG
>MB468120.1 JP 2018528272-A/2: SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO
AAGCTTTCC
>MB468016.1 JP 2018525037-A/3: POLYNUCLEOTIDE NANOPARTICLES FOR THE MODULATION OF GENE EXPRESSION AND USES THEREOF
TCAAGAAAC
>MB465664.1 JP 2018525033-A/26: Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
GCCGCCACC
>MB430112.1 JP 2019522972-A/6077: Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
CTCAACAGA
>MB430111.1 JP 2019522972-A/6076: Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
GGAATTTGT
>MB430110.1 JP 2019522972-A/6075: Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
TATTTAGCA
>MB422910.1 WO 2019181946-A/9: Nucleic Acid With Reduced Toxicity
CTAGGTCGT
>LY680716.1 KR 1020190020338-A/768: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTCACGTAA
>LY680715.1 KR 1020190020338-A/767: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATTGTCGCA
>LY680714.1 KR 1020190020338-A/766: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGTACCGTT
>LY680713.1 KR 1020190020338-A/765: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATAGACGCA
>LY680712.1 KR 1020190020338-A/764: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GATAGTGTG
>LY680711.1 KR 1020190020338-A/763: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TAATTGCGC
>LY680710.1 KR 1020190020338-A/762: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGTCCTGTT
>LY680709.1 KR 1020190020338-A/761: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CCATGTACT
>LY680708.1 KR 1020190020338-A/760: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATTCGCACA
>LY680707.1 KR 1020190020338-A/759: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AATCAGGAC
>LY680706.1 KR 1020190020338-A/758: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTGAACGCT
>LY680705.1 KR 1020190020338-A/757: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AACATTGCG
>LY680704.1 KR 1020190020338-A/756: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGTACGTCT
>LY680703.1 KR 1020190020338-A/755: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAATGTCAC
>LY680702.1 KR 1020190020338-A/754: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TAGAACGGT
>LY680701.1 KR 1020190020338-A/753: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AACTACGGT
>LY680700.1 KR 1020190020338-A/752: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TACTTACGC
>LY680699.1 KR 1020190020338-A/751: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATACAGCAC
>LY680698.1 KR 1020190020338-A/750: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGTCGACA
>LY680697.1 KR 1020190020338-A/749: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTCGTATAC
>LY680696.1 KR 1020190020338-A/748: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAACGTTAC
>LY680695.1 KR 1020190020338-A/747: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATCACGTG
>LY680694.1 KR 1020190020338-A/746: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CGTATACCT
>LY680693.1 KR 1020190020338-A/745: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CATAACGAG
>LY680692.1 KR 1020190020338-A/744: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TACTAACCG
>LY680691.1 KR 1020190020338-A/743: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGTCACAGA
>LY680690.1 KR 1020190020338-A/742: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGCGATTA
>LY680689.1 KR 1020190020338-A/741: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GATGCGATA
>LY680688.1 KR 1020190020338-A/740: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GATGACGTA
>LY680687.1 KR 1020190020338-A/739: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATGTGCAC
>LY680686.1 KR 1020190020338-A/738: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AATTCACGC
>LY680685.1 KR 1020190020338-A/737: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATACAGTCC
>LY680684.1 KR 1020190020338-A/736: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CGAGAGTAT
>LY680683.1 KR 1020190020338-A/735: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GGTCGTTAT
>LY680682.1 KR 1020190020338-A/734: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTGTTATCG
>LY680681.1 KR 1020190020338-A/733: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GACACTGAA
>LY680680.1 KR 1020190020338-A/732: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTGTTAACG
>LY680679.1 KR 1020190020338-A/731: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTCGCGTTA
>LY680678.1 KR 1020190020338-A/730: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGCCTTACA
>LY680677.1 KR 1020190020338-A/729: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGCGTTAT
>LY680676.1 KR 1020190020338-A/728: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGCATAGTG
>LY680675.1 KR 1020190020338-A/727: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TAAGACGGT
>LY680674.1 KR 1020190020338-A/726: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CATCATGTC
>LY680673.1 KR 1020190020338-A/725: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCGTTAGTC
>LY680672.1 KR 1020190020338-A/724: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AATCACGTG
>LY680671.1 KR 1020190020338-A/723: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AATGCCGTA
>LY680670.1 KR 1020190020338-A/722: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TAAGACACG
>LY680669.1 KR 1020190020338-A/721: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCACCGTA
>LY680668.1 KR 1020190020338-A/720: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACTTAGACG
>LY680667.1 KR 1020190020338-A/719: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATATCTGCG
>LY680666.1 KR 1020190020338-A/718: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GATAAGCGT
>LY680665.1 KR 1020190020338-A/717: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGCGCATA
>LY680664.1 KR 1020190020338-A/716: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CCGATAACA
>LY680663.1 KR 1020190020338-A/715: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATGACGCA
>LY680662.1 KR 1020190020338-A/714: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTACGTTGT
>LY680661.1 KR 1020190020338-A/713: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATAACGTGC
>LY680660.1 KR 1020190020338-A/712: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGCCGTTA
>LY680659.1 KR 1020190020338-A/711: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTAATCGTG
>LY680658.1 KR 1020190020338-A/710: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACTTAGCGT
>LY680657.1 KR 1020190020338-A/709: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCACGTGT
>LY680656.1 KR 1020190020338-A/708: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTACCTTAG
>LY680655.1 KR 1020190020338-A/707: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTAATCGAG
>LY680654.1 KR 1020190020338-A/706: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGTCCGTAA
>LY680653.1 KR 1020190020338-A/705: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGCGACTTA
>LY680652.1 KR 1020190020338-A/704: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGACTGTAC
>LY680651.1 KR 1020190020338-A/703: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGTGTTAC
>LY680650.1 KR 1020190020338-A/702: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTCGTGCAT
>LY680649.1 KR 1020190020338-A/701: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGCACGTAC
>LY680648.1 KR 1020190020338-A/700: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCGTCAGG
>LY680647.1 KR 1020190020338-A/699: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TACACTGCG
>LY680646.1 KR 1020190020338-A/698: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GACGTCTGA
>LY680645.1 KR 1020190020338-A/697: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGTCGACG
>LY680644.1 KR 1020190020338-A/696: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGGTGAGG
>LY680643.1 KR 1020190020338-A/695: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTCGAGATC
>LY680642.1 KR 1020190020338-A/694: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATACCTGGC
>LY680641.1 KR 1020190020338-A/693: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATAAGCGT
>LY680640.1 KR 1020190020338-A/692: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AAGACGTTA
>LY680639.1 KR 1020190020338-A/691: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TAGGACAAT
>LY680638.1 KR 1020190020338-A/690: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATTAACGCT
>LY680637.1 KR 1020190020338-A/689: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATGACACT
>LY680636.1 KR 1020190020338-A/688: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTAGCGTTA
>LY680635.1 KR 1020190020338-A/687: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGTATACAC
>LY680634.1 KR 1020190020338-A/686: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATTATGCGA
>LY680633.1 KR 1020190020338-A/685: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGACGTTA
>LY680632.1 KR 1020190020338-A/684: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGTAACTGT
>LY680631.1 KR 1020190020338-A/683: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATATCTACG
>LY680630.1 KR 1020190020338-A/682: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CATATTACG
>LY680629.1 KR 1020190020338-A/681: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACATTAAGC
>LY680628.1 KR 1020190020338-A/680: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACTGCATTA
>LY680627.1 KR 1020190020338-A/679: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATACACTG
>LY680626.1 KR 1020190020338-A/678: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GACTGTAAT
>LY680625.1 KR 1020190020338-A/677: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CACACTTAT
>LY680624.1 KR 1020190020338-A/676: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCAATAACG
>LY680623.1 KR 1020190020338-A/675: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CAGTATGTA
>LY680622.1 KR 1020190020338-A/674: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TAACGTATG
>LY680621.1 KR 1020190020338-A/673: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTGCTACAT
>LY679788.1 KR 1020190034532-A/33: GPR156 VARIANTS AND USES THEREOF
TCTCCCCAT
>LY679787.1 KR 1020190034532-A/32: GPR156 VARIANTS AND USES THEREOF
AGAGGGGTC
>LY679786.1 KR 1020190034532-A/31: GPR156 VARIANTS AND USES THEREOF
TCTCCCCAG
>LY679712.1 KR 1020190065999-A/379: CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
GCCGCCACC
>LY711804.1 KR 1020190075133-A/85: ANTIGEN-BINDING PROTEINS THAT ANTAGONIZE LEPTIN RECEPTOR
GGTGCATCC
>LY711768.1 KR 1020190075133-A/13: ANTIGEN-BINDING PROTEINS THAT ANTAGONIZE LEPTIN RECEPTOR
GCTGCATCC
>LY711365.1 KR 1020190065479-A/24: METHODS FOR RAPID AND SENSITIVE DETECTION OF HOTSPOT MUTATIONS
ATGACTTAC
>LY711363.1 KR 1020190065479-A/22: METHODS FOR RAPID AND SENSITIVE DETECTION OF HOTSPOT MUTATIONS
CGGGTCCCC
>LY711216.1 KR 1020190065455-A/69: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711211.1 KR 1020190065455-A/64: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGACGTTCT
>LY711210.1 KR 1020190065455-A/63: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGACGTTCT
>LY711206.1 KR 1020190065455-A/59: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGACGTTCA
>LY711205.1 KR 1020190065455-A/58: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
GACGTTCTT
>LY711202.1 KR 1020190065455-A/55: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGACGTTCT
>LY711198.1 KR 1020190065455-A/51: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711197.1 KR 1020190065455-A/50: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711193.1 KR 1020190065455-A/46: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCA
>LY711192.1 KR 1020190065455-A/45: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
GTCGTTCTT
>LY711190.1 KR 1020190065455-A/43: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711178.1 KR 1020190065455-A/31: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TCGTTCTTC
>LY711177.1 KR 1020190065455-A/30: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTGTCGTT
>LY711176.1 KR 1020190065455-A/29: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TTGTCGTTC
>LY711172.1 KR 1020190065455-A/25: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGACGTTCT
>LY711171.1 KR 1020190065455-A/24: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711170.1 KR 1020190065455-A/23: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711169.1 KR 1020190065455-A/22: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711168.1 KR 1020190065455-A/21: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711167.1 KR 1020190065455-A/20: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGACGTTCT
>LY711166.1 KR 1020190065455-A/19: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGACAT
>LY711165.1 KR 1020190065455-A/18: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711164.1 KR 1020190065455-A/17: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711163.1 KR 1020190065455-A/16: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711161.1 KR 1020190065455-A/14: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TTGTCGTTA
>LY711158.1 KR 1020190065455-A/11: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCA
>LY711156.1 KR 1020190065455-A/9: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TTGTCGTTC
>LY711154.1 KR 1020190065455-A/7: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711152.1 KR 1020190065455-A/5: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711151.1 KR 1020190065455-A/4: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
GTCGTTCTT
>LY711148.1 KR 1020190065455-A/1: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TGTCGTTCT
>LY711046.1 KR 1020190062612-A/733: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LY711034.1 KR 1020190062612-A/709: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LY711022.1 KR 1020190062612-A/685: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LY711010.1 KR 1020190062612-A/661: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LY710998.1 KR 1020190062612-A/637: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LY710986.1 KR 1020190062612-A/613: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LY710974.1 KR 1020190062612-A/589: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GATGCATCC
>LY710962.1 KR 1020190062612-A/565: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LY710950.1 KR 1020190062612-A/541: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LY710938.1 KR 1020190062612-A/517: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LY710926.1 KR 1020190062612-A/493: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LY710914.1 KR 1020190062612-A/469: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LY710902.1 KR 1020190062612-A/445: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LY710890.1 KR 1020190062612-A/421: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LY710878.1 KR 1020190062612-A/397: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LY710866.1 KR 1020190062612-A/373: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LY710854.1 KR 1020190062612-A/349: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LY710842.1 KR 1020190062612-A/325: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LY710830.1 KR 1020190062612-A/301: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LY710818.1 KR 1020190062612-A/277: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LY710806.1 KR 1020190062612-A/253: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LY710794.1 KR 1020190062612-A/229: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LY710782.1 KR 1020190062612-A/205: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LY710770.1 KR 1020190062612-A/181: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LY710758.1 KR 1020190062612-A/157: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LY710746.1 KR 1020190062612-A/133: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GCTGCATCC
>LY710734.1 KR 1020190062612-A/109: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GCTGCATCC
>LY710722.1 KR 1020190062612-A/85: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TGGGCATCT
>LY710710.1 KR 1020190062612-A/61: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TGGGCCTCT
>LY710698.1 KR 1020190062612-A/37: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LY710686.1 KR 1020190062612-A/13: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LY710461.1 KR 1020190057160-A/53: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGGCAGGC
>LY710455.1 KR 1020190057160-A/47: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
GCAGCAGCA
>LY710451.1 KR 1020190057160-A/43: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
AGCAGCAGC
>LY710447.1 KR 1020190057160-A/39: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGCAGCAG
>LY709990.1 KR 1020190060829-A/2: METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE
GCCACCATG
>LY709171.1 KR 1020190059312-A/18: METHODS FOR SCREENING FOR MODULATORS OF GDF15-LIKE BIOLOGICAL ACTIVITY
GCCGCCACC
>LY672946.1 KR 1020190018166-A/349: ANTI-C5 ANTIBODIES AND USES THEREOF
GATGCATCC
>LY672938.1 KR 1020190018166-A/333: ANTI-C5 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY672930.1 KR 1020190018166-A/317: ANTI-C5 ANTIBODIES AND USES THEREOF
GATGCATCC
>LY672922.1 KR 1020190018166-A/301: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672902.1 KR 1020190018166-A/261: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672894.1 KR 1020190018166-A/245: ANTI-C5 ANTIBODIES AND USES THEREOF
GATGCATCC
>LY672886.1 KR 1020190018166-A/229: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672878.1 KR 1020190018166-A/213: ANTI-C5 ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LY672870.1 KR 1020190018166-A/197: ANTI-C5 ANTIBODIES AND USES THEREOF
GATGCATCC
>LY672862.1 KR 1020190018166-A/181: ANTI-C5 ANTIBODIES AND USES THEREOF
ACTGCATCC
>LY672854.1 KR 1020190018166-A/165: ANTI-C5 ANTIBODIES AND USES THEREOF
ACTGCATCC
>LY672838.1 KR 1020190018166-A/133: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672830.1 KR 1020190018166-A/117: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672826.1 KR 1020190018166-A/109: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672818.1 KR 1020190018166-A/93: ANTI-C5 ANTIBODIES AND USES THEREOF
GATGCATCG
>LY672810.1 KR 1020190018166-A/77: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672802.1 KR 1020190018166-A/61: ANTI-C5 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY672794.1 KR 1020190018166-A/45: ANTI-C5 ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LY672786.1 KR 1020190018166-A/29: ANTI-C5 ANTIBODIES AND USES THEREOF
GATGCATCC
>LY672778.1 KR 1020190018166-A/13: ANTI-C5 ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LY672320.1 KR 1020190030206-A/349: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672312.1 KR 1020190030206-A/333: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672304.1 KR 1020190030206-A/317: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672296.1 KR 1020190030206-A/301: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
AAGATTTCT
>LY672288.1 KR 1020190030206-A/285: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672280.1 KR 1020190030206-A/269: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672272.1 KR 1020190030206-A/253: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672264.1 KR 1020190030206-A/237: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672256.1 KR 1020190030206-A/221: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCT
>LY672248.1 KR 1020190030206-A/205: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCGTCC
>LY672240.1 KR 1020190030206-A/189: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
TTTACATCC
>LY672232.1 KR 1020190030206-A/173: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672224.1 KR 1020190030206-A/157: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GCTGCATCC
>LY672216.1 KR 1020190030206-A/141: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GCTGCATCC
>LY672208.1 KR 1020190030206-A/125: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GCTGCGTCC
>LY672200.1 KR 1020190030206-A/109: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GATGCATCC
>LY672192.1 KR 1020190030206-A/93: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GCTGCATCC
>LY672184.1 KR 1020190030206-A/77: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
TCTGCATCC
>LY672176.1 KR 1020190030206-A/61: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GCTGCATCC
>LY672168.1 KR 1020190030206-A/45: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GGTGCATCC
>LY672160.1 KR 1020190030206-A/29: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GCTGCATCC
>LY672152.1 KR 1020190030206-A/13: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE
GCTGCATCC
>LY671566.1 KR 1020190003862-A/19: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>LY704545.1 KR 1020190040098-A/77: Antisense nucleic acids
TGGAGTTCC
>LY703722.1 KR 1020190037361-A/280: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703702.1 KR 1020190037361-A/260: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703692.1 KR 1020190037361-A/250: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGCGACATC
>LY703682.1 KR 1020190037361-A/240: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703672.1 KR 1020190037361-A/230: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703662.1 KR 1020190037361-A/220: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703652.1 KR 1020190037361-A/210: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703642.1 KR 1020190037361-A/200: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703632.1 KR 1020190037361-A/190: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703622.1 KR 1020190037361-A/180: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703612.1 KR 1020190037361-A/170: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703602.1 KR 1020190037361-A/160: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703592.1 KR 1020190037361-A/150: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LY703218.1 KR 1020190040320-A/589: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY703210.1 KR 1020190040320-A/573: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703202.1 KR 1020190040320-A/557: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATTCATCC
>LY703194.1 KR 1020190040320-A/541: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GGTGCATCC
>LY703186.1 KR 1020190040320-A/525: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703178.1 KR 1020190040320-A/509: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY703170.1 KR 1020190040320-A/493: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703162.1 KR 1020190040320-A/477: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY703154.1 KR 1020190040320-A/461: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703146.1 KR 1020190040320-A/445: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY703138.1 KR 1020190040320-A/429: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703130.1 KR 1020190040320-A/413: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATTCATCC
>LY703122.1 KR 1020190040320-A/397: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GGTGCATCC
>LY703114.1 KR 1020190040320-A/381: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703106.1 KR 1020190040320-A/365: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY703098.1 KR 1020190040320-A/349: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703090.1 KR 1020190040320-A/333: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GGTGCATCC
>LY703082.1 KR 1020190040320-A/317: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GTTGCATCC
>LY668793.1 KR 1020190026670-A/492: POLYNUCLEOTIDES ENCODING RELAXIN
CCRCCATGG
>LY703074.1 KR 1020190040320-A/301: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATTC
>LY703066.1 KR 1020190040320-A/285: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GTTGTATCC
>LY703058.1 KR 1020190040320-A/269: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703050.1 KR 1020190040320-A/253: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY703042.1 KR 1020190040320-A/237: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703034.1 KR 1020190040320-A/221: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
TTGGGTTCT
>LY703026.1 KR 1020190040320-A/205: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
TATGTTTCC
>LY703018.1 KR 1020190040320-A/189: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY703010.1 KR 1020190040320-A/173: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GTTGTATCA
>LY703002.1 KR 1020190040320-A/157: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY702994.1 KR 1020190040320-A/141: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY702986.1 KR 1020190040320-A/125: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY702978.1 KR 1020190040320-A/109: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY702970.1 KR 1020190040320-A/93: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY702962.1 KR 1020190040320-A/77: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY702954.1 KR 1020190040320-A/61: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY702946.1 KR 1020190040320-A/45: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GCTGCATCC
>LY702938.1 KR 1020190040320-A/29: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
TCTGCATCC
>LY702930.1 KR 1020190040320-A/13: ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
GATGCATCC
>LY668319.1 KR 1020190008339-A/68: ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
ACCACATCC
>LY668298.1 KR 1020190008339-A/39: ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
GCTGCAACA
>LY668293.1 KR 1020190008339-A/34: ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
CGTGCATCC
>LY668118.1 KR 1020190008890-A/232: POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF
CCRCCATGG
>LY667764.1 KR 1020190020297-A/269: ANTI-GITR ANTIBODIES AND USES THEREOF
GATGCATCC
>LY667756.1 KR 1020190020297-A/253: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667748.1 KR 1020190020297-A/237: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667740.1 KR 1020190020297-A/221: ANTI-GITR ANTIBODIES AND USES THEREOF
GATGCATCC
>LY667832.1 KR 1020190020297-A/405: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667788.1 KR 1020190020297-A/317: ANTI-GITR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY667780.1 KR 1020190020297-A/301: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667772.1 KR 1020190020297-A/285: ANTI-GITR ANTIBODIES AND USES THEREOF
GATGTATCC
>LY667732.1 KR 1020190020297-A/205: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667724.1 KR 1020190020297-A/189: ANTI-GITR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY667716.1 KR 1020190020297-A/173: ANTI-GITR ANTIBODIES AND USES THEREOF
ACTGCATCC
>LY667708.1 KR 1020190020297-A/157: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667700.1 KR 1020190020297-A/141: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667692.1 KR 1020190020297-A/125: ANTI-GITR ANTIBODIES AND USES THEREOF
AAGGTTTCT
>LY667684.1 KR 1020190020297-A/109: ANTI-GITR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY667676.1 KR 1020190020297-A/93: ANTI-GITR ANTIBODIES AND USES THEREOF
TCTACATCC
>LY667668.1 KR 1020190020297-A/77: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTACATCC
>LY667660.1 KR 1020190020297-A/61: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY667652.1 KR 1020190020297-A/45: ANTI-GITR ANTIBODIES AND USES THEREOF
GCTGCTTCC
>LY667644.1 KR 1020190020297-A/29: ANTI-GITR ANTIBODIES AND USES THEREOF
TCTGCATCC
>LY667636.1 KR 1020190020297-A/13: ANTI-GITR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY667260.1 KR 1020190017767-A/142: THERAPEUTIC USES OF A C-RAF INHIBITOR
TGGGCCTCT
>LY667249.1 KR 1020190017767-A/131: THERAPEUTIC USES OF A C-RAF INHIBITOR
TGGGCCTCC
>LY667235.1 KR 1020190017767-A/117: THERAPEUTIC USES OF A C-RAF INHIBITOR
TGGGCATCC
>LY663986.1 KR 1020190063445-A/15: A MICROPARTICLE COMPRISING HEDGEHOG PROTEIN AND BIOCOMPATIBLE MATERIAL AND A COMPOSITION FOR PREVENTING OR TREATING HAIR LOSS COMPRISING THE SAME
GACCACCCA
>LY663910.1 KR 1020190062290-A/32: miRNA polymer and the method for preparing the same
AGTGAGCGA
>LY663902.1 KR 1020190062290-A/24: miRNA polymer and the method for preparing the same
TCCACTCCA
>LY663901.1 KR 1020190062290-A/23: miRNA polymer and the method for preparing the same
AACAATACC
>LY662258.1 KR 1020190049483-A/11: BISPECIFIC ANTIBODY TARGETING SCF AND GALECTIN-1, AND USE THEREOF
AAGGTTTCT
>LY660605.1 KR 1020190011704-A/25: A nucleic acid complex and a nucleic acid complex pair capable of preventing amplification of a similar base sequence
GTAACTCGC
>LY660577.1 KR 1020190011703-A/25: A probe complex and a probe complex pair which can be used together with a nucleic acid complex pair
GTAACTCGC
>LY660549.1 KR 1020190011702-A/25: A kit including a nucleic acid complex pair used for detection a plurality of types of targets
GTAACTCGC
>LY660633.1 KR 1020190011705-A/25: A tagging primer kit including a forward primer with a tag and a reverse primer with a tag
GTAACTCGC
>LY694704.1 KR 1020190050991-A/2: SCALABLE BIOTECHNOLOGICAL PRODUCTION OF DNA SINGLE STRAND MOLECULES OF DEFINED SEQUENCE AND LENGTH
ACGTTGAAG
>LY694685.1 KR 1020190044079-A/305: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694677.1 KR 1020190044079-A/289: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694669.1 KR 1020190044079-A/273: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694661.1 KR 1020190044079-A/257: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694653.1 KR 1020190044079-A/241: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694645.1 KR 1020190044079-A/225: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694637.1 KR 1020190044079-A/209: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694629.1 KR 1020190044079-A/193: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694621.1 KR 1020190044079-A/177: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694613.1 KR 1020190044079-A/161: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TGGGCATCT
>LY694603.1 KR 1020190044079-A/141: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
ACTGCATTC
>LY694593.1 KR 1020190044079-A/121: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
GCTGCATCC
>LY694583.1 KR 1020190044079-A/101: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
GCTACATCC
>LY694573.1 KR 1020190044079-A/81: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
GCTGCATCC
>LY694563.1 KR 1020190044079-A/61: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
ACTGCATCC
>LY694555.1 KR 1020190044079-A/45: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TTGGGTTCT
>LY694547.1 KR 1020190044079-A/29: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TTGGGTTCT
>LY659774.1 KR 1020190011700-A/25: Nucleic acid complex pair, competitive structure, PCR kit using the same
GTAACTCGC
>LY694539.1 KR 1020190044079-A/13: METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TTGGGTTCT
>LY656606.1 KR 1020190057914-A/14: Monoclonal Antibodies for detecting Foot and Mouth Disease Virus serotype Asia1 and using the same
TATGCTTCC
>LY655976.1 KR 1020190051510-A/3: Method for Diagnosing Alzheimer's disease Using microRNA-485-3p
GTGTATGAC
>LY684739.1 KR 1020190034588-A/276: COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS ADN PD-1 INHIBITORS
TGGGCCTCT
>LY684728.1 KR 1020190034588-A/265: COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS ADN PD-1 INHIBITORS
TGGGCCTCC
>LY684714.1 KR 1020190034588-A/251: COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS ADN PD-1 INHIBITORS
TGGGCATCC
>LY685448.1 KR 1020190034626-A/131: MG7, SINGLE-CHAIN ANTIBODY SPECIFICALLY BINDING HIGHLY-GLYCOSYLATED CEA AND USE THEREOF IN DETECTION AND TREATMENT
GGGTCGCCC
>LY685312.1 KR 1020190045188-A/103: DETECTING HEPATOCELLULAR CARCINOMA
CCACGGACG
>LY685311.1 KR 1020190045188-A/102: DETECTING HEPATOCELLULAR CARCINOMA
GACGCGGAG
>LY647154.1 KR 1020190019291-A/4: Promoter of protein regulator of cytokinesis 1 for regulating cancer cell-specific gene expression and recombinant vector comprising the same
TGCCGGGAA
>LY684536.1 KR 1020190023110-A/188: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
TTGGGTTCT
>LY684526.1 KR 1020190023110-A/168: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
TGGGCATCT
>LY684516.1 KR 1020190023110-A/141: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
ACTGCATTC
>LY684506.1 KR 1020190023110-A/121: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
GCTGCATCC
>LY684496.1 KR 1020190023110-A/101: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
GCTACATCC
>LY684486.1 KR 1020190023110-A/81: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
GCTGCATCC
>LY684476.1 KR 1020190023110-A/61: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
ACTGCATCC
>LY684468.1 KR 1020190023110-A/45: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
TTGGGTTCT
>LY684460.1 KR 1020190023110-A/29: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
TTGGGTTCT
>LY682288.1 KR 1020190014125-A/35: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GGGTTAGGG
>LY682287.1 KR 1020190014125-A/34: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GAGTATGAG
>LY682280.1 KR 1020190014125-A/27: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
TTAGGGTTA
>LY682279.1 KR 1020190014125-A/26: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTT
>LY684452.1 KR 1020190023110-A/13: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
TTGGGTTCT
>LY645937.1 KR 1020190006154-A/30: Monoclonal Antibodies for detecting Foot and Mouth Disease Virus serotype O and using the same
CTTGTATCC
>LY645929.1 KR 1020190006154-A/22: Monoclonal Antibodies for detecting Foot and Mouth Disease Virus serotype O and using the same
CTTGTATCC
>MB197717.1 JP 2019516710-A/203: POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF
CCRCCATGG
>MB124212.1 JP 2019513371-A/2048: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
CCAACAATA
>MB124209.1 JP 2019513371-A/2045: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
TCACTTTGT
>MB121237.1 JP 2019511911-A/55: TGFBETA 2 ANTIBODIES
TGGGCCTCT
>MB121225.1 JP 2019511911-A/43: TGFBETA 2 ANTIBODIES
TGGGCCTCT
>MB121074.1 JP 2019512210-A/64: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
GCTGCATCC
>MB121067.1 JP 2019512210-A/57: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
GAAGCATCC
>MB121060.1 JP 2019512210-A/50: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TATGCATCC
>MB121057.1 JP 2019512210-A/47: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TATGCAGCC
>MB121054.1 JP 2019512210-A/44: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TGGGCTTCC
>MB121051.1 JP 2019512210-A/41: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
GAAGCATCC
>MB121048.1 JP 2019512210-A/38: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TGGGCTTCC
>MB120917.1 JP 2019513004-A/2: ANTIBODIES AND ELISAS FOR ALPHA-KLOTHO
TCGGCATCC
>MB120666.1 JP 2019511928-A/1: METHODS FOR PREVENTING OR REDUCING ACUTE KIDNEY INJURY
CCAGGTCAT
>LY623771.1 KR 1020180138205-A/44: ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY
CTGACCAGC
>LY623765.1 KR 1020180138205-A/32: ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY
CTGACCTCC
>LY589014.1 KR 1020180086206-A/31: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TTTTTTTAT
>LY589013.1 KR 1020180086206-A/30: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TTTTATTTT
>LY589012.1 KR 1020180086206-A/29: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
ATTTAAAAT
>LY589011.1 KR 1020180086206-A/28: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
ATTTATAAT
>LY589010.1 KR 1020180086206-A/27: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TATTATGTT
>LY589009.1 KR 1020180086206-A/26: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TATTAAAAT
>LY589008.1 KR 1020180086206-A/25: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TAATATAAT
>LY589007.1 KR 1020180086206-A/24: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TATTATAAT
>LY589006.1 KR 1020180086206-A/23: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATTAA
>LY589005.1 KR 1020180086206-A/22: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGATATCAT
>LY589004.1 KR 1020180086206-A/21: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATGAT
>LY589003.1 KR 1020180086206-A/20: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATAAT
>LY589002.1 KR 1020180086206-A/19: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATCAT
>LY587790.1 KR 1020180081042-A/118: DETECTING GASTRIC NEOPLASM
CCACGGACG
>LY587789.1 KR 1020180081042-A/117: DETECTING GASTRIC NEOPLASM
GACGCGGAG
>LY587566.1 KR 1020180080181-A/5: METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
AGCACTTTG
>LY618084.1 KR 1020180115330-A/323: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
CTGGCCTCC
>LY618078.1 KR 1020180115330-A/317: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
CTGGCATCC
>LY618072.1 KR 1020180115330-A/311: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GACACCAGC
>LY618066.1 KR 1020180115330-A/305: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GATACATCC
>LY618060.1 KR 1020180115330-A/279: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
TCTGCCTCC
>LY618054.1 KR 1020180115330-A/273: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
TCTGCATCC
>LY618048.1 KR 1020180115330-A/267: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
TTGGCCTCC
>LY618042.1 KR 1020180115330-A/261: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
CTGGCATCT
>LY618036.1 KR 1020180115330-A/255: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GACACATCC
>LY618030.1 KR 1020180115330-A/249: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GGCACATCC
>LY617745.1 KR 1020180112087-A/3: ANTIBODIES DIRECTED AGAINST ICOS AND USES THEREOF
TTTGATTAC
>LY578726.1 KR 1020180002776-A/37: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
GTTTTTGTA
>LY578710.1 KR 1020180002776-A/21: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
TCATTTGAG
>LY578708.1 KR 1020180002776-A/19: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
CGATTTGAG
>LY612461.1 KR 1020180105704-A/124: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
GCTGCATCC
>LY612454.1 KR 1020180105704-A/111: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
GAAGCATCC
>LY612447.1 KR 1020180105704-A/97: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TATGCATCC
>LY612444.1 KR 1020180105704-A/91: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TATGCAGCC
>LY612441.1 KR 1020180105704-A/86: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TGGGCTTCC
>LY612438.1 KR 1020180105704-A/80: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
GAAGCATCC
>LY612435.1 KR 1020180105704-A/74: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
TGGGCTTCC
>LY643630.1 KR 1020180137558-A/77: CONSTRUCT AND VECTOR FOR INTRAGENIC PLANT TRANSFORMATION
TCCGGATTA
>LY610302.1 KR 1020180101535-A/14: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
ATAGTATGC
>LY610240.1 KR 1020180107151-A/195: TGFBETA 2 ANTIBODIES
TGGGCCTCT
>LY610228.1 KR 1020180107151-A/183: TGFBETA 2 ANTIBODIES
TGGGCCTCT
>LY641496.1 KR 1020180124142-A/2048: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
CCAACAATA
>LY641493.1 KR 1020180124142-A/2045: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
TCACTTTGT
>LY574609.1 KR 1020180138018-A/5: Composition, kit for predicting risk of developing hypolipoproteinemia, and method using the same
CTGCTGCTG
>LY606419.1 KR 1020180088907-A/142: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCT
>LY606408.1 KR 1020180088907-A/131: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCC
>LY606394.1 KR 1020180088907-A/117: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCATCC
>LY606278.1 KR 1020180094977-A/142: COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND USES THEREOF
TGGGCCTCT
>LY606267.1 KR 1020180094977-A/131: COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND USES THEREOF
TGGGCCTCC
>LY606253.1 KR 1020180094977-A/117: COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND USES THEREOF
TGGGCATCC
>LY567166.1 KR 1020180103433-A/12: Arabidopsis BAG genes expressed in response to stress in the Arabidopsis plant
AAAACTTTC
>MP285922.1 Sequence 637 from Patent WO2019108900
TGGGCCTCT
>MP285877.1 Sequence 533 from Patent WO2019108900
TGGGCCTCT
>MP285249.1 Sequence 122 from Patent WO2019108983
GCTGCATCC
>MP285233.1 Sequence 106 from Patent WO2019108983
TGGGCATCT
>MP285217.1 Sequence 90 from Patent WO2019108983
GCTGCATCC
>MP245064.1 Sequence 25 from Patent EP3510151
GTTCCTGGC
>MP295953.1 Sequence 768 from Patent EP3480319
GTCACGTAA
>MP295952.1 Sequence 767 from Patent EP3480319
ATTGTCGCA
>MP295951.1 Sequence 766 from Patent EP3480319
TGTACCGTT
>MP295950.1 Sequence 765 from Patent EP3480319
ATAGACGCA
>MP295949.1 Sequence 764 from Patent EP3480319
GATAGTGTG
>MP295948.1 Sequence 763 from Patent EP3480319
TAATTGCGC
>MP295947.1 Sequence 762 from Patent EP3480319
TGTCCTGTT
>MP295946.1 Sequence 761 from Patent EP3480319
CCATGTACT
>MP295945.1 Sequence 760 from Patent EP3480319
ATTCGCACA
>MP295944.1 Sequence 759 from Patent EP3480319
AATCAGGAC
>MP295943.1 Sequence 758 from Patent EP3480319
TTGAACGCT
>MP295942.1 Sequence 757 from Patent EP3480319
AACATTGCG
>MP295941.1 Sequence 756 from Patent EP3480319
TGTACGTCT
>MP295940.1 Sequence 755 from Patent EP3480319
GAATGTCAC
>MP295939.1 Sequence 754 from Patent EP3480319
TAGAACGGT
>MP295938.1 Sequence 753 from Patent EP3480319
AACTACGGT
>MP295937.1 Sequence 752 from Patent EP3480319
TACTTACGC
>MP295936.1 Sequence 751 from Patent EP3480319
ATACAGCAC
>MP295935.1 Sequence 750 from Patent EP3480319
ATGTCGACA
>MP295934.1 Sequence 749 from Patent EP3480319
GTCGTATAC
>MP295933.1 Sequence 748 from Patent EP3480319
GAACGTTAC
>MP295932.1 Sequence 747 from Patent EP3480319
TATCACGTG
>MP295931.1 Sequence 746 from Patent EP3480319
CGTATACCT
>MP295930.1 Sequence 745 from Patent EP3480319
CATAACGAG
>MP295929.1 Sequence 744 from Patent EP3480319
TACTAACCG
>MP295928.1 Sequence 743 from Patent EP3480319
TGTCACAGA
>MP295927.1 Sequence 742 from Patent EP3480319
GAGCGATTA
>MP295926.1 Sequence 741 from Patent EP3480319
GATGCGATA
>MP295925.1 Sequence 740 from Patent EP3480319
GATGACGTA
>MP295924.1 Sequence 739 from Patent EP3480319
TATGTGCAC
>MP295923.1 Sequence 738 from Patent EP3480319
AATTCACGC
>MP295922.1 Sequence 737 from Patent EP3480319
ATACAGTCC
>MP295921.1 Sequence 736 from Patent EP3480319
CGAGAGTAT
>MP295920.1 Sequence 735 from Patent EP3480319
GGTCGTTAT
>MP295919.1 Sequence 734 from Patent EP3480319
CTGTTATCG
>MP295918.1 Sequence 733 from Patent EP3480319
GACACTGAA
>MP295917.1 Sequence 732 from Patent EP3480319
GTGTTAACG
>MP295916.1 Sequence 731 from Patent EP3480319
TTCGCGTTA
>MP295915.1 Sequence 730 from Patent EP3480319
TGCCTTACA
>MP295914.1 Sequence 729 from Patent EP3480319
GAGCGTTAT
>MP295913.1 Sequence 728 from Patent EP3480319
TGCATAGTG
>MP295912.1 Sequence 727 from Patent EP3480319
TAAGACGGT
>MP295911.1 Sequence 726 from Patent EP3480319
CATCATGTC
>MP295910.1 Sequence 725 from Patent EP3480319
TCGTTAGTC
>MP295909.1 Sequence 724 from Patent EP3480319
AATCACGTG
>MP295908.1 Sequence 723 from Patent EP3480319
AATGCCGTA
>MP295907.1 Sequence 722 from Patent EP3480319
TAAGACACG
>MP295906.1 Sequence 721 from Patent EP3480319
ATCACCGTA
>MP295905.1 Sequence 720 from Patent EP3480319
ACTTAGACG
>MP295904.1 Sequence 719 from Patent EP3480319
ATATCTGCG
>MP295903.1 Sequence 718 from Patent EP3480319
GATAAGCGT
>MP295902.1 Sequence 717 from Patent EP3480319
ATGCGCATA
>MP295901.1 Sequence 716 from Patent EP3480319
CCGATAACA
>MP295900.1 Sequence 715 from Patent EP3480319
TATGACGCA
>MP295899.1 Sequence 714 from Patent EP3480319
CTACGTTGT
>MP295898.1 Sequence 713 from Patent EP3480319
ATAACGTGC
>MP295897.1 Sequence 712 from Patent EP3480319
ATGCCGTTA
>MP295896.1 Sequence 711 from Patent EP3480319
GTAATCGTG
>MP295895.1 Sequence 710 from Patent EP3480319
ACTTAGCGT
>MP295894.1 Sequence 709 from Patent EP3480319
ATCACGTGT
>MP295893.1 Sequence 708 from Patent EP3480319
GTACCTTAG
>MP295892.1 Sequence 707 from Patent EP3480319
GTAATCGAG
>MP295891.1 Sequence 706 from Patent EP3480319
TGTCCGTAA
>MP295890.1 Sequence 705 from Patent EP3480319
TGCGACTTA
>MP295889.1 Sequence 704 from Patent EP3480319
AGACTGTAC
>MP295888.1 Sequence 703 from Patent EP3480319
GAGTGTTAC
>MP295887.1 Sequence 702 from Patent EP3480319
GTCGTGCAT
>MP295886.1 Sequence 701 from Patent EP3480319
TGCACGTAC
>MP295885.1 Sequence 700 from Patent EP3480319
ATCGTCAGG
>MP295884.1 Sequence 699 from Patent EP3480319
TACACTGCG
>MP295883.1 Sequence 698 from Patent EP3480319
GACGTCTGA
>MP295882.1 Sequence 697 from Patent EP3480319
ATGTCGACG
>MP295881.1 Sequence 696 from Patent EP3480319
ATGGTGAGG
>MP295880.1 Sequence 695 from Patent EP3480319
CTCGAGATC
>MP295879.1 Sequence 694 from Patent EP3480319
ATACCTGGC
>MP295878.1 Sequence 693 from Patent EP3480319
TATAAGCGT
>MP295877.1 Sequence 692 from Patent EP3480319
AAGACGTTA
>MP295876.1 Sequence 691 from Patent EP3480319
TAGGACAAT
>MP295875.1 Sequence 690 from Patent EP3480319
ATTAACGCT
>MP295874.1 Sequence 689 from Patent EP3480319
TATGACACT
>MP295873.1 Sequence 688 from Patent EP3480319
TTAGCGTTA
>MP295872.1 Sequence 687 from Patent EP3480319
AGTATACAC
>MP295871.1 Sequence 686 from Patent EP3480319
ATTATGCGA
>MP295870.1 Sequence 685 from Patent EP3480319
ATGACGTTA
>MP295869.1 Sequence 684 from Patent EP3480319
AGTAACTGT
>MP295868.1 Sequence 683 from Patent EP3480319
ATATCTACG
>MP295867.1 Sequence 682 from Patent EP3480319
CATATTACG
>MP295866.1 Sequence 681 from Patent EP3480319
ACATTAAGC
>MP295865.1 Sequence 680 from Patent EP3480319
ACTGCATTA
>MP295864.1 Sequence 679 from Patent EP3480319
TATACACTG
>MP295863.1 Sequence 678 from Patent EP3480319
GACTGTAAT
>MP295862.1 Sequence 677 from Patent EP3480319
CACACTTAT
>MP295861.1 Sequence 676 from Patent EP3480319
TCAATAACG
>MP295860.1 Sequence 675 from Patent EP3480319
CAGTATGTA
>MP295859.1 Sequence 674 from Patent EP3480319
TAACGTATG
>MP295858.1 Sequence 673 from Patent EP3480319
TTGCTACAT
>MP294450.1 Sequence 280 from Patent EP3508501
GGGGACATC
>MP294430.1 Sequence 260 from Patent EP3508501
GGGGACATC
>MP294420.1 Sequence 250 from Patent EP3508501
GGCGACATC
>MP294410.1 Sequence 240 from Patent EP3508501
GGGGACATC
>MP294400.1 Sequence 230 from Patent EP3508501
GGGGACATC
>MP294390.1 Sequence 220 from Patent EP3508501
GGGGACATC
>MP294380.1 Sequence 210 from Patent EP3508501
GGGGACATC
>MP294370.1 Sequence 200 from Patent EP3508501
GGGGACATC
>MP294360.1 Sequence 190 from Patent EP3508501
GGGGACATC
>MP292376.1 Sequence 1 from Patent EP3521485
AGCTGCTAT
>MP294350.1 Sequence 180 from Patent EP3508501
GGGGACATC
>MP294340.1 Sequence 170 from Patent EP3508501
GGGGACATC
>MP294330.1 Sequence 160 from Patent EP3508501
GGGGACATC
>MP294320.1 Sequence 150 from Patent EP3508501
GGGGACATC
>MP290264.1 Sequence 133 from Patent WO2019104160
TAGTAGTAG
>MP290263.1 Sequence 132 from Patent WO2019104160
TAATAATAA
>MP290262.1 Sequence 131 from Patent WO2019104160
TGATGATGA
>MP290261.1 Sequence 130 from Patent WO2019104160
TAATAGTAG
>MP290260.1 Sequence 129 from Patent WO2019104160
TAATGATGA
>MP290259.1 Sequence 128 from Patent WO2019104160
TGATAGTAG
>MP290258.1 Sequence 127 from Patent WO2019104160
TGATAATAA
>MP290257.1 Sequence 126 from Patent WO2019104160
TAATGATAG
>MP290256.1 Sequence 125 from Patent WO2019104160
TGATAGTAA
>MP290255.1 Sequence 124 from Patent WO2019104160
TGATAATAG
>MP287482.1 Sequence 133 from Patent WO2019104152
TAGTAGTAG
>MP287481.1 Sequence 132 from Patent WO2019104152
TAATAATAA
>MP287480.1 Sequence 131 from Patent WO2019104152
TGATGATGA
>MP287479.1 Sequence 130 from Patent WO2019104152
TAATAGTAG
>MP287478.1 Sequence 129 from Patent WO2019104152
TAATGATGA
>MP287477.1 Sequence 128 from Patent WO2019104152
TGATAGTAG
>MP287476.1 Sequence 127 from Patent WO2019104152
TGATAATAA
>MP287475.1 Sequence 126 from Patent WO2019104152
TAATGATAG
>MP287474.1 Sequence 125 from Patent WO2019104152
TGATAGTAA
>MP287473.1 Sequence 124 from Patent WO2019104152
TGATAATAG
>MP287447.1 Sequence 87 from Patent WO2019104152
CCRCCATGG
>MP290222.1 Sequence 87 from Patent WO2019104160
CCRCCATGG
>MP287374.1 Sequence 10 from Patent WO2019101604
TCGGCATCC
>MP287166.1 Sequence 45 from Patent WO2019108662
GCTGCATCC
>MP287150.1 Sequence 29 from Patent WO2019108662
TGGGCATCT
>MP287134.1 Sequence 13 from Patent WO2019108662
GCTGCATCC
>MP288761.1 Sequence 133 from Patent WO2019104195
TAGTAGTAG
>MP288760.1 Sequence 132 from Patent WO2019104195
TAATAATAA
>MP288759.1 Sequence 131 from Patent WO2019104195
TGATGATGA
>MP288758.1 Sequence 130 from Patent WO2019104195
TAATAGTAG
>MP288757.1 Sequence 129 from Patent WO2019104195
TAATGATGA
>MP288756.1 Sequence 128 from Patent WO2019104195
TGATAGTAG
>MP288755.1 Sequence 127 from Patent WO2019104195
TGATAATAA
>MP288754.1 Sequence 126 from Patent WO2019104195
TAATGATAG
>MP288753.1 Sequence 125 from Patent WO2019104195
TGATAGTAA
>MP288752.1 Sequence 124 from Patent WO2019104195
TGATAATAG
>MP288719.1 Sequence 87 from Patent WO2019104195
CCRCCATGG
>MP285987.1 Sequence 755 from Patent WO2019108900
TACACCTCC
>MP285986.1 Sequence 754 from Patent WO2019108900
TACACTAGC
>MP275322.1 Sequence 280 from Patent EP3495392
GGGGACATC
>MP275302.1 Sequence 260 from Patent EP3495392
GGGGACATC
>MP275292.1 Sequence 250 from Patent EP3495392
GGCGACATC
>MP275282.1 Sequence 240 from Patent EP3495392
GGGGACATC
>MP275272.1 Sequence 230 from Patent EP3495392
GGGGACATC
>MP275262.1 Sequence 220 from Patent EP3495392
GGGGACATC
>MP275252.1 Sequence 210 from Patent EP3495392
GGGGACATC
>MP275242.1 Sequence 200 from Patent EP3495392
GGGGACATC
>MP275232.1 Sequence 190 from Patent EP3495392
GGGGACATC
>MP275222.1 Sequence 180 from Patent EP3495392
GGGGACATC
>MP275212.1 Sequence 170 from Patent EP3495392
GGGGACATC
>MP275202.1 Sequence 160 from Patent EP3495392
GGGGACATC
>MP275192.1 Sequence 150 from Patent EP3495392
GGGGACATC
>MP272220.1 Sequence 20 from Patent EP3494975
CAGTTAGGG
>MP272219.1 Sequence 19 from Patent EP3494975
GGGTTAGAC
>MP266530.1 Sequence 48 from Patent WO2019089913
TGCCAAAGA
>MP252502.1 Sequence 36 from Patent EP3487998
RYRVASMNR
>MP252495.1 Sequence 29 from Patent EP3487998
AYRTATGBV
>MP241131.1 Sequence 47 from Patent WO2019143803
CCACCATGG
>MP239815.1 Sequence 11 from Patent WO2019142070
CCACCATGG
>MP241743.1 Sequence 103 from Patent EP3507298
CCACGGACG
>MP241742.1 Sequence 102 from Patent EP3507298
GACGCGGAG
>MP221762.1 Sequence 29 from Patent WO2019147867
GGTGCATCC
>MP221746.1 Sequence 13 from Patent WO2019147867
GGTGCATCC
>MP217038.1 Sequence 131 from Patent EP3492497
GGGTCGCCC
>MP207081.1 Sequence 1 from Patent WO2019159173
TTCCGGGAA
>MP205165.1 Sequence 50 from Patent WO2019086681
TTAACTTTA
>MP201499.1 Sequence 379 from Patent EP3475307
GCCGCCACC
>MP199575.1 Sequence 6 from Patent EP3480320
GCGGCCGCA
>MP187235.1 Sequence 16 from Patent EP3485912
TATGCTTCT
>MP187972.1 Sequence 637 from Patent WO2019099838
TGGGCCTCT
>MP187927.1 Sequence 533 from Patent WO2019099838
TGGGCCTCT
>MP184368.1 Sequence 2 from Patent EP3528852
GCCACCATG
>MP188037.1 Sequence 755 from Patent WO2019099838
TACACCTCC
>MP188036.1 Sequence 754 from Patent WO2019099838
TACACTAGC
>MP180828.1 Sequence 5 from Patent EP3494212
TTCAAGAGA
>MB029447.1 JP 2019511243-A/14: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
ATAGTATGC
>MB028339.1 JP 2019509031-A/266: METHODS AND COMPOSITIONS FOR MODIFYING A MUTANT DYSTROPHIN GENE IN A CELL'S GENOME
CTGAGAAGT
>MB028335.1 JP 2019509031-A/262: METHODS AND COMPOSITIONS FOR MODIFYING A MUTANT DYSTROPHIN GENE IN A CELL'S GENOME
AGCTTCTCA
>MB023705.1 JP 2019509012-A/295: NUCLEOBASE EDITORS AND USES THEREOF
GGSGGSGGS
>MB004890.1 JP 2017538427-A/423: CRISPR-BASED COMPOSITIONS AND METHODS OF USE
TTTCTTTGC
>MB004887.1 JP 2017538427-A/420: CRISPR-BASED COMPOSITIONS AND METHODS OF USE
AAGTGCCTG
>MB004884.1 JP 2017538427-A/417: CRISPR-BASED COMPOSITIONS AND METHODS OF USE
TGGAATATG
>MB004881.1 JP 2017538427-A/414: CRISPR-BASED COMPOSITIONS AND METHODS OF USE
ATGGTCAAG
>MB003721.1 JP 2017537641-A/5: EXPRESSION ELEMENT, EXPRESSION CASSETTE, AND VECTOR CONTAINING THE SAME
TAAGGAGGT
>MB022286.1 WO 2019077887-A/4: Logical engineering of D- and T-arms of tRNA that enhances D-amino acid and beta amino acid incorporation
AGCCTGGTA
>MB015818.1 JP 2018502922-A/7: METHODS AND COMPOSITIONS FOR EBOLA VIRUS VACCINATION
TCTCTCCNA
>MB013981.1 JP 2018501796-A/4: METHODS FOR TAGGING DNA-ENCODED LIBRARIES
TGGCTGAGG
>MA903654.1 JP 2018029625-A/183: Human Antibodies to Clostridium Difficile Toxins
GGTGCATCC
>MA903646.1 JP 2018029625-A/175: Human Antibodies to Clostridium Difficile Toxins
GGTACATCC
>MA903638.1 JP 2018029625-A/167: Human Antibodies to Clostridium Difficile Toxins
GGTGCATCC
>MA903630.1 JP 2018029625-A/159: Human Antibodies to Clostridium Difficile Toxins
GGTGCATCC
>MA903622.1 JP 2018029625-A/151: Human Antibodies to Clostridium Difficile Toxins
GATGCATCC
>MA903614.1 JP 2018029625-A/143: Human Antibodies to Clostridium Difficile Toxins
GCTGCATCC
>MA903606.1 JP 2018029625-A/135: Human Antibodies to Clostridium Difficile Toxins
GCTGCATCC
>MA903598.1 JP 2018029625-A/127: Human Antibodies to Clostridium Difficile Toxins
TCTGCATCC
>MA903590.1 JP 2018029625-A/119: Human Antibodies to Clostridium Difficile Toxins
TCTGCATCC
>MA903582.1 JP 2018029625-A/111: Human Antibodies to Clostridium Difficile Toxins
GCTGCATCC
>MA903574.1 JP 2018029625-A/103: Human Antibodies to Clostridium Difficile Toxins
GCTGCGTCC
>MA903566.1 JP 2018029625-A/95: Human Antibodies to Clostridium Difficile Toxins
GCTGCATCC
>MA903558.1 JP 2018029625-A/87: Human Antibodies to Clostridium Difficile Toxins
GGTGTTTCC
>MA903550.1 JP 2018029625-A/79: Human Antibodies to Clostridium Difficile Toxins
ACTGCATCC
>MA903542.1 JP 2018029625-A/71: Human Antibodies to Clostridium Difficile Toxins
GCTGCTTCC
>MA903534.1 JP 2018029625-A/63: Human Antibodies to Clostridium Difficile Toxins
AAGGCGTCT
>MA903526.1 JP 2018029625-A/55: Human Antibodies to Clostridium Difficile Toxins
GCTGCATCC
>MA903518.1 JP 2018029625-A/47: Human Antibodies to Clostridium Difficile Toxins
AGGGCGTCT
>MA903510.1 JP 2018029625-A/39: Human Antibodies to Clostridium Difficile Toxins
AAGGCGTCT
>MA903502.1 JP 2018029625-A/31: Human Antibodies to Clostridium Difficile Toxins
AAGGCGTCT
>MA903494.1 JP 2018029625-A/23: Human Antibodies to Clostridium Difficile Toxins
TGGGCATCT
>MA903486.1 JP 2018029625-A/15: Human Antibodies to Clostridium Difficile Toxins
TGGACATCT
>MB013965.1 JP 2018504896-A/11: PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULES
CGACGACGA
>MA903478.1 JP 2018029625-A/7: Human Antibodies to Clostridium Difficile Toxins
GGTACATCC
>MA901340.1 JP 2018035196-A/20: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
CAGTTAGGG
>MA901339.1 JP 2018035196-A/19: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
GGGTTAGAC
>MB013059.1 JP 2017538418-A/30: Methods and Compositions for Detecting Antibiotic Resistant Bacteria
AATAAATCA
>MA899636.1 JP 2018015010-A/1: ENGINEERING T-CELL RECEPTORS
TCTGCTAGC
>MA898771.1 JP 2018021076-A/35: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GGGTTAGGG
>MA898770.1 JP 2018021076-A/34: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GAGTATGAG
>MA898763.1 JP 2018021076-A/27: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
TTAGGGTTA
>MA898762.1 JP 2018021076-A/26: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTT
>MA898160.1 JP 2018002737-A/63: IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
GCCGCCACC
>MA897840.1 JP 2017225461-A/180: COMPOSITIONS AND METHOD FOR DETECTING HUMAN PARVOVIRUS NUCLEIC ACID AND FOR DETECTING HEPATITIS A VIRUS NUCLEIC ACIDS IN SINGLE-PLEX OR MULTIPLEX ASSAYS
CATGGACAG
>MA897587.1 JP 2018002728-A/53: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGGCAGGC
>MA897581.1 JP 2018002728-A/47: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
GCAGCAGCA
>MA897577.1 JP 2018002728-A/43: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
AGCAGCAGC
>MA897573.1 JP 2018002728-A/39: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGCAGCAG
>MA989727.1 JP 2017530968-A/39: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
CTTTACAAA
>MA989723.1 JP 2017530968-A/35: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
GCATTATCC
>MA989722.1 JP 2017530968-A/34: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
GCATTATCC
>MA989706.1 JP 2017530968-A/18: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
TTTACAAAA
>MA989705.1 JP 2017530968-A/17: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
CTTTACAAA
>MA989704.1 JP 2017530968-A/16: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
CTTGTAAAA
>MA879849.1 JP 2019500858-A/7: KITS FOR DETECTION OF HEPCIDIN
CGTGCATCC
>MA878625.1 JP 2018537130-A/31: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TTTTTTTAT
>MA878624.1 JP 2018537130-A/30: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TTTTATTTT
>MA878623.1 JP 2018537130-A/29: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
ATTTAAAAT
>MA878622.1 JP 2018537130-A/28: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
ATTTATAAT
>MA878621.1 JP 2018537130-A/27: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TATTATGTT
>MA878620.1 JP 2018537130-A/26: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TATTAAAAT
>MA878619.1 JP 2018537130-A/25: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TAATATAAT
>MA878618.1 JP 2018537130-A/24: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TATTATAAT
>MA878617.1 JP 2018537130-A/23: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATTAA
>MA878616.1 JP 2018537130-A/22: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGATATCAT
>MA878615.1 JP 2018537130-A/21: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATGAT
>MA878614.1 JP 2018537130-A/20: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATAAT
>MA878613.1 JP 2018537130-A/19: MODIFIED BIDIRECTIONAL CATALASE PROMOTER FROM BACILLUS
TGTTATCAT
>MA859907.1 JP 2018537087-A/43: VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
AGGAGCCTG
>MA859735.1 JP 2018537969-A/27: Modification of 3' Terminal Ends of Nucleic Acids by DNA Polymerase Theta
ATCGAGAGG
>MA886755.1 WO 2019049939-A/3: Methods and Compositions for Expanding Cells
CGGGGTGAC
>MA886279.1 JP 2019038823-A/103: Human Antibodies to PD-1
GCTGCATCC
>MA886271.1 JP 2019038823-A/95: Human Antibodies to PD-1
GGGGCAAGT
>MA886263.1 JP 2019038823-A/87: Human Antibodies to PD-1
GCTGCGTCC
>MA886255.1 JP 2019038823-A/79: Human Antibodies to PD-1
GCTGCATCC
>MA886247.1 JP 2019038823-A/71: Human Antibodies to PD-1
TCTGCATCC
>MA886239.1 JP 2019038823-A/63: Human Antibodies to PD-1
GGTGCATCC
>MA886231.1 JP 2019038823-A/55: Human Antibodies to PD-1
GCTGCATCC
>MA886223.1 JP 2019038823-A/47: Human Antibodies to PD-1
GCTGCATCC
>MA886183.1 JP 2019038823-A/7: Human Antibodies to PD-1
GCTGCATCC
>MA886215.1 JP 2019038823-A/39: Human Antibodies to PD-1
GCTGCATCC
>MA886207.1 JP 2019038823-A/31: Human Antibodies to PD-1
ACTGCATCC
>MA886199.1 JP 2019038823-A/23: Human Antibodies to PD-1
GGTGCATCC
>MA886191.1 JP 2019038823-A/15: Human Antibodies to PD-1
GGTGCATCC
>MA884172.1 JP 2019501660-A/21: RODENTS HAVING AN ENGINEERED HEAVY CHAIN DIVERSITY REGION
AGCTTCTTG
>MP144744.1 Sequence 149 from Patent WO2019067682
GCTGCATCC
>MP144680.1 Sequence 85 from Patent WO2019067682
TCTGCATCC
>MP144672.1 Sequence 77 from Patent WO2019067682
GGTGCATCC
>MP144664.1 Sequence 69 from Patent WO2019067682
GGTACATCC
>MP144760.1 Sequence 165 from Patent WO2019067682
GGTGCATCC
>MP142734.1 Sequence 492 from Patent EP3458034
CCRCCATGG
>MP140388.1 Sequence 84 from Patent EP3458106
CCRCCATGG
>MP135128.1 Sequence 10 from Patent EP3183266
GCCACATCC
>MP134317.1 Sequence 188 from Patent WO2019038771
CTTTTTTTT
>MP134312.1 Sequence 183 from Patent WO2019038771
CTATATATA
>MP134308.1 Sequence 179 from Patent WO2019038771
CTTTTTTTT
>MP134306.1 Sequence 177 from Patent WO2019038771
ATTTTTTTT
>MP134294.1 Sequence 165 from Patent WO2019038771
CTTTTTTTT
>MP134281.1 Sequence 152 from Patent WO2019038771
CTATATATA
>MP134253.1 Sequence 124 from Patent WO2019038771
CAAAAAAAA
>MP134242.1 Sequence 113 from Patent WO2019038771
AATATATAT
>MP134226.1 Sequence 97 from Patent WO2019038771
CAAATTATA
>MP134206.1 Sequence 77 from Patent WO2019038771
CTTTTTTTT
>MP134204.1 Sequence 75 from Patent WO2019038771
CTTTTTTTT
>MP134198.1 Sequence 69 from Patent WO2019038771
CTTTTTTTT
>MP134193.1 Sequence 64 from Patent WO2019038771
CTTTTTTTT
>MP130644.1 Sequence 305 from Patent WO2019040471
TGGGCATCT
>MP130628.1 Sequence 289 from Patent WO2019040471
TGGGCATCT
>MP130612.1 Sequence 273 from Patent WO2019040471
TGGGCATCT
>MP130596.1 Sequence 257 from Patent WO2019040471
TGGGCATCT
>MP130580.1 Sequence 241 from Patent WO2019040471
TGGGCATCT
>MP130564.1 Sequence 225 from Patent WO2019040471
TGGGCATCT
>MP130548.1 Sequence 209 from Patent WO2019040471
TGGGCATCT
>MP130532.1 Sequence 193 from Patent WO2019040471
TGGGCATCT
>MP130516.1 Sequence 177 from Patent WO2019040471
TGGGCATCT
>MP130500.1 Sequence 161 from Patent WO2019040471
TGGGCATCT
>MP130480.1 Sequence 141 from Patent WO2019040471
ACTGCATTC
>MP130460.1 Sequence 121 from Patent WO2019040471
GCTGCATCC
>MP130440.1 Sequence 101 from Patent WO2019040471
GCTACATCC
>MP130420.1 Sequence 81 from Patent WO2019040471
GCTGCATCC
>MP130400.1 Sequence 61 from Patent WO2019040471
ACTGCATCC
>MP130104.1 Sequence 229 from Patent EP3470432
GATGCATCC
>MP130080.1 Sequence 205 from Patent EP3470432
GTTGCATCC
>MP130056.1 Sequence 181 from Patent EP3470432
GCTGCATCC
>MP130032.1 Sequence 157 from Patent EP3470432
TTGGGTTCT
>MP130008.1 Sequence 133 from Patent EP3470432
AGTGCCTCC
>MP129984.1 Sequence 109 from Patent EP3470432
GCTGCATCC
>MP129960.1 Sequence 85 from Patent EP3470432
TTGGGTTCT
>MP129936.1 Sequence 61 from Patent EP3470432
GCTGTATCC
>MP129912.1 Sequence 37 from Patent EP3470432
GCTGCATCC
>MP129888.1 Sequence 13 from Patent EP3470432
GCTGCATCC
>MP130384.1 Sequence 45 from Patent WO2019040471
TTGGGTTCT
>MP130368.1 Sequence 29 from Patent WO2019040471
TTGGGTTCT
>MP130352.1 Sequence 13 from Patent WO2019040471
TTGGGTTCT
>MP130128.1 Sequence 253 from Patent EP3470432
GATGCATCC
>MP124853.1 Sequence 36 from Patent EP3411494
GCCCCGGAT
>MP124852.1 Sequence 35 from Patent EP3411494
GCCTTGGTA
>MP124825.1 Sequence 8 from Patent EP3411494
CGGTTCCTT
>MP124824.1 Sequence 7 from Patent EP3411494
GCCAAGGAA
>MP124823.1 Sequence 6 from Patent EP3411494
GGAAAGTAA
>MP124822.1 Sequence 5 from Patent EP3411494
TACCAAGGC
>MP124821.1 Sequence 4 from Patent EP3411494
ATCCGGGGC
>MP124820.1 Sequence 3 from Patent EP3411494
TTACTTTCC
>MP119749.1 Sequence 40 from Patent EP3442567
GAAAACACC
>MP119721.1 Sequence 12 from Patent EP3442567
GGAAACACC
>MP118108.1 Sequence 20 from Patent EP3456333
CAGTTAGGG
>MP118107.1 Sequence 19 from Patent EP3456333
GGGTTAGAC
>MP117194.1 Sequence 17 from Patent WO2019055495
TTTTTGTTT
>MP117144.1 Sequence 34 from Patent WO2019055829
AGGTCATCA
>MP117143.1 Sequence 33 from Patent WO2019055829
AGGTCGTCA
>MP117142.1 Sequence 32 from Patent WO2019055829
AGCATTAAA
>MP117141.1 Sequence 31 from Patent WO2019055829
CATTGAACC
>MP117140.1 Sequence 30 from Patent WO2019055829
CCATGACGT
>MP117139.1 Sequence 29 from Patent WO2019055829
CCATGATGT
>MP117129.1 Sequence 19 from Patent WO2019055829
CACTCTTGC
>MP117061.1 Sequence 280 from Patent WO2019055896
GCCGCTGCC
>MP117039.1 Sequence 258 from Patent WO2019055896
GCCGCTGCC
>MP116979.1 Sequence 198 from Patent WO2019055896
GCCGCTGCC
>MP116951.1 Sequence 170 from Patent WO2019055896
GCGGCCGCA
>MP115245.1 Sequence 14 from Patent WO2019053430
TCCACCGTG
>MP115244.1 Sequence 13 from Patent WO2019053430
TCCACCGTC
>MP110543.1 Sequence 99 from Patent WO2019043395
TCGAGTCTG
>MP180226.1 Sequence 146 from Patent WO2019068880
TNNNCTATC
>MP180225.1 Sequence 145 from Patent WO2019068880
CNNNCTATC
>MP180224.1 Sequence 144 from Patent WO2019068880
ANNNCTATC
>MP180222.1 Sequence 142 from Patent WO2019068880
GNNNCTATC
>MP106393.1 Sequence 12 from Patent WO2019076931
TGGCCCCAA
>MP106392.1 Sequence 11 from Patent WO2019076931
TTGGGGCCA
>MP103659.1 Sequence 75 from Patent WO2019079437
GGCAGCGGA
>MP103093.1 Sequence 397 from Patent EP3453723
GCTGCATCC
>MP103077.1 Sequence 381 from Patent EP3453723
GCTGCATCC
>MP103061.1 Sequence 365 from Patent EP3453723
GATGCATCC
>MP103045.1 Sequence 349 from Patent EP3453723
GATGCATCC
>MP103029.1 Sequence 333 from Patent EP3453723
TGGGCATCT
>MP103013.1 Sequence 317 from Patent EP3453723
ACTGCATCC
>MP102997.1 Sequence 301 from Patent EP3453723
GCTGCATCC
>MP102981.1 Sequence 285 from Patent EP3453723
AAGGCGTCT
>MP102965.1 Sequence 269 from Patent EP3453723
AAGGCATCT
>MP102949.1 Sequence 253 from Patent EP3453723
TTGGGTTCT
>MP102933.1 Sequence 237 from Patent EP3453723
GCTGCATCC
>MP102917.1 Sequence 221 from Patent EP3453723
GCTGCATCC
>MP102901.1 Sequence 205 from Patent EP3453723
AAGGCGTCT
>MP102885.1 Sequence 189 from Patent EP3453723
AAGGCGTCT
>MP102869.1 Sequence 173 from Patent EP3453723
TTGGGTTCT
>MP102853.1 Sequence 157 from Patent EP3453723
AAGGCGTCT
>MP102837.1 Sequence 141 from Patent EP3453723
AAGGCGTCT
>MP102821.1 Sequence 125 from Patent EP3453723
GGTGCATCC
>MP102805.1 Sequence 109 from Patent EP3453723
AAGGCGTCT
>MP102789.1 Sequence 93 from Patent EP3453723
AAGGCGTCT
>MP102773.1 Sequence 77 from Patent EP3453723
GCTGCATCC
>MP102757.1 Sequence 61 from Patent EP3453723
AAGACGTCT
>MP102741.1 Sequence 45 from Patent EP3453723
AAGGCGTCT
>MP102725.1 Sequence 29 from Patent EP3453723
TGGGCATCT
>MP102709.1 Sequence 13 from Patent EP3453723
TGGGCATCT
>MP167836.1 Sequence 41 from Patent EP3470997
CATCGGGAA
>MP167834.1 Sequence 39 from Patent EP3470997
CGTTGCATC
>MP167833.1 Sequence 38 from Patent EP3470997
TGATGCAAC
>MP167830.1 Sequence 35 from Patent EP3470997
CGGATCTAC
>MP167829.1 Sequence 34 from Patent EP3470997
TGTAGATCC
>MP167826.1 Sequence 31 from Patent EP3470997
CCCGTCATA
>MP167825.1 Sequence 30 from Patent EP3470997
TTATGACGG
>MP167822.1 Sequence 27 from Patent EP3470997
CACAGAGAC
>MP167821.1 Sequence 26 from Patent EP3470997
TGTCTCTGT
>MP167818.1 Sequence 23 from Patent EP3470997
CCCTTTAGC
>MP167817.1 Sequence 22 from Patent EP3470997
TGCTAAAGG
>MP167814.1 Sequence 19 from Patent EP3470997
CAATTCGCG
>MP167813.1 Sequence 18 from Patent EP3470997
TCGCGAATT
>MP167811.1 Sequence 16 from Patent EP3470997
TGGAATGAG
>MP166436.1 Sequence 141 from Patent EP3450458
GCTGCATCC
>MP166420.1 Sequence 125 from Patent EP3450458
GCTGCATCC
>MP166404.1 Sequence 109 from Patent EP3450458
GCTGCATCC
>MP166388.1 Sequence 93 from Patent EP3450458
TGGGCATCT
>MP166372.1 Sequence 77 from Patent EP3450458
AGTGCATCC
>MP166356.1 Sequence 61 from Patent EP3450458
GCTGCATCC
>MP166340.1 Sequence 45 from Patent EP3450458
GCTGCATCC
>MP166324.1 Sequence 29 from Patent EP3450458
TGGGCATCT
>MP166308.1 Sequence 13 from Patent EP3450458
AAGGCGTCT
>MP166703.1 Sequence 408 from Patent EP3450458
GCTGCATCC
>MP166687.1 Sequence 392 from Patent EP3450458
GCTGCATCC
>MP166660.1 Sequence 365 from Patent EP3450458
GCTGCATCC
>MP166644.1 Sequence 349 from Patent EP3450458
ACTACATCC
>MP166628.1 Sequence 333 from Patent EP3450458
AAGGCGTCT
>MP166612.1 Sequence 317 from Patent EP3450458
GCTGCATCC
>MP166596.1 Sequence 301 from Patent EP3450458
GGTGCATCC
>MP166580.1 Sequence 285 from Patent EP3450458
GCTGCATCC
>MP166564.1 Sequence 269 from Patent EP3450458
GCTGCATCC
>MP166548.1 Sequence 253 from Patent EP3450458
TCTGCATCC
>MP166532.1 Sequence 237 from Patent EP3450458
GCTGCATCC
>MP166516.1 Sequence 221 from Patent EP3450458
GCTGCATCC
>MP166500.1 Sequence 205 from Patent EP3450458
GCTGCATCC
>MP166484.1 Sequence 189 from Patent EP3450458
GCTGCATCC
>MP166468.1 Sequence 173 from Patent EP3450458
ACTGCATCC
>MP166452.1 Sequence 157 from Patent EP3450458
GCTGCATCC
>MA839955.1 JP 2018535655-A/11121: ASGR INHIBITORS
ACCTACCTC
>MA839036.1 JP 2018535655-A/10202: ASGR INHIBITORS
CAGGACTGC
>MA838953.1 JP 2018535655-A/10119: ASGR INHIBITORS
CAGGACTGC
>MA838940.1 JP 2018535655-A/10106: ASGR INHIBITORS
AGGGACTTC
>MA846907.1 JP 2018537516-A/83: OPTIMIZED ANTI-CD3 BISPECIFIC ANTIBODIES AND USES THEREOF
GCTGCATCC
>MA846312.1 JP 2018535948-A/47: Antigen-Binding Proteins that Activate the Leptin Receptor
GGTGCATCC
>MA846272.1 JP 2018535948-A/7: Antigen-Binding Proteins that Activate the Leptin Receptor
GCTGCATCC
>MA846078.1 JP 2018536392-A/283: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCC
>MA846070.1 JP 2018536392-A/275: Anti-LAG3 Antibodies and Uses Thereof
GGTGCATCC
>MA846062.1 JP 2018536392-A/267: Anti-LAG3 Antibodies and Uses Thereof
GGTGCATCC
>MA846058.1 JP 2018536392-A/263: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCC
>MA846018.1 JP 2018536392-A/223: Anti-LAG3 Antibodies and Uses Thereof
TTGGTTTCT
>MA846010.1 JP 2018536392-A/215: Anti-LAG3 Antibodies and Uses Thereof
GATGCATCC
>MA846002.1 JP 2018536392-A/207: Anti-LAG3 Antibodies and Uses Thereof
GGTGCATCC
>MA845994.1 JP 2018536392-A/199: Anti-LAG3 Antibodies and Uses Thereof
GATGCATCC
>MA845986.1 JP 2018536392-A/191: Anti-LAG3 Antibodies and Uses Thereof
AAGATTTCT
>MA845978.1 JP 2018536392-A/183: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCA
>MA845970.1 JP 2018536392-A/175: Anti-LAG3 Antibodies and Uses Thereof
GATGCATCC
>MA845962.1 JP 2018536392-A/167: Anti-LAG3 Antibodies and Uses Thereof
TTGGTTTCT
>MA845954.1 JP 2018536392-A/159: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCC
>MA845946.1 JP 2018536392-A/151: Anti-LAG3 Antibodies and Uses Thereof
TGGGCATCT
>MA845938.1 JP 2018536392-A/143: Anti-LAG3 Antibodies and Uses Thereof
TGGGCATCT
>MA845930.1 JP 2018536392-A/135: Anti-LAG3 Antibodies and Uses Thereof
TGGGCATCT
>MA845922.1 JP 2018536392-A/127: Anti-LAG3 Antibodies and Uses Thereof
GGTGCATCC
>MA845914.1 JP 2018536392-A/119: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCC
>MA845906.1 JP 2018536392-A/111: Anti-LAG3 Antibodies and Uses Thereof
GCTACATCC
>MA845898.1 JP 2018536392-A/103: Anti-LAG3 Antibodies and Uses Thereof
GGTTCATCC
>MA845890.1 JP 2018536392-A/95: Anti-LAG3 Antibodies and Uses Thereof
GATGCATCC
>MA845882.1 JP 2018536392-A/87: Anti-LAG3 Antibodies and Uses Thereof
GATGCATCC
>MA845874.1 JP 2018536392-A/79: Anti-LAG3 Antibodies and Uses Thereof
GATGCATCC
>MA845866.1 JP 2018536392-A/71: Anti-LAG3 Antibodies and Uses Thereof
GGTGCTTCC
>MA845858.1 JP 2018536392-A/63: Anti-LAG3 Antibodies and Uses Thereof
AAGGTTTCT
>MA845850.1 JP 2018536392-A/55: Anti-LAG3 Antibodies and Uses Thereof
GGTGCGTCC
>MA845842.1 JP 2018536392-A/47: Anti-LAG3 Antibodies and Uses Thereof
GCTACATCC
>MA845834.1 JP 2018536392-A/39: Anti-LAG3 Antibodies and Uses Thereof
GGTGCATCC
>MA845826.1 JP 2018536392-A/31: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCC
>MA845818.1 JP 2018536392-A/23: Anti-LAG3 Antibodies and Uses Thereof
GGTGCATCC
>MA845810.1 JP 2018536392-A/15: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCC
>MA845802.1 JP 2018536392-A/7: Anti-LAG3 Antibodies and Uses Thereof
GCTGCATCC
>MA812432.1 JP 2018191598-A/768: A set of random primers and a method for producing a DNA library using the same
GTCACGTAA
>MA812431.1 JP 2018191598-A/767: A set of random primers and a method for producing a DNA library using the same
ATTGTCGCA
>MA812430.1 JP 2018191598-A/766: A set of random primers and a method for producing a DNA library using the same
TGTACCGTT
>MA812429.1 JP 2018191598-A/765: A set of random primers and a method for producing a DNA library using the same
ATAGACGCA
>MA812428.1 JP 2018191598-A/764: A set of random primers and a method for producing a DNA library using the same
GATAGTGTG
>MA812427.1 JP 2018191598-A/763: A set of random primers and a method for producing a DNA library using the same
TAATTGCGC
>MA812426.1 JP 2018191598-A/762: A set of random primers and a method for producing a DNA library using the same
TGTCCTGTT
>MA812425.1 JP 2018191598-A/761: A set of random primers and a method for producing a DNA library using the same
CCATGTACT
>MA812424.1 JP 2018191598-A/760: A set of random primers and a method for producing a DNA library using the same
ATTCGCACA
>MA812423.1 JP 2018191598-A/759: A set of random primers and a method for producing a DNA library using the same
AATCAGGAC
>MA812422.1 JP 2018191598-A/758: A set of random primers and a method for producing a DNA library using the same
TTGAACGCT
>MA812421.1 JP 2018191598-A/757: A set of random primers and a method for producing a DNA library using the same
AACATTGCG
>MA812420.1 JP 2018191598-A/756: A set of random primers and a method for producing a DNA library using the same
TGTACGTCT
>MA812419.1 JP 2018191598-A/755: A set of random primers and a method for producing a DNA library using the same
GAATGTCAC
>MA812418.1 JP 2018191598-A/754: A set of random primers and a method for producing a DNA library using the same
TAGAACGGT
>MA812417.1 JP 2018191598-A/753: A set of random primers and a method for producing a DNA library using the same
AACTACGGT
>MA812416.1 JP 2018191598-A/752: A set of random primers and a method for producing a DNA library using the same
TACTTACGC
>MA812415.1 JP 2018191598-A/751: A set of random primers and a method for producing a DNA library using the same
ATACAGCAC
>MA812414.1 JP 2018191598-A/750: A set of random primers and a method for producing a DNA library using the same
ATGTCGACA
>MA812413.1 JP 2018191598-A/749: A set of random primers and a method for producing a DNA library using the same
GTCGTATAC
>MA812412.1 JP 2018191598-A/748: A set of random primers and a method for producing a DNA library using the same
GAACGTTAC
>MA812411.1 JP 2018191598-A/747: A set of random primers and a method for producing a DNA library using the same
TATCACGTG
>MA812410.1 JP 2018191598-A/746: A set of random primers and a method for producing a DNA library using the same
CGTATACCT
>MA812409.1 JP 2018191598-A/745: A set of random primers and a method for producing a DNA library using the same
CATAACGAG
>MA812408.1 JP 2018191598-A/744: A set of random primers and a method for producing a DNA library using the same
TACTAACCG
>MA812407.1 JP 2018191598-A/743: A set of random primers and a method for producing a DNA library using the same
TGTCACAGA
>MA812406.1 JP 2018191598-A/742: A set of random primers and a method for producing a DNA library using the same
GAGCGATTA
>MA812405.1 JP 2018191598-A/741: A set of random primers and a method for producing a DNA library using the same
GATGCGATA
>MA812404.1 JP 2018191598-A/740: A set of random primers and a method for producing a DNA library using the same
GATGACGTA
>MA812403.1 JP 2018191598-A/739: A set of random primers and a method for producing a DNA library using the same
TATGTGCAC
>MA812402.1 JP 2018191598-A/738: A set of random primers and a method for producing a DNA library using the same
AATTCACGC
>MA812401.1 JP 2018191598-A/737: A set of random primers and a method for producing a DNA library using the same
ATACAGTCC
>MA812400.1 JP 2018191598-A/736: A set of random primers and a method for producing a DNA library using the same
CGAGAGTAT
>MA812399.1 JP 2018191598-A/735: A set of random primers and a method for producing a DNA library using the same
GGTCGTTAT
>MA812398.1 JP 2018191598-A/734: A set of random primers and a method for producing a DNA library using the same
CTGTTATCG
>MA812397.1 JP 2018191598-A/733: A set of random primers and a method for producing a DNA library using the same
GACACTGAA
>MA812396.1 JP 2018191598-A/732: A set of random primers and a method for producing a DNA library using the same
GTGTTAACG
>MA812395.1 JP 2018191598-A/731: A set of random primers and a method for producing a DNA library using the same
TTCGCGTTA
>MA812394.1 JP 2018191598-A/730: A set of random primers and a method for producing a DNA library using the same
TGCCTTACA
>MA812393.1 JP 2018191598-A/729: A set of random primers and a method for producing a DNA library using the same
GAGCGTTAT
>MA812392.1 JP 2018191598-A/728: A set of random primers and a method for producing a DNA library using the same
TGCATAGTG
>MA812391.1 JP 2018191598-A/727: A set of random primers and a method for producing a DNA library using the same
TAAGACGGT
>MA812390.1 JP 2018191598-A/726: A set of random primers and a method for producing a DNA library using the same
CATCATGTC
>MA812389.1 JP 2018191598-A/725: A set of random primers and a method for producing a DNA library using the same
TCGTTAGTC
>MA812388.1 JP 2018191598-A/724: A set of random primers and a method for producing a DNA library using the same
AATCACGTG
>MA812387.1 JP 2018191598-A/723: A set of random primers and a method for producing a DNA library using the same
AATGCCGTA
>MA812386.1 JP 2018191598-A/722: A set of random primers and a method for producing a DNA library using the same
TAAGACACG
>MA812385.1 JP 2018191598-A/721: A set of random primers and a method for producing a DNA library using the same
ATCACCGTA
>MA812384.1 JP 2018191598-A/720: A set of random primers and a method for producing a DNA library using the same
ACTTAGACG
>MA812383.1 JP 2018191598-A/719: A set of random primers and a method for producing a DNA library using the same
ATATCTGCG
>MA812382.1 JP 2018191598-A/718: A set of random primers and a method for producing a DNA library using the same
GATAAGCGT
>MA812381.1 JP 2018191598-A/717: A set of random primers and a method for producing a DNA library using the same
ATGCGCATA
>MA812380.1 JP 2018191598-A/716: A set of random primers and a method for producing a DNA library using the same
CCGATAACA
>MA812379.1 JP 2018191598-A/715: A set of random primers and a method for producing a DNA library using the same
TATGACGCA
>MA812378.1 JP 2018191598-A/714: A set of random primers and a method for producing a DNA library using the same
CTACGTTGT
>MA812377.1 JP 2018191598-A/713: A set of random primers and a method for producing a DNA library using the same
ATAACGTGC
>MA812376.1 JP 2018191598-A/712: A set of random primers and a method for producing a DNA library using the same
ATGCCGTTA
>MA812375.1 JP 2018191598-A/711: A set of random primers and a method for producing a DNA library using the same
GTAATCGTG
>MA812374.1 JP 2018191598-A/710: A set of random primers and a method for producing a DNA library using the same
ACTTAGCGT
>MA812373.1 JP 2018191598-A/709: A set of random primers and a method for producing a DNA library using the same
ATCACGTGT
>MA812372.1 JP 2018191598-A/708: A set of random primers and a method for producing a DNA library using the same
GTACCTTAG
>MA812371.1 JP 2018191598-A/707: A set of random primers and a method for producing a DNA library using the same
GTAATCGAG
>MA812370.1 JP 2018191598-A/706: A set of random primers and a method for producing a DNA library using the same
TGTCCGTAA
>MA812369.1 JP 2018191598-A/705: A set of random primers and a method for producing a DNA library using the same
TGCGACTTA
>MA812368.1 JP 2018191598-A/704: A set of random primers and a method for producing a DNA library using the same
AGACTGTAC
>MA812367.1 JP 2018191598-A/703: A set of random primers and a method for producing a DNA library using the same
GAGTGTTAC
>MA812366.1 JP 2018191598-A/702: A set of random primers and a method for producing a DNA library using the same
GTCGTGCAT
>MA812365.1 JP 2018191598-A/701: A set of random primers and a method for producing a DNA library using the same
TGCACGTAC
>MA812364.1 JP 2018191598-A/700: A set of random primers and a method for producing a DNA library using the same
ATCGTCAGG
>MA812363.1 JP 2018191598-A/699: A set of random primers and a method for producing a DNA library using the same
TACACTGCG
>MA812362.1 JP 2018191598-A/698: A set of random primers and a method for producing a DNA library using the same
GACGTCTGA
>MA812361.1 JP 2018191598-A/697: A set of random primers and a method for producing a DNA library using the same
ATGTCGACG
>MA812360.1 JP 2018191598-A/696: A set of random primers and a method for producing a DNA library using the same
ATGGTGAGG
>MA812359.1 JP 2018191598-A/695: A set of random primers and a method for producing a DNA library using the same
CTCGAGATC
>MA812358.1 JP 2018191598-A/694: A set of random primers and a method for producing a DNA library using the same
ATACCTGGC
>MA812357.1 JP 2018191598-A/693: A set of random primers and a method for producing a DNA library using the same
TATAAGCGT
>MA812356.1 JP 2018191598-A/692: A set of random primers and a method for producing a DNA library using the same
AAGACGTTA
>MA812355.1 JP 2018191598-A/691: A set of random primers and a method for producing a DNA library using the same
TAGGACAAT
>MA812354.1 JP 2018191598-A/690: A set of random primers and a method for producing a DNA library using the same
ATTAACGCT
>MA812353.1 JP 2018191598-A/689: A set of random primers and a method for producing a DNA library using the same
TATGACACT
>MA812352.1 JP 2018191598-A/688: A set of random primers and a method for producing a DNA library using the same
TTAGCGTTA
>MA812351.1 JP 2018191598-A/687: A set of random primers and a method for producing a DNA library using the same
AGTATACAC
>MA812350.1 JP 2018191598-A/686: A set of random primers and a method for producing a DNA library using the same
ATTATGCGA
>MA812349.1 JP 2018191598-A/685: A set of random primers and a method for producing a DNA library using the same
ATGACGTTA
>MA812348.1 JP 2018191598-A/684: A set of random primers and a method for producing a DNA library using the same
AGTAACTGT
>MA812347.1 JP 2018191598-A/683: A set of random primers and a method for producing a DNA library using the same
ATATCTACG
>MA812346.1 JP 2018191598-A/682: A set of random primers and a method for producing a DNA library using the same
CATATTACG
>MA812345.1 JP 2018191598-A/681: A set of random primers and a method for producing a DNA library using the same
ACATTAAGC
>MA812344.1 JP 2018191598-A/680: A set of random primers and a method for producing a DNA library using the same
ACTGCATTA
>MA812343.1 JP 2018191598-A/679: A set of random primers and a method for producing a DNA library using the same
TATACACTG
>MA812342.1 JP 2018191598-A/678: A set of random primers and a method for producing a DNA library using the same
GACTGTAAT
>MA812341.1 JP 2018191598-A/677: A set of random primers and a method for producing a DNA library using the same
CACACTTAT
>MA812340.1 JP 2018191598-A/676: A set of random primers and a method for producing a DNA library using the same
TCAATAACG
>MA812339.1 JP 2018191598-A/675: A set of random primers and a method for producing a DNA library using the same
CAGTATGTA
>MA812338.1 JP 2018191598-A/674: A set of random primers and a method for producing a DNA library using the same
TAACGTATG
>MA812337.1 JP 2018191598-A/673: A set of random primers and a method for producing a DNA library using the same
TTGCTACAT
>MA807964.1 JP 2018528945-A/5: METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
AGCACTTTG
>MA808059.1 JP 2018529329-A/62: ARTIFICIAL NUCLEIC ACID MOLECULES
GGCCCGAAG
>MA807565.1 JP 2018529759-A/27: Connexin 45 Inhibition for Therapy
TTCAAGAGA
>MA807352.1 JP 2018530309-A/1: SUPER RESOLUTION IMAGING OF PROTEIN-PROTEIN INTERACTIONS
GATGACATC
>MA820832.1 JP 2018535251-A/11: PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
TAGTATTAC
>MA818751.1 WO 2018221735-A/7: New oligonucleotide
AGTTAGAAT
>MA818746.1 WO 2018221735-A/2: New oligonucleotide
GGTTAGGGT
>MP088377.1 Sequence 9 from Patent EP3438257
TCTGACGAC
>MP098539.1 Sequence 5 from Patent EP3437662
ATGCCGTTT
>MP098536.1 Sequence 2 from Patent EP3437662
CTGTTTACG
>MP055699.1 Sequence 4 from Patent EP3406267
GTAGTTTGT
>MP054555.1 Sequence 31 from Patent EP3404042
GATGCGTCC
>MP054539.1 Sequence 15 from Patent EP3404042
AGTAATAAT
>MP052014.1 Sequence 49 from Patent EP3418300
TGGGCTTCA
>MP051992.1 Sequence 27 from Patent EP3418300
TGGGCATCT
>MP051976.1 Sequence 11 from Patent EP3418300
TGGGCATCT
>MP051683.1 Sequence 191 from Patent EP3418301
AAGGCGTCT
>MP051649.1 Sequence 157 from Patent EP3418301
GTTGCAGCC
>MP051633.1 Sequence 141 from Patent EP3418301
AAGGTTTCT
>MP051617.1 Sequence 125 from Patent EP3418301
ACTGCATCC
>MP051601.1 Sequence 109 from Patent EP3418301
CCTGCATCC
>MP051585.1 Sequence 93 from Patent EP3418301
ACTACTTCC
>MP051569.1 Sequence 77 from Patent EP3418301
AAGGCGTCT
>MP051553.1 Sequence 61 from Patent EP3418301
AAGGCGTCT
>MP051537.1 Sequence 45 from Patent EP3418301
GCTGCATCC
>MP051521.1 Sequence 29 from Patent EP3418301
AAGGCGTCT
>MP051505.1 Sequence 13 from Patent EP3418301
GCTGCATCC
>MP047825.1 Sequence 47 from Patent EP3419998
CTGGTGTCT
>MP047819.1 Sequence 41 from Patent EP3419998
CTTGTATCC
>MP047813.1 Sequence 35 from Patent EP3419998
CTTGTATCC
>MP047807.1 Sequence 29 from Patent EP3419998
GGGGCATCC
>MP045940.1 Sequence 1 from Patent EP3420348
CCAGGTCAT
>MP046122.1 Sequence 67 from Patent EP3419988
TGTCACGGG
>MP042927.1 Sequence 20 from Patent WO2018213789
GCCGCCGCC
>MP042919.1 Sequence 12 from Patent WO2018213789
CCGCCGCCG
>MP042107.1 Sequence 51 from Patent WO2018209320
AGCAAGTTA
>MP042106.1 Sequence 50 from Patent WO2018209320
TTAGAGCTA
>MP040736.1 Sequence 54 from Patent WO2018211453
TGGGCCTCT
>MP039265.1 Sequence 1 from Patent WO2018203049
GTTTTTTTC
>MP032893.1 Sequence 33 from Patent WO2018220546
TGGGCCTCT
>MP031629.1 Sequence 61 from Patent WO2018222854
GCTGCATCC
>MP031613.1 Sequence 45 from Patent WO2018222854
TGGGCATCT
>MP031597.1 Sequence 29 from Patent WO2018222854
AGTGCATCC
>MP031581.1 Sequence 13 from Patent WO2018222854
TTGAGTTCT
>MP030132.1 Sequence 45 from Patent WO2018219995
TCTAAGTTG
>MP030131.1 Sequence 44 from Patent WO2018219995
TCCAAGTTG
>MP031869.1 Sequence 301 from Patent WO2018222854
GGTGCATCC
>MP031837.1 Sequence 269 from Patent WO2018222854
GCTGCATCC
>MP031821.1 Sequence 253 from Patent WO2018222854
GAAGCATCT
>MP031805.1 Sequence 237 from Patent WO2018222854
GGTTCATCC
>MP031789.1 Sequence 221 from Patent WO2018222854
GGTGCGTCC
>MP031773.1 Sequence 205 from Patent WO2018222854
GGTGTATCC
>MP031757.1 Sequence 189 from Patent WO2018222854
GATGCTTTT
>MP031741.1 Sequence 173 from Patent WO2018222854
TTGGGTTCT
>MP031725.1 Sequence 157 from Patent WO2018222854
GATGCATCC
>MP031709.1 Sequence 141 from Patent WO2018222854
GAGGCGTCC
>MP031693.1 Sequence 125 from Patent WO2018222854
GCTACATCC
>MP031677.1 Sequence 109 from Patent WO2018222854
AGTGCATCC
>MP031661.1 Sequence 93 from Patent WO2018222854
AAGGCGTCT
>MP031645.1 Sequence 77 from Patent WO2018222854
GCTGCATCC
>MP029732.1 Sequence 73 from Patent WO2018226861
GGTGCATCC
>MP029716.1 Sequence 57 from Patent WO2018226861
GGTGCATCC
>MP029700.1 Sequence 41 from Patent WO2018226861
GGTGGATCC
>MP029684.1 Sequence 25 from Patent WO2018226861
GGTGTATTC
>MP025483.1 Sequence 22 from Patent EP3409685
GGTGGTTCT
>MP024850.1 Sequence 14 from Patent EP3408396
ATAGTATGC
>MP021610.1 Sequence 39 from Patent EP3417052
GCTCYTGGA
>MP084331.1 Sequence 3 from Patent WO2018200847
GAGGTNNTC
>MP018957.1 Sequence 28 from Patent WO2018201047
GGTGGCGGA
>MP018774.1 Sequence 755 from Patent WO2018198091
TACACCTCC
>MP018773.1 Sequence 754 from Patent WO2018198091
TACACTAGC
>MP018709.1 Sequence 637 from Patent WO2018198091
TGGGCCTCT
>MP018664.1 Sequence 533 from Patent WO2018198091
TGGGCCTCT
>MP016214.1 Sequence 8 from Patent WO2019018551
CTCAGTTCG
>MP015542.1 Sequence 35 from Patent WO2019018383
TTGTCCGAC
>MP015541.1 Sequence 34 from Patent WO2019018383
CCTGACCCA
>MP013677.1 Sequence 755 from Patent WO2019018730
TACACCTCC
>MP013676.1 Sequence 754 from Patent WO2019018730
TACACTAGC
>MP013612.1 Sequence 637 from Patent WO2019018730
TGGGCCTCT
>MP013567.1 Sequence 533 from Patent WO2019018730
TGGGCCTCT
>MP012974.1 Sequence 18 from Patent EP3397765
GAATCATGG
>MP077669.1 Sequence 35 from Patent WO2018236825
GCCGCCACC
>MP075998.1 Sequence 755 from Patent WO2019006007
TACACCTCC
>MP075997.1 Sequence 754 from Patent WO2019006007
TACACTAGC
>MP075933.1 Sequence 637 from Patent WO2019006007
TGGGCCTCT
>MP075888.1 Sequence 533 from Patent WO2019006007
TGGGCCTCT
>MP007241.1 Sequence 44 from Patent EP3432925
CTGACCAGC
>MP007229.1 Sequence 32 from Patent EP3432925
CTGACCTCC
>MP007103.1 Sequence 228 from Patent EP3411482
TCGGCATCC
>MP006881.1 Sequence 31 from Patent WO2018215787
GGAAGCGGA
>MP003356.1 Sequence 124 from Patent EP3411070
GCTGCATCC
>MP003343.1 Sequence 111 from Patent EP3411070
GAAGCATCC
>MP003329.1 Sequence 97 from Patent EP3411070
TATGCATCC
>MP003323.1 Sequence 91 from Patent EP3411070
TATGCAGCC
>MP003318.1 Sequence 86 from Patent EP3411070
TGGGCTTCC
>MP003312.1 Sequence 80 from Patent EP3411070
GAAGCATCC
>MP003306.1 Sequence 74 from Patent EP3411070
TGGGCTTCC
>MP070273.1 Sequence 1637 from Patent WO2018229715
TGGGCCTCT
>MP070228.1 Sequence 1533 from Patent WO2018229715
TGGGCCTCT
>MP070130.1 Sequence 755 from Patent WO2018229715
TACACCTCC
>MP070129.1 Sequence 754 from Patent WO2018229715
TACACTAGC
>MP069322.1 Sequence 755 from Patent WO2018237173
TACACCTCC
>MP069321.1 Sequence 754 from Patent WO2018237173
TACACTAGC
>MP069258.1 Sequence 637 from Patent WO2018237173
TGGGCCTCT
>MP069213.1 Sequence 533 from Patent WO2018237173
TGGGCCTCT
>LQ997785.1 Sequence 15 from Patent EP3427752
GCTGCATTC
>MP066066.1 Sequence 2 from Patent WO2018231818
ACTNNNTGC
>MP066065.1 Sequence 1 from Patent WO2018231818
ACTNNNTGA
>MP065063.1 Sequence 16 from Patent EP3431502
AGGGCTTCT
>MP062552.1 Sequence 5 from Patent EP3431493
CCTCTCGGG
>MP062551.1 Sequence 4 from Patent EP3431493
GGAGAGCCC
>FI849975.1 I.S07.4420_JSR05 Maize transposon insertions from ISU and BTI Zea mays genomic clone I.S07.4420_JSR05, genomic survey sequence
GCCCTGCAG
>FI849974.1 I.S07.4393_JSR05 Maize transposon insertions from ISU and BTI Zea mays genomic clone I.S07.4393_JSR05, genomic survey sequence
GCCCTGCAG
>FI617665.1 Wang-Penn1-June-201-week14-ApoI-016767_3551_0890 Carl June Integration Site Library Homo sapiens genomic, genomic survey sequence
CTATACNTC
>FI617570.1 Wang-Penn1-June-201-week6-ApoI-048762_3788_3429 Carl June Integration Site Library Homo sapiens genomic, genomic survey sequence
CGTTGCCCG
>CZ288300.1 cp57e03.f Candida parapsilosis Random Genomic Library Candida parapsilosis genomic clone cp57e03, genomic survey sequence
GATCCCCCT
>CW985814.1 KBrH011P15R KBrH, Brassica rapa HindIII BAC library Brassica rapa subsp. pekinensis genomic clone KBrH011P15, genomic survey sequence
AGATCTATA
>ET388908.1 S0116B05_SP6 CHORI-214 Salmo salar genomic clone S0116B05 3', genomic survey sequence
CAAAATGAG
>ET364070.1 S0032E11_SP6 CHORI-214 Salmo salar genomic clone S0032E11 3', genomic survey sequence
TCAATGAGG
>ET341670.1 S0231O04_SP6 CHORI-214 Salmo salar genomic clone S0231O04 3', genomic survey sequence
TTGTTTCTG
>ET329092.1 S0105F24_SP6 CHORI-214 Salmo salar genomic clone S0105F24 3', genomic survey sequence
CCGCCCCAA
>ET326750.1 S0280G23_SP6 CHORI-214 Salmo salar genomic clone S0280G23 3', genomic survey sequence
CTCGCCTGC
>ET272009.1 S0339F09_SP6 CHORI-214 Salmo salar genomic clone S0339F09 3', genomic survey sequence
TTGTTGGAT
>ET272498.1 S0221G08_SP6 CHORI-214 Salmo salar genomic clone S0221G08 3', genomic survey sequence
CCCTATGAA
>ET271610.1 S0209G02_SP6 CHORI-214 Salmo salar genomic clone S0209G02 3', genomic survey sequence
TGTTTCCCA
>ET253199.1 S0094E23_T7 CHORI-214 Salmo salar genomic clone S0094E23 5', genomic survey sequence
TGCTCTCCT
>ET253035.1 S0224G05_SP6 CHORI-214 Salmo salar genomic clone S0224G05 3', genomic survey sequence
CCCATGGTC
>EI101189.1 br-0.1.17593449.fwd Arabidopsis thaliana strain br-0 polymorphism sequences Arabidopsis thaliana genomic, genomic survey sequence
ATAAAAAAA
>CL693808.1 PRI0162c_D05_2 - PRI0162c.BR (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
TCTTTTTTT
>CL685442.1 PRI0141b_A07_2 - PRI0141b.BR (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
AGCCACTTA
>CL682760.1 PRI0134d_H05_2 - PRI0134d.BR (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
TTTCTTCTG
>CL682372.1 PRI0133d_D05_2 - PRI0133d.BR (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
AGATCGGAC
>CL681447.1 PRI0131a_G08_2 - PRI0131a.BR (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
TTGTCCTTA
>CL672804.1 PRI017d_E02 - PRI017d.B21 (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
CACCTCCGA
>CL670968.1 PRI0163c_B10 - PRI0163c.B21 (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
GGCTTGCTA
>CL664176.1 PRI0146b_F06 - PRI0146b.B21 (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
CTAGTGCGT
>CL663893.1 PRI0145c_F07 - PRI0145c.B21.1 (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
ATCCCACCC
>CL663701.1 PRI0145a_F06 - PRI0145a.B21.1 (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
TGTGCTTTC
>CL661512.1 PRI013a_C03 - PRI013a.B21 (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
CTACTTATT
>CL659917.1 PRI0135c_F08 - PRI0135c.B21 (9) Mixed stage fosmid library of P. pacificus var. California Pristionchus pacificus genomic, genomic survey sequence
CGGGGATCC
>CL314040.1 mth2-130O15_T7 Medicago truncatula BAC end sequences Medicago truncatula genomic 5', genomic survey sequence
NTTGTTTTG
>MA678840.1 JP 2017121243-A/27006: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGCCTAG
>MA698141.1 JP 2017121243-A/46307: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGTGTAG
>MA739477.1 JP 2017153491-A/223: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTGCATCC
>MA739469.1 JP 2017153491-A/215: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>MA739461.1 JP 2017153491-A/207: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>MA739453.1 JP 2017153491-A/199: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGGCATCT
>MA739445.1 JP 2017153491-A/191: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TCTGCATCC
>MA739437.1 JP 2017153491-A/183: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>MA739429.1 JP 2017153491-A/175: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
ACTTCATCC
>MA739421.1 JP 2017153491-A/167: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTGCATCC
>MA739413.1 JP 2017153491-A/159: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>MA739405.1 JP 2017153491-A/151: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>MA739397.1 JP 2017153491-A/143: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>MA739389.1 JP 2017153491-A/135: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>MA739381.1 JP 2017153491-A/127: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>MA739373.1 JP 2017153491-A/119: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>MA739365.1 JP 2017153491-A/111: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>MA739357.1 JP 2017153491-A/103: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>MA739349.1 JP 2017153491-A/95: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTTCTTCC
>MA739341.1 JP 2017153491-A/87: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>MA739333.1 JP 2017153491-A/79: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AGGGCGTCT
>MA739325.1 JP 2017153491-A/71: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GATGCATCC
>MA739317.1 JP 2017153491-A/63: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGACGTCT
>MA739309.1 JP 2017153491-A/55: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GATGCATCC
>MA739301.1 JP 2017153491-A/47: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>MA739293.1 JP 2017153491-A/39: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGACATCT
>MA739285.1 JP 2017153491-A/31: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>MA739277.1 JP 2017153491-A/23: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGGCATCT
>MA739269.1 JP 2017153491-A/15: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>MA739261.1 JP 2017153491-A/7: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>MA696372.1 JP 2017121243-A/44538: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGCTTAG
>MA797878.1 JP 2018528264-A/88: 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER
TGGGCCTCT
>MA797867.1 JP 2018528264-A/77: 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER
TGGGCCTCC
>MA797853.1 JP 2018528264-A/63: 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER
TGGGCATCC
>MA663077.1 JP 2017121243-A/11243: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGTGTAG
>ET235057.1 S0152F16_SP6 CHORI-214 Salmo salar genomic clone S0152F16 3', genomic survey sequence
TTGCGCCCC
>ET227468.1 S0137B22_SP6 CHORI-214 Salmo salar genomic clone S0137B22 3', genomic survey sequence
CTAGTGGGA
>DU672395.1 Bst004937 lambda03 Boechera stricta genomic clone SAD-EX-06-T3_I20, genomic survey sequence
AGCGCTNNT
>DU672365.1 Bst004907 lambda03 Boechera stricta genomic clone SAD-EX-06-T3_H12, genomic survey sequence
GATATCTCT
>DU671133.1 Bst003675 lambda03 Boechera stricta genomic clone SAD-EX-04-T7_B17, genomic survey sequence
GGAGTANNA
>DU670964.1 Bst003506 lambda03 Boechera stricta genomic clone SAD-EX-04-T3_K12, genomic survey sequence
TGAGCGTAT
>DU670949.1 Bst003491 lambda03 Boechera stricta genomic clone SAD-EX-04-T3_J19, genomic survey sequence
ACTNGTGAG
>DU670664.1 Bst003206 lambda03 Boechera stricta genomic clone SAD-EX-03-T7_N17, genomic survey sequence
TCGCACNTA
>DU670002.1 Bst002544 lambda03 Boechera stricta genomic clone SAD-EX-03-T3_B13, genomic survey sequence
TGCGTGGCG
>DU669901.1 Bst002443 lambda03 Boechera stricta genomic clone SAD-EX-02-T7_N01, genomic survey sequence
CGGACANTG
>DU758272.1 ASNG1834.b2 HF200_10-06-02 uncultured marine microorganism HF200_10-06-02 genomic clone HF0200_078B02, genomic survey sequence
CAAACTCTA
>DU739263.1 APKI5084.b2 HF70_10-07-02 uncultured marine microorganism HF70_10-07-02 genomic clone HF0070_059D12, genomic survey sequence
CTTGACCAA
>DU644306.1 Ciuffi-HIV-293t-wt-r2C2.rev Human Integration Site Library-Ciuffi-HIV-293t-wt Homo sapiens genomic, genomic survey sequence
CTTACAAAC
>DU643206.1 Ciuffi-HIV-293T-wt-r2C2 Human Integration Site Library-Ciuffi-HIV-293t-wt Homo sapiens genomic, genomic survey sequence
CTTACAAAC
>BZ424971.1 100022746-5061 Aspergillus terreus random genomic DNA clone library Aspergillus terreus genomic, genomic survey sequence
TGGNNACGA
>MA768924.1 JP 2017528134-A/43: PRODUCTION OF STEVIOL GLYCOSIDES IN RECOMBINANT HOSTS
CCATCAAGA
>MA661308.1 JP 2017121243-A/9474: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGCCTAG
>MA768021.1 JP 2017525375-A/24: METHODS FOR RAPID AND SENSITIVE DETECTION OF HOTSPOT MUTATIONS
ATGACTTAC
>MA768019.1 JP 2017525375-A/22: METHODS FOR RAPID AND SENSITIVE DETECTION OF HOTSPOT MUTATIONS
CGGGTCCCC
>MA767271.1 JP 2017525362-A/2: Factor H specific antibodies and uses thereof
GCCACATCC
>MA767037.1 JP 2017513956-A/540: NUCLEIC ACID VACCINES
CCRCCATGG
>MA786360.1 JP 2018525609-A/4: CELL BASED ASSAY FOR DETERMINING ANTIBODY OR LIGAND BINDING AND FUNCTION
GGGACTTCC
>MA764920.1 JP 2017523790-A/24: TARGETING MICRORNAS FOR METABOLIC DISORDERS
CAATGCTGC
>MA764603.1 JP 2017523781-A/5: AN ANTAGONISTIC PD-1 APTAMER AND ITS APPLICATIONS IN CANCER THERAPY RELATED APPLICATIONS
GTACATCAN
>MA764601.1 JP 2017523781-A/3: AN ANTAGONISTIC PD-1 APTAMER AND ITS APPLICATIONS IN CANCER THERAPY RELATED APPLICATIONS
GTACAGTTN
>MA764599.1 JP 2017523781-A/1: AN ANTAGONISTIC PD-1 APTAMER AND ITS APPLICATIONS IN CANCER THERAPY RELATED APPLICATIONS
CCATCTCCC
>MA784998.1 JP 2018526975-A/201: CYS80 CONJUGATED IMMUNOGLOBULINS
GCCGCTTCT
>MA784995.1 JP 2018526975-A/198: CYS80 CONJUGATED IMMUNOGLOBULINS
GCCGCTTCT
>MA784992.1 JP 2018526975-A/195: CYS80 CONJUGATED IMMUNOGLOBULINS
GCTGCATCC
>MA784989.1 JP 2018526975-A/192: CYS80 CONJUGATED IMMUNOGLOBULINS
GAAGCATCC
>MA784986.1 JP 2018526975-A/189: CYS80 CONJUGATED IMMUNOGLOBULINS
GATGCATCC
>MA784983.1 JP 2018526975-A/186: CYS80 CONJUGATED IMMUNOGLOBULINS
TCTGCATCC
>MA784980.1 JP 2018526975-A/183: CYS80 CONJUGATED IMMUNOGLOBULINS
TCTGCATCC
>MA784977.1 JP 2018526975-A/180: CYS80 CONJUGATED IMMUNOGLOBULINS
TTGGCCTCC
>MA784974.1 JP 2018526975-A/177: CYS80 CONJUGATED IMMUNOGLOBULINS
TTGGCCTCC
>MA784971.1 JP 2018526975-A/174: CYS80 CONJUGATED IMMUNOGLOBULINS
TTGGCCTCC
>MA784968.1 JP 2018526975-A/171: CYS80 CONJUGATED IMMUNOGLOBULINS
CTGGCATCC
>MA784965.1 JP 2018526975-A/168: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTACA
>MA784962.1 JP 2018526975-A/165: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTACA
>MA784959.1 JP 2018526975-A/162: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCAACC
>MA784956.1 JP 2018526975-A/159: CYS80 CONJUGATED IMMUNOGLOBULINS
AGGGCATCC
>MA784953.1 JP 2018526975-A/156: CYS80 CONJUGATED IMMUNOGLOBULINS
TACGCCTCC
>MA784950.1 JP 2018526975-A/153: CYS80 CONJUGATED IMMUNOGLOBULINS
TACGCCTCC
>MA784947.1 JP 2018526975-A/150: CYS80 CONJUGATED IMMUNOGLOBULINS
TACGCATCC
>MA784944.1 JP 2018526975-A/147: CYS80 CONJUGATED IMMUNOGLOBULINS
TACGCTTCC
>MA784941.1 JP 2018526975-A/144: CYS80 CONJUGATED IMMUNOGLOBULINS
TACGCGTCG
>MA784938.1 JP 2018526975-A/141: CYS80 CONJUGATED IMMUNOGLOBULINS
TACGCCTCC
>MA784935.1 JP 2018526975-A/138: CYS80 CONJUGATED IMMUNOGLOBULINS
TACGCCTCC
>MA784932.1 JP 2018526975-A/135: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTAGT
>MA784929.1 JP 2018526975-A/132: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTAGT
>MA784926.1 JP 2018526975-A/129: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTAGT
>MA784923.1 JP 2018526975-A/126: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTAGT
>MA784920.1 JP 2018526975-A/123: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTAGT
>MA784917.1 JP 2018526975-A/120: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTAGT
>MA784914.1 JP 2018526975-A/117: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCTAGT
>MA784911.1 JP 2018526975-A/114: CYS80 CONJUGATED IMMUNOGLOBULINS
TATGCATCC
>MA744543.1 JP 2015506701-A/4: SYNTHETIC BRASSICA-DERIVED CHLOROPLAST TRANSIT PEPTIDES
GCTTCTTCT
>MA744496.1 JP 2017512503-A/21: MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS
CGATACTGC
>MA744495.1 JP 2017512503-A/20: MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS
CGATACTGC
>MA680609.1 JP 2017121243-A/28775: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGTGTAG
>MA782791.1 JP 2018158922-A/140: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782771.1 JP 2018158922-A/120: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782761.1 JP 2018158922-A/110: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGCGACATC
>MA782751.1 JP 2018158922-A/100: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782741.1 JP 2018158922-A/90: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782731.1 JP 2018158922-A/80: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782721.1 JP 2018158922-A/70: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782711.1 JP 2018158922-A/60: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782701.1 JP 2018158922-A/50: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782691.1 JP 2018158922-A/40: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782681.1 JP 2018158922-A/30: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782671.1 JP 2018158922-A/20: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA782661.1 JP 2018158922-A/10: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>MA761879.1 JP 2017520249-A/69: Modulation of Nitrate Content in Plants
CAGCTTGTG
>MA761825.1 JP 2017520249-A/15: Modulation of Nitrate Content in Plants
CAGCTGCTG
>MA671843.1 JP 2017121243-A/20009: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGTTTAG
>MA670074.1 JP 2017121243-A/18240: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGCCTAG
>MA642075.1 JP 2017105801-A/21: CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES
GCCGCCACC
>MA689375.1 JP 2017121243-A/37541: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGTGTAG
>MA687606.1 JP 2017121243-A/35772: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
ATGGCCTAG
>CU870796.1 CU870796 Senescent mycelium Podospora anserina cDNA clone HH0ABG2YH19, mRNA sequence
AAAAAAAAA
>CU869546.1 CU869546 hetR/hetV incompatible mycelium Podospora anserina cDNA clone HH0ABH2YJ16, mRNA sequence
AAAAAAAAA
>CU873047.1 CU873047 Young perithecia of less than 48h Podospora anserina cDNA clone HH0ABD5YH04, mRNA sequence
AAAAAAAAA
>CU883594.1 CU883594 Perithecia older than 48h Podospora anserina cDNA clone HH0ABE1YN05, mRNA sequence
AAAAAAAAA
>CU882325.1 CU882325 Perithecia older than 48h Podospora anserina cDNA clone HH0ABE3YB15, mRNA sequence
AAAAAAAAA
>CU872533.1 CU872533 Young perithecia of less than 48h Podospora anserina cDNA clone HH0ABD6YL06, mRNA sequence
AAAAAAAAA
>AM230382.1 AM230382 Dreissena polymorpha library (Xu W) Dreissena polymorpha cDNA clone BG17_B11, mRNA sequence
AGTGAATTC
>AL043188.1 DKFZp434G2223_r1 434 (synonym: htes3) Homo sapiens cDNA clone DKFZp434G2223, mRNA sequence
TCTGGATTT
>AL043090.1 DKFZp434C1223_r1 434 (synonym: htes3) Homo sapiens cDNA clone DKFZp434C1223, mRNA sequence
CCCCCCCCC
>GW796561.1 AmnE011001P0045N06.y_phred13_vc Alexandrium minutum normalized EST library Alexandrium minutum cDNA, mRNA sequence
TGGCTCTGG
>GW873963.1 385542 Chlamydomonas CCMP681 3oC normalized cDNA Chlamydomonas sp. CCMP681 cDNA, mRNA sequence
GGATTTCGT
>GW855588.1 COV688-2006-06-05 COV Gadus morhua cDNA, mRNA sequence
TTTTTTTTT
>GW860679.1 CTA429f1-2007-12-12 CTA Gadus morhua cDNA, mRNA sequence
CCCCCCCCC
>GW857535.1 CPY2266-2005-12-01 CPY Gadus morhua cDNA, mRNA sequence
TATCTCTAC
>GW857449.1 CPY1775-2005-11-27 CPY Gadus morhua cDNA, mRNA sequence
GCTCCAATG
>GW860386.1 CTA1478-2006-03-02 CTA Gadus morhua cDNA, mRNA sequence
CCCCTTTTT
>GW860068.1 CSMi377f1-2007-08-21 CSMI Gadus morhua cDNA, mRNA sequence
AGTGTTACG
>GW846556.1 CHO338-2005-10-20 CHO Gadus morhua cDNA, mRNA sequence
TTATATGAT
>GW849139.1 CHY615-2006-04-18 CHY Gadus morhua cDNA, mRNA sequence
AAAAAAAAA
>GW843729.1 0090_CEf1549_A02_016 CEM Gadus morhua cDNA, mRNA sequence
GTGGGGGGT
>GW843522.1 CE3187-2005-03-07 CEM Gadus morhua cDNA, mRNA sequence
CCCTCCTTC
>GW843474.1 CE3125-2005-03-07 CEM Gadus morhua cDNA, mRNA sequence
CCCAGCTCC
>GW843408.1 CE3008-2005-03-07 CEM Gadus morhua cDNA, mRNA sequence
CCCGCCCAG
>GW842849.1 CE1654-2005-02-08 CEM Gadus morhua cDNA, mRNA sequence
TCCACCCCC
>JZ720593.1 thiosemicarbazideEST0759 Paracoccidioides thiosemicarbazide Library Paracoccidioides lutzii cDNA, mRNA sequence
TAGGGGTGG
>JG293442.1 TSB1_938 Suppression subtracted cDNA library TSB1 of fusarium wilt stressed Cicer arietinum cDNA Cicer arietinum cDNA, mRNA sequence
ACAAGTGAA
>JG445547.1 04145 (Cs-2011) Coleochaete scutata cDNA library Coleochaete scutata cDNA clone Coleo-C-a-28b05.t7, mRNA sequence
TGACTCATA
>JG445312.1 02340 (Cs-2011) Coleochaete scutata cDNA library Coleochaete scutata cDNA clone Coleo-C-a-24d10.t7, mRNA sequence
GGGGAAGNC
>JG443477.1 01087 Ks-2011 Klebsormidium subtile cDNA library Klebsormidium subtile cDNA clone klebsor-C-a-12h10.t7, mRNA sequence
GGTTGGGGC
>JG438725.1 00888 Coleochaete scutata cDNA library Coleochaete scutata cDNA clone Coleo-G-a-05f04.sp6, mRNA sequence
GTCTACCAG
>HS077606.1 KYERRC001_18-E11-T3.ab1 Panax ginseng in vitro-cultured adventitious root cDNA library Panax ginseng cDNA, mRNA sequence
GCACGAGGA
>HS080163.1 KYERRC001_45-F07-T3.ab1 Panax ginseng in vitro-cultured adventitious root cDNA library Panax ginseng cDNA, mRNA sequence
GCACGAGGC
>HS078835.1 KYERRC001_31-E10-T3.ab1 Panax ginseng in vitro-cultured adventitious root cDNA library Panax ginseng cDNA, mRNA sequence
CAGTCAGAC
>HS078419.1 KYERRC001_27-B09-T3.ab1 Panax ginseng in vitro-cultured adventitious root cDNA library Panax ginseng cDNA, mRNA sequence
GCACGAGGG
>EV284178.1 Trc_21-24_C01.g Central Nervous System (CNS) from one juvenile Tritonia diomedea Tritonia diomedea cDNA, mRNA sequence
CTCATCGTG
>GT296836.1 NAS10613-2008-09-30.ab1 Salmon notochord cDNA library from day degrees 450-850 Salmo salar cDNA, mRNA sequence
CTTCCTATG
>HO698262.1 NLG1235-2007-06-29.ab1 Lepeophtheirus salmonis NLG Lepeophtheirus salmonis cDNA, mRNA sequence
AAAAAAAAA
>HO687619.1 zslaa0_007855.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
GGCCATTAC
>HO694804.1 zslaa0_016182.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
TATATATAT
>HO686965.1 zslaa0_007120.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
GGAAGCGGC
>HO690473.1 zslaa0_011213.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
CCGGGAATT
>HO690115.1 zslaa0_010804.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
AGCGAGGAA
>HO697512.1 LPU1991-2007-09-05.ab1 Lepeophtheirus salmonis LPU Lepeophtheirus salmonis cDNA, mRNA sequence
AAAAAAATT
>HO696082.1 zslaa0_018456.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
TAATAACAC
>HO681283.1 LNO2072-2007-02-20.ab1 Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
AGAAAGAAA
>HO684163.1 zslaa0_002664.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
CATACATTA
>HO683353.1 zslaa0_001360.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
CATAACTTC
>HO683037.1 zslaa0_000504.z1.scf Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
GAAGCGGCC
>HO679653.1 LNO790-2007-01-25.ab1 Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
CCTGGATTT
>HO679597.1 LNO893-2007-01-03.ab1 Lepeophtheirus salmonis LNO Lepeophtheirus salmonis cDNA, mRNA sequence
GTCAGTGAG
>HO672212.1 HA649-2005-02-24.ab1 Lepeophtheirus salmonis HA Lepeophtheirus salmonis cDNA, mRNA sequence
GTTCTCTCT
>HO672055.1 HA316-2004-08-13.ab1 Lepeophtheirus salmonis HA Lepeophtheirus salmonis cDNA, mRNA sequence
TGGTTACAT
>HO667121.1 491_FN1378_F10_079.ab1 Lepeophtheirus salmonis FB Lepeophtheirus salmonis cDNA, mRNA sequence
CCCCCCCCC
>GW354130.1 CCASHART06h02R Pigeonpea Asha root cDNA Library Cajanus cajan cDNA, mRNA sequence
CCTTGACAG
>GR282985.1 896512 Chlamydomonas reinhardtii (CC-503 strain) cells grown in liquid culture under constant light Chlamydomonas reinhardtii cDNA clone 9142_E08_ORF 5' similar to EC 1.8.1.4, dihydrolipoyl dehydrogenase, SKA_Chlre2_kg.scaffold_1000106, mRNA sequence
TTATTTGCG
>GO322624.1 FCMI-PM-2409 WSSV infected Penaeus monodon cDNA library Penaeus monodon cDNA clone FCMI-PM-2409 3', mRNA sequence
CTGGAGCAG
>GO250488.1 Gpa-EST-P1-12-02___E05_020 Parasitic stage nematodes 7 days post infection Globodera pallida cDNA, mRNA sequence
TTCCCCCCC
>GH720955.1 TNE.003L15F011204 TNE Pisum sativum cDNA clone TNE003L15, mRNA sequence
TGGCCGGTT
>EL630883.1 Finnerty_Lab_EST_Nematostella_vectensis_7_30 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL631074.1 Finnerty_Lab_EST_Nematostella_vectensis_9_75 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL631072.1 Finnerty_Lab_EST_Nematostella_vectensis_9_11 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL631017.1 Finnerty_Lab_EST_Nematostella_vectensis_8_93 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL630990.1 Finnerty_Lab_EST_Nematostella_vectensis_8_8 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL630977.1 Finnerty_Lab_EST_Nematostella_vectensis_8_3 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL630950.1 Finnerty_Lab_EST_Nematostella_vectensis_8_2 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL630948.1 Finnerty_Lab_EST_Nematostella_vectensis_8_1 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL630947.1 Finnerty_Lab_EST_Nematostella_vectensis_7_91 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>EL630909.1 Finnerty_Lab_EST_Nematostella_vectensis_7_84 Finnerty Lab Nematostella vectensis cDNA library Nematostella vectensis cDNA, mRNA sequence
AAAGGGTTT
>ES059008.1 090378_1414_2252 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>ES045764.1 078659_3209_3073 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
CCGGAATGC
>ES018244.1 053410_0589_2958 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>ES166683.1 197998_0274_2313 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>ES057803.1 089328_1078_3576 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>ES165546.1 196552_1388_2380 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
TATTGCAAC
>EL992634.1 027903_2319_1152 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>ES121403.1 147299_0230_0725 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGAAGCAT
>ES079687.1 108746_1297_2334 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
GATAACAAC
>ES075613.1 105082_0398_1015 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>ES192253.1 239225_3110_3610 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
GGGAATGCA
>ES074637.1 104187_0881_1283 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>ES175124.1 208823_2110_0878 Arabidopsis ovule high throughput cDNA library Arabidopsis thaliana cDNA, mRNA sequence
AAGCAGTGG
>EV443669.1 agen0049_013d_g07_p1ca Goat early pregnancy (d4-8) cDNA library Capra hircus cDNA 5', mRNA sequence
GAAAAAAAA
>EV440364.1 agen0049_008b_d05_q1ca Goat early pregnancy (d4-8) cDNA library Capra hircus cDNA 3', mRNA sequence
GGCCGCCCT
>ES284208.1 PZ005F3.R germinating cysts of P. brassicae Phytophthora brassicae cDNA, mRNA sequence
GCACGAGGC
>EY395619.1 pME_04-B07-pME-S Aplysia kurodai nervous system 5' EST library Aplysia kurodai cDNA, mRNA sequence
TGGCCTACT
>EY395348.1 pME_01-C01-pME-S Aplysia kurodai nervous system 5' EST library Aplysia kurodai cDNA, mRNA sequence
GTTGGCCTA
>FD475997.1 3P9T7_H07_T7_060 frumisis3 Triticum turgidum subsp. durum cDNA clone 3P9T7_H07_T7_060, mRNA sequence
ACCACGCTA
>FD476409.1 3P1S-Rip_D04_SP6_030 frumisis3 Triticum turgidum subsp. durum cDNA clone 3P1S-Rip_D04_SP6_030, mRNA sequence
CGGCCTGGC
>FD475702.1 3P9T7_G05_T7_036 frumisis3 Triticum turgidum subsp. durum cDNA clone 3P9T7_G05_T7_036, mRNA sequence
TTCCTGTAC
>EC611683.1 VDSF_9_fwd_Run02_Cp357_MD1/ E04.esd VDSF Euglena gracilis UTEX Euglena gracilis cDNA, mRNA sequence
TGTACCTAG
>EC611629.1 VDSF_9_fwd_Run02_Cp357_MD1/ D01.esd VDSF Euglena gracilis UTEX Euglena gracilis cDNA, mRNA sequence
TTTAGTATC
>EC610767.1 VDSF_5_fwd_Run01_Cp357_MD1/ B01.esd VDSF Euglena gracilis UTEX Euglena gracilis cDNA, mRNA sequence
AGCTTTAGA
>EC609950.1 VDSF_11_F_Run01_Cp357_MD1/ H12.esd VDSF Euglena gracilis UTEX Euglena gracilis cDNA, mRNA sequence
AGGAGTCGC
>EC609926.1 VDSF_11_F_Run01_Cp357_MD1/ G12.esd VDSF Euglena gracilis UTEX Euglena gracilis cDNA, mRNA sequence
AAGCCTTCG
>EX949676.1 lj98h05.g7 Gnetum gnemon leaf (NYBG) Gnetum gnemon cDNA 3', mRNA sequence
GGCACGAGG
>EX941233.1 lb88f11.g1 Ginkgo ovule (NYBG) Ginkgo biloba cDNA 3', mRNA sequence
GCCTCGGCC
>EX937228.1 iy71c11.g1 Ginkgo ovule (NYBG) Ginkgo biloba cDNA 3', mRNA sequence
GCCTCGGCC
>EX937378.1 iy73d06.g1 Ginkgo ovule (NYBG) Ginkgo biloba cDNA 3', mRNA sequence
GCCTCGGCC
>CV179280.1 CSECS015G08_POSn0036 CabSau Normalised Berry Postveraison Stage 36 (POSn0036) Vitis vinifera cDNA clone CSECS015G08 3', mRNA sequence
GGGTCGACC
>CO818814.1 CSECS120A07_PREn0028 CabSau Normalised Berry Fruit Set Stage 28 (PREn0028) Vitis vinifera cDNA clone CSECS120A07 3', mRNA sequence
ATCTAGAAC
>CO785802.1 BL284C_D07 6-Day Axolotl Tail Blastema (6DAxBL) Ambystoma mexicanum cDNA 5' similar to hypothetical protein, mRNA sequence
TATAGACAG
>DR026242.1 Osmo00110 F. cylindrus osmotic stress library Fragilariopsis cylindrus cDNA clone FcylESTa35b12.s1, mRNA sequence
TGGAGTTTT
>CD744103.1 IRB2Q4_A02_Q4_006 Infected Rat Blood-fed (IRB) An.gam. 30 hr Abdomen Library Anopheles gambiae cDNA 5', mRNA sequence
AAAACAATT
>CA853471.1 B08F06.seq cDNA Peking library 12hr SCN3 Glycine max cDNA clone B08F06 5', mRNA sequence
NAAGCTGNC
>CA853359.1 B07D04.seq cDNA Peking library 12hr SCN3 Glycine max cDNA clone B07D04 5', mRNA sequence
TGAGCTGCT
>CA853358.1 B07D03.seq cDNA Peking library 12hr SCN3 Glycine max cDNA clone B07D03 5', mRNA sequence
AAAGCTNGT
>CA851674.1 D16C10_F22_05.ab1 cDNA Peking library 2, 4 day SCN3 Glycine max cDNA clone D16C10 5', mRNA sequence
ACAAAAGGN
>CA850970.1 D08G04_N16_14.ab1 cDNA Peking library 2, 4 day SCN3 Glycine max cDNA clone D08G04 5', mRNA sequence
TTTTTGNTG
>CA850899.1 D07H02_O14_15.ab1 cDNA Peking library 2, 4 day SCN3 Glycine max cDNA clone D07H02 5', mRNA sequence
GATGATGGG
>CA850813.1 D06G10_G10_14.ab1 cDNA Peking library 2, 4 day SCN3 Glycine max cDNA clone D06G10 5', mRNA sequence
TTGTTTATG
>BU101621.1 PRODG1GID193F1 Compugen_targeted_mRNA_sequencing Homo sapiens cDNA, mRNA sequence
ATCGTACTA
>MA634342.1 JP 2018521689-A/22: COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME
TCTAATGGG
>MA634341.1 JP 2018521689-A/21: COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME
AATAATAAC
>MA634340.1 JP 2018521689-A/20: COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME
TCCCACGAC
>MA634339.1 JP 2018521689-A/19: COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME
TCTAACATC
>MA633347.1 JP 2018520667-A/55: T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA
GGTAAAAAC
>MA633344.1 JP 2018520667-A/52: T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA
GATGATGAC
>MA633341.1 JP 2018520667-A/49: T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA
GGTAAAAAC
>MA633338.1 JP 2018520667-A/46: T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA
TATAATAAC
>MA633335.1 JP 2018520667-A/43: T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA
GATGTCAGT
>MA633332.1 JP 2018520667-A/40: T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA
TATAATACT
>MA633329.1 JP 2018520667-A/37: T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA
TATGATAGC
>MA632703.1 JP 2018523988-A/1: TOMATO PLANTS HAVING FRUIT WITH YELLOW AND RED SEGMENTS
ATCTGGATA
>MA626086.1 JP 2018139611-A/186: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GGCAACAAC
>MA626073.1 JP 2018139611-A/173: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGCATCC
>MA626063.1 JP 2018139611-A/163: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
AAGAATAAT
>MA626044.1 JP 2018139611-A/144: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GGTAACAAC
>MA626036.1 JP 2018139611-A/136: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
ACTACATCC
>MA626028.1 JP 2018139611-A/128: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GACGTCACT
>MA626013.1 JP 2018139611-A/113: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GCTGCATCC
>MA625999.1 JP 2018139611-A/99: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
CAAGATACG
>MA625977.1 JP 2018139611-A/77: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GGTGCATCC
>MA625969.1 JP 2018139611-A/69: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGTCGAT
>MA625961.1 JP 2018139611-A/61: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
CAAGATTCC
>MA625953.1 JP 2018139611-A/53: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GAGGTTTCT
>MA625945.1 JP 2018139611-A/45: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGGCAGT
>MA625937.1 JP 2018139611-A/37: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGTCAGT
>MA625929.1 JP 2018139611-A/29: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GACAATGAT
>MA625921.1 JP 2018139611-A/21: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
AAAGACACT
>MA625913.1 JP 2018139611-A/13: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGATAGC
>MA625905.1 JP 2018139611-A/5: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
AAGGCGTCT
>MA625822.1 JP 2018138590-A/2: METHODS FOR TAGGING DNA-ENCODED LIBRARIES
GCAGCACCC
>MA427520.1 JP 2018140938-A/1: Artificial Nucleoside, Artificial Nucleotide and Artificial Oligonucleotide
TTTTTTTTT
>MA410998.1 JP 2018517674-A/75: mRNA containing composition for treatment of tumor disease
GGGTTTGGG
>MA410987.1 JP 2018517674-A/64: mRNA containing composition for treatment of tumor disease
GGTTTTTGG
>MA407398.1 JP 2018519796-A/3: Compositions and methods for allergen detection
AGCGTGTAA
>MA407388.1 JP 2018518459-A/11: SECRETORY TNT CAR CELL IMMUNOTHERAPY
AGGAAAAAC
>MA406987.1 JP 2018518939-A/252: CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL
WGGAAANHN
>MA405165.1 WO 2018151225-A/21: agent and method for promoting muscle differentiation, oligodeoxynucleotide and its activator for promoting muscle differentiation, and oligodeoxynucleotide
TGAGGGTGA
>MA404879.1 WO 2018143477-A/153: Method for enginerring genome of dicotyledonous plants
TCCGCCTGG
>MA404867.1 WO 2018143477-A/141: Method for enginerring genome of dicotyledonous plants
CCATATTTC
>LQ941838.1 Sequence 285 from Patent WO2014137674
GCTGCATCC
>LQ941822.1 Sequence 269 from Patent WO2014137674
GCTGCATCC
>LQ941806.1 Sequence 253 from Patent WO2014137674
TTTACATCC
>LQ941790.1 Sequence 237 from Patent WO2014137674
GCTGCATCC
>LQ941774.1 Sequence 221 from Patent WO2014137674
GCTGCATCC
>LQ941758.1 Sequence 205 from Patent WO2014137674
AAGGCGTCT
>LQ941742.1 Sequence 189 from Patent WO2014137674
AGGTCGTCT
>LQ941726.1 Sequence 173 from Patent WO2014137674
GCTGCATCC
>LQ941710.1 Sequence 157 from Patent WO2014137674
TGGGCATCT
>LQ941694.1 Sequence 141 from Patent WO2014137674
AAGATTTCT
>LQ941678.1 Sequence 125 from Patent WO2014137674
TGGGCATCT
>LQ941662.1 Sequence 109 from Patent WO2014137674
GGTGCATCC
>LQ941646.1 Sequence 93 from Patent WO2014137674
GCTGCATCC
>LQ941630.1 Sequence 77 from Patent WO2014137674
TCTGCATCC
>LQ941614.1 Sequence 61 from Patent WO2014137674
GCTGCATCC
>LQ941598.1 Sequence 45 from Patent WO2014137674
GCTACATCC
>LQ941582.1 Sequence 29 from Patent WO2014137674
AAGGCGTCT
>LQ941566.1 Sequence 13 from Patent WO2014137674
GGTCCATCC
>LQ994983.1 Sequence 19 from Patent EP2574345
GGTGACTAC
>LQ994006.1 Sequence 493 from Patent WO2013048883
GCTGCATCC
>LQ993990.1 Sequence 477 from Patent WO2013048883
GGTGTATCC
>LQ993974.1 Sequence 461 from Patent WO2013048883
GCTGCATCC
>LQ993958.1 Sequence 445 from Patent WO2013048883
GCTGCATCC
>LQ993942.1 Sequence 429 from Patent WO2013048883
AGTGCATCC
>LQ993926.1 Sequence 413 from Patent WO2013048883
GGTACATCC
>LQ993910.1 Sequence 397 from Patent WO2013048883
GGAGCATCC
>LQ993894.1 Sequence 381 from Patent WO2013048883
GAAACATCC
>LQ993878.1 Sequence 365 from Patent WO2013048883
GGAGCATCC
>LQ993862.1 Sequence 349 from Patent WO2013048883
GGAGCATCC
>LQ993846.1 Sequence 333 from Patent WO2013048883
TGGGCATCT
>LQ993830.1 Sequence 317 from Patent WO2013048883
GATGCATCC
>LQ993814.1 Sequence 301 from Patent WO2013048883
GGTGCATCC
>LQ993798.1 Sequence 285 from Patent WO2013048883
ACTGCATCC
>LQ993782.1 Sequence 269 from Patent WO2013048883
TGGGCATCT
>LQ993766.1 Sequence 253 from Patent WO2013048883
GCTGCATCC
>LQ993750.1 Sequence 237 from Patent WO2013048883
ACTTCATCC
>LQ993734.1 Sequence 221 from Patent WO2013048883
GGTGCATCC
>LQ993718.1 Sequence 205 from Patent WO2013048883
TGGGCATCC
>LQ993702.1 Sequence 189 from Patent WO2013048883
GATGCATCC
>LQ993686.1 Sequence 173 from Patent WO2013048883
GCTGCATCC
>LQ993670.1 Sequence 157 from Patent WO2013048883
ACTACATCC
>LQ993654.1 Sequence 141 from Patent WO2013048883
TGGGCATCC
>LQ993638.1 Sequence 125 from Patent WO2013048883
GCTGCATCC
>LQ993622.1 Sequence 109 from Patent WO2013048883
GGTGCATCC
>LQ993606.1 Sequence 93 from Patent WO2013048883
GCTGCATCC
>LQ993590.1 Sequence 77 from Patent WO2013048883
GCTGCATCC
>LQ993574.1 Sequence 61 from Patent WO2013048883
GCTGCATCC
>LQ993558.1 Sequence 45 from Patent WO2013048883
GCTGCAACC
>LQ993542.1 Sequence 29 from Patent WO2013048883
GCTGCATCC
>LQ993526.1 Sequence 13 from Patent WO2013048883
GCTGCATCC
>LQ993102.1 Sequence 127 from Patent EP2580329
RGAGGKAGG
>LQ993093.1 Sequence 118 from Patent EP2580329
TTMCGGGAA
>LQ993084.1 Sequence 109 from Patent EP2580329
TGTCTGTCT
>LQ993071.1 Sequence 96 from Patent EP2580329
WTGATTGNT
>LQ993062.1 Sequence 87 from Patent EP2580329
WANTAAWTA
>LQ993058.1 Sequence 83 from Patent EP2580329
YSATTGGYY
>LQ993057.1 Sequence 82 from Patent EP2580329
CGGCCATCT
>LQ993044.1 Sequence 69 from Patent EP2580329
YCTCCCAAA
>LQ993018.1 Sequence 43 from Patent EP2580329
CACTTCCTG
>LQ993008.1 Sequence 33 from Patent EP2580329
GGNNTTYCC
>LQ993006.1 Sequence 31 from Patent EP2580329
SCGATCGAT
>LQ992999.1 Sequence 24 from Patent EP2580329
GRGGSTGGG
>LQ992991.1 Sequence 16 from Patent EP2580329
GCAGCTGNY
>LQ992990.1 Sequence 15 from Patent EP2580329
SCYNNNGGC
>LQ992011.1 Sequence 53 from Patent WO2013049135
CTCGCAAGC
>LQ991984.1 Sequence 26 from Patent WO2013049135
CTGCGGAAC
>LQ977516.1 Sequence 733 from Patent WO2013039969
TTGGGTTTT
>LQ977492.1 Sequence 709 from Patent WO2013039969
GGTGCATCC
>LQ977468.1 Sequence 685 from Patent WO2013039969
AAGGTTTCT
>LQ977444.1 Sequence 661 from Patent WO2013039969
AAGGTTTCT
>LQ977420.1 Sequence 637 from Patent WO2013039969
AAGGTTTCT
>LQ977396.1 Sequence 613 from Patent WO2013039969
GGTGCATCC
>LQ977372.1 Sequence 589 from Patent WO2013039969
GATGCATCC
>LQ977348.1 Sequence 565 from Patent WO2013039969
GGTGCATCC
>LQ977324.1 Sequence 541 from Patent WO2013039969
GGTGCATCC
>LQ977300.1 Sequence 517 from Patent WO2013039969
TTGGGTTTT
>LQ977276.1 Sequence 493 from Patent WO2013039969
GGTGCATCC
>LQ977252.1 Sequence 469 from Patent WO2013039969
AAGGCGTCT
>LQ977228.1 Sequence 445 from Patent WO2013039969
AAGGCGTCT
>LQ977204.1 Sequence 421 from Patent WO2013039969
AAGGCGTCT
>LQ977180.1 Sequence 397 from Patent WO2013039969
AAGGCGTCT
>LQ977156.1 Sequence 373 from Patent WO2013039969
GGTGCATCC
>LQ977132.1 Sequence 349 from Patent WO2013039969
AAGGCGTCT
>LQ977108.1 Sequence 325 from Patent WO2013039969
AAGGTTTCT
>LQ977084.1 Sequence 301 from Patent WO2013039969
TTGGGTTCT
>LQ977060.1 Sequence 277 from Patent WO2013039969
TTGGGTTTT
>LQ977036.1 Sequence 253 from Patent WO2013039969
TTGGGTTTT
>LQ977012.1 Sequence 229 from Patent WO2013039969
TTGGGTTCT
>LQ976988.1 Sequence 205 from Patent WO2013039969
TTGGGTTCT
>LQ976964.1 Sequence 181 from Patent WO2013039969
TTGGGTTCT
>LQ976940.1 Sequence 157 from Patent WO2013039969
AAGGTTTCT
>LQ976916.1 Sequence 133 from Patent WO2013039969
GCTGCATCC
>LQ976892.1 Sequence 109 from Patent WO2013039969
GCTGCATCC
>LQ976868.1 Sequence 85 from Patent WO2013039969
TGGGCATCT
>LQ976844.1 Sequence 61 from Patent WO2013039969
TGGGCCTCT
>LQ976820.1 Sequence 37 from Patent WO2013039969
AAGGCGTCT
>LQ976796.1 Sequence 13 from Patent WO2013039969
GGTGCATCC
>LQ976147.1 Sequence 17 from Patent WO2013037727
GGTACCAAC
>LQ975426.1 Sequence 11 from Patent EP2662451
CAGGTACGG
>LQ968371.1 Sequence 834 from Patent WO2014159595
TTGGGTTCT
>LQ968355.1 Sequence 818 from Patent WO2014159595
AAGATTTCT
>LQ968339.1 Sequence 802 from Patent WO2014159595
GATGCATCC
>LQ968323.1 Sequence 786 from Patent WO2014159595
GATATATCC
>LQ968307.1 Sequence 770 from Patent WO2014159595
AAGATTTCT
>LQ968291.1 Sequence 754 from Patent WO2014159595
AAGATTTCT
>LQ968275.1 Sequence 738 from Patent WO2014159595
AAGATTTCT
>LQ966628.1 Sequence 589 from Patent WO2014159010
GATGCATCC
>LQ966612.1 Sequence 573 from Patent WO2014159010
GCTGCATCC
>LQ966596.1 Sequence 557 from Patent WO2014159010
GATTCATCC
>LQ966580.1 Sequence 541 from Patent WO2014159010
GGTGCATCC
>LQ966564.1 Sequence 525 from Patent WO2014159010
GCTGCATCC
>LQ966548.1 Sequence 509 from Patent WO2014159010
GATGCATCC
>LQ966532.1 Sequence 493 from Patent WO2014159010
GCTGCATCC
>LQ966516.1 Sequence 477 from Patent WO2014159010
GATGCATCC
>LQ966500.1 Sequence 461 from Patent WO2014159010
GCTGCATCC
>LQ966484.1 Sequence 445 from Patent WO2014159010
GATGCATCC
>LQ966468.1 Sequence 429 from Patent WO2014159010
GCTGCATCC
>LQ966452.1 Sequence 413 from Patent WO2014159010
GATTCATCC
>LQ966436.1 Sequence 397 from Patent WO2014159010
GGTGCATCC
>LQ966420.1 Sequence 381 from Patent WO2014159010
GCTGCATCC
>LQ966404.1 Sequence 365 from Patent WO2014159010
GATGCATCC
>LQ966388.1 Sequence 349 from Patent WO2014159010
GCTGCATCC
>LQ966372.1 Sequence 333 from Patent WO2014159010
GGTGCATCC
>LQ966356.1 Sequence 317 from Patent WO2014159010
GTTGCATCC
>LQ966340.1 Sequence 301 from Patent WO2014159010
GATGCATTC
>LQ966324.1 Sequence 285 from Patent WO2014159010
GTTGTATCC
>LQ966308.1 Sequence 269 from Patent WO2014159010
GCTGCATCC
>LQ966292.1 Sequence 253 from Patent WO2014159010
GATGCATCC
>LQ966276.1 Sequence 237 from Patent WO2014159010
GCTGCATCC
>LQ966260.1 Sequence 221 from Patent WO2014159010
TTGGGTTCT
>LQ966244.1 Sequence 205 from Patent WO2014159010
TATGTTTCC
>LQ966228.1 Sequence 189 from Patent WO2014159010
GCTGCATCC
>LQ966212.1 Sequence 173 from Patent WO2014159010
GTTGTATCA
>LQ966196.1 Sequence 157 from Patent WO2014159010
GATGCATCC
>LQ966180.1 Sequence 141 from Patent WO2014159010
GCTGCATCC
>LQ966164.1 Sequence 125 from Patent WO2014159010
GATGCATCC
>LQ966148.1 Sequence 109 from Patent WO2014159010
GATGCATCC
>LQ966132.1 Sequence 93 from Patent WO2014159010
GATGCATCC
>LQ966116.1 Sequence 77 from Patent WO2014159010
GATGCATCC
>LQ966100.1 Sequence 61 from Patent WO2014159010
GATGCATCC
>LQ966084.1 Sequence 45 from Patent WO2014159010
GCTGCATCC
>LQ966068.1 Sequence 29 from Patent WO2014159010
TCTGCATCC
>LQ966052.1 Sequence 13 from Patent WO2014159010
GATGCATCC
>LQ964033.1 Sequence 62 from Patent EP2780473
GCGCGAGCG
>LQ961711.1 Sequence 10 from Patent WO2014155097
TGTGATATA
>LQ961335.1 Sequence 66 from Patent WO2014160627
GCGGCCGCA
>LQ960464.1 Sequence 349 from Patent WO2014159822
TCTACATCC
>LQ960448.1 Sequence 333 from Patent WO2014159822
GGTGCATCC
>LQ960432.1 Sequence 317 from Patent WO2014159822
AAGATTTCT
>LQ960416.1 Sequence 301 from Patent WO2014159822
GGTGCATCC
>LQ960400.1 Sequence 285 from Patent WO2014159822
GGTGCATCC
>LQ960384.1 Sequence 269 from Patent WO2014159822
GGTGCATCC
>LQ960368.1 Sequence 253 from Patent WO2014159822
TTGGGTTCT
>LQ960352.1 Sequence 237 from Patent WO2014159822
GCTGCGTCC
>LQ960336.1 Sequence 221 from Patent WO2014159822
TGGGCATCT
>LQ960320.1 Sequence 205 from Patent WO2014159822
GATGCATCC
>LQ960304.1 Sequence 189 from Patent WO2014159822
GCTGCATCC
>LQ960288.1 Sequence 173 from Patent WO2014159822
TTGGGTTCT
>LQ960272.1 Sequence 157 from Patent WO2014159822
TTGGGTTCT
>LQ960256.1 Sequence 141 from Patent WO2014159822
GGTGCATCC
>LQ960240.1 Sequence 125 from Patent WO2014159822
GGTGCATCC
>LQ960224.1 Sequence 109 from Patent WO2014159822
GCTGCATCC
>LQ960208.1 Sequence 93 from Patent WO2014159822
GATGTATCC
>LQ960192.1 Sequence 77 from Patent WO2014159822
GCTGCATCC
>LQ960176.1 Sequence 61 from Patent WO2014159822
GCTTCATCC
>LQ960160.1 Sequence 45 from Patent WO2014159822
GGTGCATCC
>LQ960144.1 Sequence 29 from Patent WO2014159822
GGTGCATCC
>LQ960128.1 Sequence 13 from Patent WO2014159822
GCTGCATCC
>LQ959639.1 Sequence 4 from Patent WO2014173570
ATGCCGTTT
>LQ959636.1 Sequence 1 from Patent WO2014173570
CTGTTTACG
>LQ958175.1 Sequence 12 from Patent WO2014033262
AAGACCCAT
>LQ958620.1 Sequence 10 from Patent WO2014174111
TCTGGATCC
>LQ958583.1 Sequence 28 from Patent WO2014174511
TTTGTGTAG
>LQ958582.1 Sequence 27 from Patent WO2014174511
TTCAAGAGA
>LQ956072.1 Sequence 14 from Patent EP2787077
ACTCGCTCC
>LQ954099.1 Sequence 22 from Patent WO2014193229
CGCTSCCCG
>LQ954098.1 Sequence 21 from Patent WO2014193229
CGCTCCCCG
>LQ953634.1 Sequence 733 from Patent WO2014194111
TTGGGTTTT
>LQ953610.1 Sequence 709 from Patent WO2014194111
GGTGCATCC
>LQ953586.1 Sequence 685 from Patent WO2014194111
AAGGTTTCT
>LQ953562.1 Sequence 661 from Patent WO2014194111
AAGGTTTCT
>LQ953538.1 Sequence 637 from Patent WO2014194111
AAGGTTTCT
>LQ953514.1 Sequence 613 from Patent WO2014194111
GGTGCATCC
>LQ953490.1 Sequence 589 from Patent WO2014194111
GATGCATCC
>LQ953466.1 Sequence 565 from Patent WO2014194111
GGTGCATCC
>LQ953442.1 Sequence 541 from Patent WO2014194111
GGTGCATCC
>LQ953418.1 Sequence 517 from Patent WO2014194111
TTGGGTTTT
>LQ953394.1 Sequence 493 from Patent WO2014194111
GGTGCATCC
>LQ953370.1 Sequence 469 from Patent WO2014194111
AAGGCGTCT
>LQ953346.1 Sequence 445 from Patent WO2014194111
AAGGCGTCT
>LQ953322.1 Sequence 421 from Patent WO2014194111
AAGGCGTCT
>LQ953298.1 Sequence 397 from Patent WO2014194111
AAGGCGTCT
>LQ953274.1 Sequence 373 from Patent WO2014194111
GGTGCATCC
>LQ953250.1 Sequence 349 from Patent WO2014194111
AAGGCGTCT
>LQ953226.1 Sequence 325 from Patent WO2014194111
AAGGTTTCT
>LQ953202.1 Sequence 301 from Patent WO2014194111
TTGGGTTCT
>LQ953178.1 Sequence 277 from Patent WO2014194111
TTGGGTTTT
>LQ953154.1 Sequence 253 from Patent WO2014194111
TTGGGTTTT
>LQ953130.1 Sequence 229 from Patent WO2014194111
TTGGGTTCT
>LQ953106.1 Sequence 205 from Patent WO2014194111
TTGGGTTCT
>LQ953082.1 Sequence 181 from Patent WO2014194111
TTGGGTTCT
>LQ953058.1 Sequence 157 from Patent WO2014194111
AAGGTTTCT
>LQ953034.1 Sequence 133 from Patent WO2014194111
GCTGCATCC
>LQ953010.1 Sequence 109 from Patent WO2014194111
GCTGCATCC
>LQ952986.1 Sequence 85 from Patent WO2014194111
TGGGCATCT
>LQ952962.1 Sequence 61 from Patent WO2014194111
TGGGCCTCT
>LQ952938.1 Sequence 37 from Patent WO2014194111
AAGGCGTCT
>LQ952914.1 Sequence 13 from Patent WO2014194111
GGTGCATCC
>LQ952812.1 Sequence 733 from Patent WO2014194168
TTGGGTTTT
>LQ952788.1 Sequence 709 from Patent WO2014194168
GGTGCATCC
>LQ952764.1 Sequence 685 from Patent WO2014194168
AAGGTTTCT
>LQ952740.1 Sequence 661 from Patent WO2014194168
AAGGTTTCT
>LQ952716.1 Sequence 637 from Patent WO2014194168
AAGGTTTCT
>LQ952692.1 Sequence 613 from Patent WO2014194168
GGTGCATCC
>LQ952668.1 Sequence 589 from Patent WO2014194168
GATGCATCC
>LQ952644.1 Sequence 565 from Patent WO2014194168
GGTGCATCC
>LQ952620.1 Sequence 541 from Patent WO2014194168
GGTGCATCC
>LQ952596.1 Sequence 517 from Patent WO2014194168
TTGGGTTTT
>LQ952572.1 Sequence 493 from Patent WO2014194168
GGTGCATCC
>LQ952548.1 Sequence 469 from Patent WO2014194168
AAGGCGTCT
>LQ952524.1 Sequence 445 from Patent WO2014194168
AAGGCGTCT
>LQ952500.1 Sequence 421 from Patent WO2014194168
AAGGCGTCT
>LQ952476.1 Sequence 397 from Patent WO2014194168
AAGGCGTCT
>LQ952452.1 Sequence 373 from Patent WO2014194168
GGTGCATCC
>LQ952428.1 Sequence 349 from Patent WO2014194168
AAGGCGTCT
>LQ952404.1 Sequence 325 from Patent WO2014194168
AAGGTTTCT
>LQ952380.1 Sequence 301 from Patent WO2014194168
TTGGGTTCT
>LQ952356.1 Sequence 277 from Patent WO2014194168
TTGGGTTTT
>LQ952332.1 Sequence 253 from Patent WO2014194168
TTGGGTTTT
>LQ952308.1 Sequence 229 from Patent WO2014194168
TTGGGTTCT
>LQ952284.1 Sequence 205 from Patent WO2014194168
TTGGGTTCT
>LQ952260.1 Sequence 181 from Patent WO2014194168
TTGGGTTCT
>LQ952236.1 Sequence 157 from Patent WO2014194168
AAGGTTTCT
>LQ952212.1 Sequence 133 from Patent WO2014194168
GCTGCATCC
>LQ952188.1 Sequence 109 from Patent WO2014194168
GCTGCATCC
>LQ952164.1 Sequence 85 from Patent WO2014194168
TGGGCATCT
>LQ952140.1 Sequence 61 from Patent WO2014194168
TGGGCCTCT
>LQ952116.1 Sequence 37 from Patent WO2014194168
AAGGCGTCT
>LQ952092.1 Sequence 13 from Patent WO2014194168
GGTGCATCC
>LQ945623.1 Sequence 21 from Patent EP2692862
TATGCGATT
>LQ945622.1 Sequence 20 from Patent EP2692862
ATGCGATTA
>LQ945619.1 Sequence 17 from Patent EP2692862
TACCGGGCT
>LQ945613.1 Sequence 11 from Patent EP2692862
AATCGCATA
>LQ945612.1 Sequence 10 from Patent EP2692862
TAATCGCAT
>LQ945609.1 Sequence 7 from Patent EP2692862
AGCCCGGTA
>LQ945303.1 Sequence 1 from Patent EP2806948
GACCACCCA
>LQ928692.1 Sequence 24 from Patent WO2018193072
ACATTCCTG
>LQ928686.1 Sequence 18 from Patent WO2018193072
TTCCAGGAA
>LQ928682.1 Sequence 14 from Patent WO2018193072
CGCCATTTT
>LQ928679.1 Sequence 11 from Patent WO2018193072
ACAGGAAGT
>LQ928678.1 Sequence 10 from Patent WO2018193072
ACCGGAAGT
>LQ928677.1 Sequence 9 from Patent WO2018193072
GGGGCGGGG
>LQ928671.1 Sequence 3 from Patent WO2018193072
ATTGCATCA
>LQ925727.1 Sequence 19 from Patent EP3394262
CANCNNNGC
>LQ925720.1 Sequence 12 from Patent EP3394262
CCNGCCANA
>LQ925716.1 Sequence 8 from Patent EP3394262
GGNNCNGCA
>LQ925669.1 Sequence 319 from Patent WO2018190990
TGGGCATCT
>LQ925651.1 Sequence 301 from Patent WO2018190990
GCTGCATCA
>LQ925635.1 Sequence 285 from Patent WO2018190990
GCTGCTTCC
>LQ925619.1 Sequence 269 from Patent WO2018190990
GCTGCATCC
>LQ925603.1 Sequence 253 from Patent WO2018190990
GTTGCATCC
>LQ925587.1 Sequence 237 from Patent WO2018190990
GCTGCGTCC
>LQ925571.1 Sequence 221 from Patent WO2018190990
GCTGCATCC
>LQ925555.1 Sequence 205 from Patent WO2018190990
GCTGCATCC
>LQ925539.1 Sequence 189 from Patent WO2018190990
GCTGCATCC
>LQ925523.1 Sequence 173 from Patent WO2018190990
GCTGCGTCC
>LQ925507.1 Sequence 157 from Patent WO2018190990
GCTGCAGCC
>LQ925491.1 Sequence 141 from Patent WO2018190990
GCTGCATCC
>LQ925475.1 Sequence 125 from Patent WO2018190990
GCTGCATCC
>LQ925459.1 Sequence 109 from Patent WO2018190990
GCTGCATCC
>LQ925443.1 Sequence 93 from Patent WO2018190990
GCTGCATCC
>LQ925427.1 Sequence 77 from Patent WO2018190990
GCTGCATCC
>LQ925411.1 Sequence 61 from Patent WO2018190990
GCTGCATCC
>LQ925395.1 Sequence 45 from Patent WO2018190990
GGTGCATCC
>LQ925379.1 Sequence 29 from Patent WO2018190990
GCTGCATCC
>LQ925363.1 Sequence 13 from Patent WO2018190990
GCTGCATCC
>LQ927086.1 Sequence 459 from Patent WO2018189382
TTCGTCGTT
>LQ927079.1 Sequence 452 from Patent WO2018189382
TTCGACGTT
>LQ923749.1 Sequence 37 from Patent EP3394261
CANCNNNGC
>LQ923747.1 Sequence 35 from Patent EP3394261
ACNCCNGAA
>LQ923741.1 Sequence 29 from Patent EP3394261
GCCAACANG
>LQ923729.1 Sequence 17 from Patent EP3394261
AGGCANGNC
>LQ923728.1 Sequence 16 from Patent EP3394261
AGGCANGNC
>LQ923726.1 Sequence 14 from Patent EP3394261
GNNCANANG
>LQ923725.1 Sequence 13 from Patent EP3394261
AACCCNCNG
>LQ915239.1 Sequence 2 from Patent EP3392338
GCAGCACCC
>MA391510.1 JP 2018512435-A/7: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GGTGTATCC
>MA391685.1 JP 2018512435-A/182: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391677.1 JP 2018512435-A/174: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
ACTACATCC
>MA391666.1 JP 2018512435-A/163: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
AAGATTTCT
>MA391662.1 JP 2018512435-A/159: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
TTGGGTTCT
>MA391654.1 JP 2018512435-A/151: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391646.1 JP 2018512435-A/143: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GGTGCATCC
>MA391638.1 JP 2018512435-A/135: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
TTGGGTTCT
>MA391630.1 JP 2018512435-A/127: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GGTGCATCC
>MA391622.1 JP 2018512435-A/119: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GGTGCATCC
>MA391614.1 JP 2018512435-A/111: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GGTGCATCC
>MA391606.1 JP 2018512435-A/103: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GGTGCATCC
>MA391598.1 JP 2018512435-A/95: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTACATCC
>MA391590.1 JP 2018512435-A/87: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GGTGCATCC
>MA391582.1 JP 2018512435-A/79: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391574.1 JP 2018512435-A/71: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GTTGCATCC
>MA391566.1 JP 2018512435-A/63: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
CGGATGTCC
>MA391558.1 JP 2018512435-A/55: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391550.1 JP 2018512435-A/47: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391542.1 JP 2018512435-A/39: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391534.1 JP 2018512435-A/31: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391526.1 JP 2018512435-A/23: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA391518.1 JP 2018512435-A/15: METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS
GCTGCATCC
>MA389319.1 JP 2018513127-A/22: METHODS OF POLYNUCLEOTIDE PREPARATION USING MULTIVALENT CATION SALT COMPOSITIONS
CAGTTAGGG
>MA389318.1 JP 2018513127-A/21: METHODS OF POLYNUCLEOTIDE PREPARATION USING MULTIVALENT CATION SALT COMPOSITIONS
GGGTTAGAC
>MA388246.1 JP 2018512120-A/18: Fusion Protein Comprising a Ligand Binding Domain of VEGF and PDGF
GGAGACACT
>MA388243.1 JP 2018512120-A/15: Fusion Protein Comprising a Ligand Binding Domain of VEGF and PDGF
GGAGACACC
>MA388840.1 JP 2018513681-A/37: CAS 9 RETROVIRAL INTEGRASE AND CAS 9 RECOMBINASE SYSTEMS FOR TARGETED INCORPORATION OF A DNA SEQUENCE INTO A GENOME OF A CELL OR ORGANISM
GGGGGAAGT
>MA402284.1 JP 2018515138-A/37: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
GTTTTTGTA
>MA402268.1 JP 2018515138-A/21: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
TCATTTGAG
>MA402266.1 JP 2018515138-A/19: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
CGATTTGAG
>MA395766.1 JP 2018109056-A/127: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GATGCATCC
>MA395754.1 JP 2018109056-A/115: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GATGCATCC
>MA395742.1 JP 2018109056-A/103: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GTTGCATCC
>MA395730.1 JP 2018109056-A/91: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>MA395718.1 JP 2018109056-A/79: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
TTGGGTTCT
>MA395706.1 JP 2018109056-A/67: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
AGTGCCTCC
>MA395694.1 JP 2018109056-A/55: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>MA395682.1 JP 2018109056-A/43: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
TTGGGTTCT
>MA395670.1 JP 2018109056-A/31: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGTATCC
>MA395658.1 JP 2018109056-A/19: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>MA395646.1 JP 2018109056-A/7: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>MA395494.1 JP 2018110590-A/275: RNAse H-Based Assays Utilizing Modified RNA Monomers
TAGCTGAAG
>MA395493.1 JP 2018110590-A/274: RNAse H-Based Assays Utilizing Modified RNA Monomers
AAGCTGAAG
>MA395492.1 JP 2018110590-A/273: RNAse H-Based Assays Utilizing Modified RNA Monomers
GAGCTGAAG
>MA395491.1 JP 2018110590-A/272: RNAse H-Based Assays Utilizing Modified RNA Monomers
CAGCTGAAG
>MA393497.1 JP 2018110581-A/23: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCTTCA
>MA393487.1 JP 2018110581-A/13: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCATCT
>MA393479.1 JP 2018110581-A/5: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCATCT
>LQ905159.1 Sequence 12 from Patent EP3380515
CGTGCATCC
>MA377343.1 JP 2018099031-A/14: Method for Determining the Presence of c-Met Positive Tumor
AAACTACCT
>MA377341.1 JP 2018099031-A/12: Method for Determining the Presence of c-Met Positive Tumor
GATTCCGTT
>MA377339.1 JP 2018099031-A/10: Method for Determining the Presence of c-Met Positive Tumor
AGATGTAGC
>MA377337.1 JP 2018099031-A/8: Method for Determining the Presence of c-Met Positive Tumor
CAATGTAGC
>MA377335.1 JP 2018099031-A/6: Method for Determining the Presence of c-Met Positive Tumor
ATGGTGCTA
>LY531922.1 KR 1020170098978-A/19: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>LY530485.1 KR 1020170102002-A/7: METHODS AND COMPOSITIONS FOR EBOLA VIRUS VACCINATION
TCTCTCCNA
>LY530478.1 KR 1020170098947-A/11: METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY
TCTCTCCNA
>LY530132.1 KR 1020170102328-A/301: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530124.1 KR 1020170102328-A/285: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530116.1 KR 1020170102328-A/269: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530108.1 KR 1020170102328-A/253: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530100.1 KR 1020170102328-A/237: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCCTCC
>LY530092.1 KR 1020170102328-A/221: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GGTGCATCC
>LY530084.1 KR 1020170102328-A/205: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530076.1 KR 1020170102328-A/189: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530068.1 KR 1020170102328-A/173: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530060.1 KR 1020170102328-A/157: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530052.1 KR 1020170102328-A/141: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GGTGCATCC
>LY530044.1 KR 1020170102328-A/125: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GGTGCATCC
>LY530036.1 KR 1020170102328-A/109: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GTTGCATCC
>LY530028.1 KR 1020170102328-A/93: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530020.1 KR 1020170102328-A/77: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530012.1 KR 1020170102328-A/61: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY530004.1 KR 1020170102328-A/45: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GCTGCATCC
>LY529996.1 KR 1020170102328-A/29: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
TGGGCATCT
>LY529988.1 KR 1020170102328-A/13: HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
GGTGCATCC
>LY526689.1 KR 1020170098888-A/6325: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ACGGCGTCT
>LY526681.1 KR 1020170098888-A/6309: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526673.1 KR 1020170098888-A/6293: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGTATCC
>LY526665.1 KR 1020170098888-A/6277: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526657.1 KR 1020170098888-A/6261: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTTGCATCC
>LY526649.1 KR 1020170098888-A/6245: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526641.1 KR 1020170098888-A/6229: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526633.1 KR 1020170098888-A/6213: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526625.1 KR 1020170098888-A/6197: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ATTGCTTCC
>LY526617.1 KR 1020170098888-A/6181: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GTTGCTTCC
>LY526609.1 KR 1020170098888-A/6165: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCG
>LY526601.1 KR 1020170098888-A/6149: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTTGCCTCC
>LY526593.1 KR 1020170098888-A/6133: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GTTGCATCC
>LY526585.1 KR 1020170098888-A/6117: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTTGCATCC
>LY526577.1 KR 1020170098888-A/6101: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ATTGCTTCC
>LY526569.1 KR 1020170098888-A/6085: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTATATCC
>LY526561.1 KR 1020170098888-A/6069: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGTTTCC
>LY526553.1 KR 1020170098888-A/6053: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GTTGCATCC
>LY526545.1 KR 1020170098888-A/6037: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526537.1 KR 1020170098888-A/6021: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATACATCC
>LY526529.1 KR 1020170098888-A/6005: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526521.1 KR 1020170098888-A/5989: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526513.1 KR 1020170098888-A/5973: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTGGGTTTT
>LY526505.1 KR 1020170098888-A/5957: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTATATTT
>LY526497.1 KR 1020170098888-A/5941: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTGGGTTCT
>LY526489.1 KR 1020170098888-A/5925: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526481.1 KR 1020170098888-A/5909: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526473.1 KR 1020170098888-A/5893: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526465.1 KR 1020170098888-A/5877: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTGGGTTCT
>LY526457.1 KR 1020170098888-A/5861: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTACGTCC
>LY526449.1 KR 1020170098888-A/5845: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTGGGTTCT
>LY526441.1 KR 1020170098888-A/5829: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526433.1 KR 1020170098888-A/5813: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GACACATCC
>LY526425.1 KR 1020170098888-A/5797: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526417.1 KR 1020170098888-A/5781: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526409.1 KR 1020170098888-A/5765: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATACATCC
>LY526401.1 KR 1020170098888-A/5749: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATACATCC
>LY526393.1 KR 1020170098888-A/5733: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526385.1 KR 1020170098888-A/5717: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526377.1 KR 1020170098888-A/5701: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AATGCATCC
>LY526369.1 KR 1020170098888-A/5685: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTACATCC
>LY526361.1 KR 1020170098888-A/5669: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526353.1 KR 1020170098888-A/5653: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526345.1 KR 1020170098888-A/5637: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526337.1 KR 1020170098888-A/5621: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526329.1 KR 1020170098888-A/5605: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGAACATCC
>LY526321.1 KR 1020170098888-A/5589: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTACATCC
>LY526313.1 KR 1020170098888-A/5573: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526305.1 KR 1020170098888-A/5557: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTACATCC
>LY526297.1 KR 1020170098888-A/5541: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526289.1 KR 1020170098888-A/5525: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATTCATCC
>LY526281.1 KR 1020170098888-A/5509: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526273.1 KR 1020170098888-A/5493: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526265.1 KR 1020170098888-A/5477: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526257.1 KR 1020170098888-A/5461: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526249.1 KR 1020170098888-A/5445: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526241.1 KR 1020170098888-A/5429: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526233.1 KR 1020170098888-A/5413: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGTATCC
>LY526225.1 KR 1020170098888-A/5397: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526217.1 KR 1020170098888-A/5381: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526209.1 KR 1020170098888-A/5365: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526201.1 KR 1020170098888-A/5349: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ACTGCATCA
>LY526193.1 KR 1020170098888-A/5333: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GTTGCATCC
>LY526185.1 KR 1020170098888-A/5317: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGTTTCT
>LY526177.1 KR 1020170098888-A/5301: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TGGGCATCT
>LY526169.1 KR 1020170098888-A/5285: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TTGGGTTCT
>LY526161.1 KR 1020170098888-A/5269: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ACTGCATCC
>LY526153.1 KR 1020170098888-A/5253: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526145.1 KR 1020170098888-A/5237: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526137.1 KR 1020170098888-A/5221: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GTTGCATCC
>LY526129.1 KR 1020170098888-A/5205: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>LY526121.1 KR 1020170098888-A/5189: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ACTGCATCC
>LY526113.1 KR 1020170098888-A/5173: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ACTGCATCC
>LY526105.1 KR 1020170098888-A/5157: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY526097.1 KR 1020170098888-A/5141: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY526089.1 KR 1020170098888-A/5125: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY526081.1 KR 1020170098888-A/5109: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY526073.1 KR 1020170098888-A/5093: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GAGGCGTCT
>LY526065.1 KR 1020170098888-A/5077: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TGGGCATCT
>LY526057.1 KR 1020170098888-A/5061: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526049.1 KR 1020170098888-A/5045: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY526041.1 KR 1020170098888-A/5029: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TGGGCATCT
>LY526033.1 KR 1020170098888-A/5013: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY526025.1 KR 1020170098888-A/4997: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GAGGCGTCT
>LY526017.1 KR 1020170098888-A/4981: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY526009.1 KR 1020170098888-A/4965: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY526001.1 KR 1020170098888-A/4949: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY525993.1 KR 1020170098888-A/4933: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
ACTGCCTCC
>LY525985.1 KR 1020170098888-A/4917: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY525977.1 KR 1020170098888-A/4901: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TGGGCATCT
>LY525969.1 KR 1020170098888-A/4885: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TGGGCATCT
>LY525961.1 KR 1020170098888-A/4869: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
TGGTCATCT
>LY525953.1 KR 1020170098888-A/4853: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY525945.1 KR 1020170098888-A/4837: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GAGGCGTCT
>LY525937.1 KR 1020170098888-A/4821: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY525929.1 KR 1020170098888-A/4805: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY525921.1 KR 1020170098888-A/4789: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGCGTCT
>LY525913.1 KR 1020170098888-A/4773: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY525905.1 KR 1020170098888-A/4757: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY525897.1 KR 1020170098888-A/4741: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
AAGGTTTCT
>LY525889.1 KR 1020170098888-A/4725: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GATGCATCC
>LY549870.1 KR 1020170138548-A/364: RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
GGGTTTGGG
>LY549859.1 KR 1020170138548-A/353: RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
GGTTTTTGG
>LY525817.1 KR 1020170098888-A/4581: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTGCATCC
>LY525809.1 KR 1020170098888-A/4565: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GCTTCATCC
